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ABSTRACT
cis-Diamminedichloroplatinum(II), or cisplatin, is the most successful cancer drug
ever discovered. It has been used for over 30 years in the treatment of several types of
malignancies, with the highest success rates in testicular cancer patients. Despite the
triumphs of this drug, the exact mechanisms of cell-killing by cisplatin are not fully
understood. A more complete understanding of the ability of this drug to target and
destroy cancer cells will lead to advances in overcoming the intrinsic and acquired
resistance that many cancer patients encounter with cisplatin. Cisplatin can form several
distinct DNA adducts, which are toxic to cells if not repaired. By identifying proteins that
bind to platinum-modified DNA, the work in this thesis focuses on the early stages of
DNA adduct processing.
The first chapter of this thesis gives a review of the identification of proteins with
an affinity for platinum-modified DNA in the literature. Different techniques are
discussed, and the proteins identified by these methodologies are discussed.
The methodologies previously used to identify proteins with an affinity for
platinum-modified DNA have led to important advances in our knowledge of the cellular
processing of these adducts. The development of an assay that can survey the entire
nuclear milieu, allowing for multiprotein complexes to stay intact and proteins to
compete for binding to the damaged DNA has been difficult. These challenges were
addressed by using a photo-active cisplatin analogue, cis-[Pt(NH3)(N-(6-aminohexyl)-4-
benzophenonamide)C12] (PtBP6). Site-specifically modified DNA probes were
synthesized and used to identify proteins photo-cross-linked by the benzophenone-
modified platinum complex. A 25-bp probe containing a 1,2-d(GpG) and 1,3-d(GpTpG)
intrastrand adduct of PtBP6 were synthesized and used in photo-cross-linking
experiments. The results demonstrated that the 1,2-d(GpG) adduct binds more strongly to
HMG-domain proteins, and the 1,3-d(GpTpG) adduct exclusively binds a nucleotide
excision repair protein RPA1. A probe containing a mismatched 1,2-d(GpG) adduct was
also synthesized, and this DNA photo-cross-linked more strongly to the mismatch repair
protein, Msh2.
These results demonstrate that PtBP6-modified DNA mimics the behavior of
cisplatin-modified DNA published in the literature. These experiments also identify
PARP-1 as a protein with an affinity for platinum-modified DNA. This protein will bind
to other types of DNA damage, but had not been previously implicated in platinum-DNA
damage binding. Photo-cross-linking experiments were carried out using nuclear extracts
from cancer cells with varying sensitivity to cisplatin. The results indicate that expression
levels of PARP-1 may effect the cell's ability to survive cisplatin exposure. The proteins
photo-cross-linked by different nuclear extracts were consistent, however, indicating that
DNA damage recognition is not the mechanism for cisplatin resistance in these cell lines.
In order to ensure that the proteins identified using the 25-bp probe were not
binding to the blunt ends of the DNA and being photo-cross-linked, a 90 base dumbbell
probe was synthesized. In this probe, the DNA contains no blunt ends but two loops,
which are 19 bases from the platinum adduct. Photo-cross-linking experiments using this
probe confirmed the binding of each of the proteins identified using the 25-bp probe. The
photo-cross-linking of DDBI, RFC1 and RFC2 demonstrates that a longer platinum-
modified DNA probe is a better substrate for recognition by nucleotide excision repair
proteins. This work also indicates that both mismatch repair recognition complexes
Msh2/Msh3 and Msh2/Msh6 bind to platinum-damaged DNA. The affinity of chromatin
remodeling proteins for platinum-damaged DNA was also established in this work.
The characterization of PARP-1 as a protein with an affinity for platinum-
damaged DNA was first discovered using photo-cross-linking experiments with PtBP6.
Prior to this discovery, the ability of PARP inhibitors to sensitize cells to cisplatin had
already been investigated. Conflicting results are reported in the literature about the
efficacy of these inhibitors as potentiators of cisplatin toxicity. In order to probe the
mechanism of the interaction, assays were carried out using PARP inhibitors synthesized
by Alison Ondrus of the Movassaghi lab. These experiments indicated that the activity of
PARP proteins following exposure to platinum-modified DNA may be cell-line
dependent. We were unable to detect a significant increase in PARP activity following
exposure to cisplatin, however, in any cell line tested. These results suggest that more
mechanistic studies into the effect of the activity of PARP proteins on cancer cells
exposed to cisplatin are warranted.
Initial photo-cross-linking experiments using a duplex containing a benzophenone
moiety on the DNA indicated that this type of probe could be used to identify proteins
with an affinity for various types of DNA lesions. Also, photo-cross-linking using a 157-
bp probe, site-specifically modified with PtBP6, indicated that there are some obstacles to
overcome when performing these types of experiments with longer DNA probes. Initial
NMR spectroscopic studies of a PtBP6-modified d(GpG) were carried out to characterize
the orientational isomers of this type of DNA lesion.
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Chapter 1: Nuclear Proteins with an Affinity for Platinum-Modified DNA.
I. INTRODUCTION
The anticancer drug cis-diamminedichloroplatinum(II) (cisplatin) was FDA-approved for
the treatment of testicular cancer over 30 years ago. Today, this drug is still first-line
chemotherapy for several types of malignancies.1 Despite years of study, the mechanism of
antitumor activity of cisplatin is still not fully understood. Cisplatin continues to be the subject of
intense investigation because the drug is not effective on all tumors, and patients treated with the
drug may develop resistance to platinum-based therapy.' In order identify factors that lead to
resistance to cisplatin, it is important to understand the four steps of the antitumor activity of
cisplatin (Figure 1.1).
Cisplatin enters the cell by both passive and active transport mechanisms (Figure 1.1i).
While it was originally thought that cisplatin enters the cell by passive diffusion, the role of the
copper transporter protein CTR1 in cisplatin uptake has recently been established.2 The low
intracellular concentration of chloride ions induces the aquation of cisplatin, referred to as the
activation step (Figure 1.1ii). For another FDA-approved anticancer drug, oxaliplatin, these two
steps occur simultaneously, due to non-chloride leaving groups of the drug and the ability of the
organic cation transporters OCTI and OCT2 to transport the activated form of the oxaliplatin
(Figure 1.li).3 Once activated, the compounds [Pt(NH 3)2(H20) 2]2+ and [Pt(NH 3)2(H20)Cl] , will
bind to several intracellular targets.
One important target of these aquated platinum compounds is the nucleophilic N7 of
purine residues. An interaction between an ammine hydrogen atom and the C6 oxo of guanine
make this base the more favorable for binding than adenine. 4 These DNA-bound platinum
complexes will then bind to a second target on the DNA, resulting in DNA adducts. The most
common adduct is the 1,2-d(GpG) intrastrand cross-link in which cisplatin binds to the N7
positions of two consecutive guanosine residues. Cisplatin can also form a 1,3-d(GpNpG)
intrastrand cross-link in which the bound guanosine residues are separated by one nucleotide,
and an interstrand adduct where cisplatin binds to residues on opposite strands of the DNA
(Figure 1.2). All of these platinum adducts cause bending and unwinding of the DNA. 1 The
bulky lesions are a recognition site for nuclear factors5 and will block polymerases. 6
Consequentially, processing of the DNA-damage must result in repaired DNA in order for the
cell to survive.
The resistance mechanisms which make cisplatin ineffective in certain patients may
derive from each of the four steps of cisplatin cytotoxicity. For example, cisplatin uptake is
reduced when the gene encoding the copper uptake transporter CTR1 is mutated or deleted.2 An
increase in "decoy" binding sites for the platinum inside the cell, such as glutathione, can
decrease the number of platinum-DNA adducts that form, reducing cytotoxicity.7 This chapter
will focus on the processing of platinum adducts following DNA-binding. The signaling
pathways that are initiated following recognition of platinum-DNA adducts may have an
important effect on the ability of the cell to repair damaged DNA or signal cell death through
apoptosis.
II. METHODS USED TO IDENTIFY PLATINUM-DNA BINDING PROTEINS
The evaluation of cellular proteins that bind to platinated DNA dates back many years.
Globally platinated as well as site-specifically platinated DNA constructs were synthesized.8
The globally platinated fragments were radiolabeled and incubated with cytosolic and nuclear
extracts from several cell lines, including HeLa cells. The mixtures were then analyzed by native
PAGE, which allows protein-DNA interactions to remain intact. Any bound proteins will slow
the elution of the radiolabeled DNA down the gel. This type of assay is referred to as a gel
retardation assay or electrophoretic mobility shift assay (EMSA, Figure 1.3). Increasing levels of
platinum adducts on the DNA caused more of the DNA to be shifted to a large upper band
comprising a DNA-protein complex. Complex formation was eliminated by proteinase K, which
degrades the proteins, or by adding platinated competitor DNA that was not radiolabeled. Using
site-specifically modified probes, the authors showed that protein complexation occurs readily
for the 1,2-d(GpG) and 1,2-d(ApG) adducts, but not for the 1,3-d(GpTpG) adduct or the adducts
of the inactive trans-diamminedichloroplatinum(II) compound. This work highlighted the
importance of proteins with an affinity for platinum-modified DNA, although the proteins bound
to the probe were not identified in this work.
EMSAs were used to show that a protein that binds to cisplatin-modified DNA is not
present in the nuclear extracts of cells deficient in xeroderma pigmentosum complementation
group E (XPE). 9' 10 These types of cells have defects in DNA damage repair." The authors
named the protein XPE binding factor, which was later purified and characterized as the 125 kDa
protein, DNA damage binding protein-i (DDB1).12 EMSAs have provided a mechanistic
understanding of in vivo observations. For instance, after the discovery that E. coli cells lacking
certain mismatch repair proteins were more resistant to cisplatin, .3 it was demonstrated that the
mismatch repair protein, MutSa binds to cisplatin-modified DNA. 14 Cells expressing high levels
of the protein YB-1 are resistant to several DNA-damaging agents, 5 '16 which led to the
discovery that YB-1 binds to cisplatin-damaged DNA using EMSAs. 17
EMSAs can also be used to probe the platinum-damaged DNA-binding abilities of known
DNA damage response proteins. Based on the discovery that the protein binds to bent DNA
structures, the affinity of the methylated-DNA repair protein 3-methyladenine DNA glycosylase
(AAG) for cisplatin-modified DNA was demonstrated."8 An interest in the interactions between
transcription machinery and NER led to the finding that the transcription factor TATA-binding
protein (TBP) has an affinity for cisplatin-modified DNA. 9 While EMSAs are useful for
investigating known proteins, the methodology is not feasible for identifying every protein that
binds to cisplatin-modified DNA, since it would be necessary to purify and test each nuclear
protein individually.
In order to survey the entire proteome for proteins that bind to cisplatin-damaged DNA,
different methodologies had to be used. One of these methods, southwestern blotting (Figure
1.3), necessitates resolving the nuclear proteins by SDS-PAGE. The proteins are then transferred
to a membrane, which is incubated with radiolabeled DNA containing cisplatin adducts. The
molecular weight of the bound proteins can be estimated based on the migration of the protein
down the gel. Using this methodology, platinum-DNA-specific proteins of 28 and 100 kDa were
characterized. 20 The same type of methodology was used to identify proteins of 25, 48 and 97
kDa that bind specifically to cisplatin-damaged DNA.2 1 Southwestern blotting is able to
characterize cisplatin-damaged DNA-binding proteins by molecular weight, but the identification
of the protein is not achieved by this method.
Screening of cDNA libraries (Figure 1.3) is another method that was able to identify
proteins with an affinity for platinum-modified DNA. In this type of assay, E. coli cells are
transfected with a library of plasmids, each expressing a human protein. Each cell is able to take
up only one plasmid and expresses a singular human protein. The contents of each cell are
transferred onto a membrane that is then treated with radiolabeled DNA. The DNA will be
immobilized on spots belonging to cells that express a relevant DNA-damage recognition
protein. Using this methodology, recombinant phages of the platinum-DNA binding proteins
were isolated20 and an 80 kDa protein containing an HMG-domain, structure specific recognition
protein (SSRP1), was identified.22 This protein is a subunit of the transcription elongation
complex FACT.23 The identification of SSRP1 led to the investigation of the cisplatin-modified
DNA-binding properties of other HMG-domain proteins using EMSAs, including high mobility
group protein-i (HMGB 1), upstream binding factor-i (UBF 1), mitochondrial transcription factor
mtTFA, lymphoid enhancer binding factor (LEF-1) and sex-determining factor (SRY).24 -27
Despite the successes of southwestern blotting and cDNA library screening methods in
identifying proteins that bind to platinum-modified DNA, these methods do not allow for
multiprotein complexes to remain intact. One example of this type of interaction is the FACT
complex itself. The HMG-domain protein SSRP1 binds strongly to cisplatin-modified DNA only
in the presence of the other subunit, SPT16.28 EMSA methodology allows for proteins to bind in
their native states, but does not afford a proteome-wide survey of isolable protein-DNA
complexes. Southwestern blotting and cDNA library methods allow for better characterization of
bound proteins, but require the proteins to be sequestered prior to DNA-binding.
In order to isolate proteins that bind to platinum-modified DNA as multiprotein
complexes, unplatinated or cisplatin-modified DNA was immobilized on cellulose.29 The
cellulose was incubated with cell extracts and then washed to remove unbound proteins. The
cellulose was then heated in denaturing buffer to dissociate the DNA-bound proteins and these
proteins were analyzed by SDS-PAGE. This method was able to identify that HMGB1 and
HMGB2 bind specifically to cisplatin-modified DNA. In a similar manner, platinated calf
thymus DNA was immobilized onto a sepharose column and the column was incubated with
HeLa cell-free extracts (Figure 1.3). 30 The column was washed with a low-salt buffer to remove
free proteins and then washed with a buffer containing 0.75 M NaCI to dissociate proteins that
bind with high affinity to the platinum-modified DNA. The collected protein fraction was then
subjected to EMSAs to confirm that the collected proteins bind to cisplatin-modified DNA. This
method was able to identify HMGB1, DNA-PK, RPA and XPA. The roles of these proteins in
the cellular response to cisplatin-damaged DNA will be discussed later in this review.
Another method that has been used to isolate cisplatin-modified DNA-binding proteins is
chemical cross-linking. A cisplatin analogue containing a photoactive aryl azide moiety was
synthesized to photo-cross-link platinum-damaged DNA binding proteins. 31 Control experiments
from this work revealed that cisplatin itself can form DNA-platinum-protein complexes more
efficiently with HMGB1 than the aryl azide analogues when irradiated at 254 and 302 nm.
Irradiation at 365 nm was much less efficient. Irradiation using a laser at 325 or 350 nm could
also activate the Pt-DNA bond and form DNA-platinum-protein complexes. 32 This type of
photo-cross-linking requires an extremely close interaction between the platinum site and the
protein, since a platinum-protein bond must be formed.
Benzophenone, with an activation wavelength of 360 nm, is an ideal photo-cross-linker
for this application since this wavelength should not significantly activate the cisplatin-DNA
bond.3 1,33 A cisplatin analogue containing a benzophenone moiety connected by a six-carbon
linker was synthesized.34 This compound was reacted with biotinylated DNA containing a single
1,2-d(GpG) site. The platinated DNA was exposed to nuclear extracts from HeLa cells and
irradiated at 365 nm. The biotinylated DNA-platinum-protein complexes could be isolated from
unbound nuclear proteins using streptavidin-coated magnetic beads, which form a tight complex
with the tethered biotin moiety. This method is superior to the cellulose- and sepharose-based
assays described earlier because a covalent bond is formed between the platinated DNA and the
protein, eliminating the need to attenuate the washing conditions to differentiate between
weakly- and tightly-bound proteins. Once the unbound proteins were washed away, the
remaining proteins were resolved by SDS-PAGE, and several DNA-platinum-protein complexes
were identified. Two of these proteins were characterized by mass spectrometry as HMGB I and
PARP-1. 34 This methodology allows for exposure of the platinated DNA to the entire nuclear
milieu, followed by isolation and identification of the photo-cross-linked proteins. One major
advantage of this method is that proteins can compete for binding to the platinum-modified
DNA, providing a more realistic DNA-damage environment.
III. HUMAN PROTEINS THAT BIND PLATINUM-MODIFIED DNA AND IMPLICATIONS
IN DNA REPAIR
Many types of proteins have an affinity for platinum-modified DNA. Each of these
proteins may contribute to the repair of the damaged DNA, or conversely, may lead to cellular
death signaling. In the context of a cancer cell, identifying the proteins that lead to cell death
could lead to improved therapeutic strategies. The section examines some of the proteins with an
affinity for platinum-modified DNA (Table 1.1).
Nucleotide excision repair (NER) proteins
NER is the repair process implicated in the removal of cisplatin adducts from DNA.' This
repair results in an excised DNA fragment of approximately 32 bases.35 The resulting gap in the
remaining DNA is subsequently filled in by DNA polymerases and ligases.36 The DNA-damage
sensing is carried out by two different mechanisms, global genome repair (GGR) or
transcription-coupled repair (TC-NER). In GGR, the DNA damage is recognized by XPC-
RAD23B or XPA-RPA,36 while in TC-NER, damage recognition is initiated by the stalling of a
polymerase at the damaged base. 37 The XPA-RPA complex has an affinity for cisplatin-damaged
DNA.38 The protein mentioned earlier that causes a mobility shift in cisplatin-modified DNA and
is not present in XPE cells9'10 has been identified as DNA damage binding protein-i (DDB1), a
protein involved in NER. 12', 39
The 1,3-d(GpTpG) adduct is repaired more efficiently by NER than the 1,2-d(GpG)
adduct.35 The reason for this difference is most likely two-fold. EMSA studies using purified
RPA1 indicate that the protein has a 1.5-2-fold stronger affinity for the 1,3-d(GpNpG) than the
1,2-d(GpG) cisplatin cross-link, demonstrating that the 1,3-d(GpNpG) adduct is more readily
recognized by the NER machinery. HMG-domain proteins will block DNA repair of cisplatin-
damaged DNA by NER.35 As mentioned previously in this chapter, HMG-domain proteins bind
to the 1,2-d(GpG) but not the 1,3-d(GpNpG) adduct. 26 So repair of the 1,2-d(GpG) adduct will be
shielded by these proteins, but repair of the 1 ,-3d(GpNpG) adduct will not.
HMG-domain proteins
HMGB1 and HMGB2. HMGB1 and HMGB2 are chromosomal proteins that bind to
distorted DNA structures, such as four-way junctions, and induce further bending of the DNA.41
Each protein consists of two HMG-box domains and an acidic C-terminus. Both HMG domains
of HMGB1 bind to cisplatin-modified DNA, though HMGB1 domain A binds 100-fold more
strongly to 1,2-d(ApGpGpA) cisplatin adducts than domain B. 42 HMGB1 binding to cisplatin-
modified DNA will block repair by NER.35 Supporting this model, analysis of the NCI library of
cancer cell lines reveals a correlation between cells expressing high levels or HMGB1 and
cisplatin sensitivity. 43'44 Also, treatment of breast cancer cells with estrogen, which causes the
cells to overexpress HMGB , sensitizes the cells to cisplatin.45 The consequences of HMGB1
binding to cisplatin-modified DNA are discussed in a recent review.5 HMGB2 also binds to
cisplatin-modified DNA, 29 and is likely to have the same effects on cisplatin-damaged DNA
processing as HMGB 1.
UBF1. Upstream binding factor 1 (UBFl) is a transcription factor that exhibits sequence-
specific binding to DNA and interacts with a number of cellular factors to induce the polymerase
activity of RNA polymerase I (Pol I) 46,47 UBF is inactivated during mitosis when Pol 1 is
dormant and then activated in late G,, correlating with the onset of Pol I activity.48 UBF1 binds
strongly to cDDP-damaged DNA but not trans-DDP damaged DNA.2 7 This strong interaction of
UBF1 to cisplatin-damaged DNA is a consequence of the presence of 6 HMG domains in the
protein.49 There are about 5 x 105 UBFI molecules per cell, compared to between 10' and 106
cisplatin-DNA adducts in patients treated with the drug.49 The possibility exists that cisplatin-
DNA adducts act as decoy binding sites for UBFl, leading to hijacking of the protein from
rDNA promoter regions. This idea is supported by the fact that cisplatin treatment will lower
rRNA levels in vivo,50 although this may be related to stalling of the polymerase at platinum
lesions analogous to the behavior of RNA Polymerase II.6
UBFl expression is correlated to cisplatin sensitivity in hepatocellular carcinoma cell
lines."' Hepatocellular carcinoma cell lines expressing UBFI are threefold more sensitive to
cisplatin than cell lines lacking in UBFI expression. If the hijacking hypothesis is correct, these
results suggest that UBF1 hijacking by cisplatin lesions leads to cisplatin resistance. Lowered
expression of UBF1, which makes cells more resistant to cisplatin, would make titration of the
protein away from Pol I promoter regions easier. This model fits if UBF1 hijacking leads to cell
cycle arrest, since cell cycle arrest is generally associated with increased repair of cisplatin
adducts. 52 Another possibility is that UBFI blocks DNA repair machinery in a similar fashion to
other HMG-domain proteins, such as HMGB1. If this is the case, then high levels of UBF1
expression would lead to sensitization of cells to cisplatin, in accord with the behavior of the
hepatocellular carcinoma cells in the described study.5 '
Other HMG-domain-containing transcription factors. As mentioned previously, the
structure-specific recognition protein (SSRP1) subunit of the facilitates chromatin transcription
(FACT) complex binds to cisplatin-modified DNA.28 Binding of this protein complex to
cisplatin-modified DNA may compromise its ability to remodel chromatin. The binding of the
sequence-specific lymphoid enhancer-binding factor (LEF-1) to a native recognition site is about
ten times stronger than binding to cisplatin-modified DNA,53 so it is unlikely that cisplatin-
modified DNA could sequester the transcription factor from native functions. The protein still
may play a role in shielding the adducts from NER as demonstrated with other HMG-domain
proteins." Testis-specific cisplatin-damaged DNA-binding proteins are of particular interest due
to the sensitivity of testicular cancer to cisplatin treatment.! Unlike LEF-1, the binding affinity of
testis-specific sex-determining factor SRY to cisplatin-damaged DNA is strong enough to
compete with a putative native recognition sequence.54 The binding of SRY also blocks NER of
the lesion. 54 Mitochondrial transcription factor mtTFA binds to cisplatin-modified DNA and also
prevents the repair of the lesion by blocking NER. 25' 35 The interaction of mtTFA with the tumor
suppressor p53 may also play a role in the response to cisplatin-damaged DNA. 5 These results
demonstrate that the binding of HMG-domain transcription factors to cisplatin-damaged DNA
has several possible consequences, including hijacking of the transcription factor from native
functions, shielding the adduct from repair and interactions with other DNA damage repair
related proteins, such as p53.
Transcription factors lacking an HMG-domain
TBP. The TATA-binding protein (TBP) is the recognition element of TFIID, which binds
the TATA box and initiates transcription of RNA polymerases I, II and 111.56 TBP will recognize
cisplatin-damaged DNA,'1 and this affinity is enhanced if the platination site is located near a
TATA box.57 This affinity is likely due to structural similarities between the TATA box bound
by TBP and DNA containing a 1,2-d(GpG) intrastrand adduct of cisplatin. 9 Binding to damaged
DNA may sequester the protein from transcription initiation sites, leading to a decrease in
transcription characteristic of cells treated with cisplatin. 8 Alternatively, the affinity of TBP for
cisplatin-damaged DNA near a TATA box could lead to increased turn-on of transcription at the
cisplatin-flanked TATA box sites.57 One role of TBP following exposure to cisplatin-damaged
DNA may not be transcription-related, as TBP bound to cisplatin-modified DNA will block NER
from repairing the lesion.' 9
YB-1. Y-box binding protein-i (YB-1) is a nucleic acid binding protein containing a cold-
shock domain (CSD). Under normal conditions, 90% of the protein is present in the cytoplasm,
and translocation to the nucleus occurs when the cell is under stress.60 YB-1 is involved in stress
response, transcription, translation and is often correlated with cellular proliferation. 6 The
protein will bind to cisplatin-modified DNA, 7 and several cell lines resistant to cisplatin showed
an increase in expression of YB-i. " Knockdown of the protein using RNAi in these cell lines
conferred a twofold sensitivity to cisplatin. 5 Although the role of YB-1 in DNA repair is not
fully understood, YB-I interacts with proliferating cell nuclear antigen (PCNA) 17 as well as
tumor suppressor p53, 6 1 two proteins involved in DNA repair..
Mismatch repair (MMR) proteins
Msh2. MutS homolog 2 (Msh2) has an affinity for the 1,2-d(GpG) intrastrand cross-link
of cisplatin. 4 '62 Msh2 is a MMR protein that binds to the site of a mismatched base.63 Cell lines
deficient in MMR are generally more resistant to cisplatin damage;6 4-68 however, the extent of
resistance in MMR-deficient cells may be minimal.69 This discrepancy may be due to certain
MMR mutations that can disrupt repair of mismatches without disabling MMR-dependent
apoptosis signaling pathways. 70 This hypothesis is supported by a molecular modeling study
demonstrating that different residues of Msh2 and Msh6 are involved in hydrogen bonding with
mismatched DNA versus cisplatin-modified DNA.7 1 MMR-deficient cells have an increased
probability of DNA polymerases bypassing cisplatin adducts, and it is suggested that Msh2 may
be responsible for blocking DNA polymerases from translesion synthesis that can lead to
mutagenesis. The blocking of DNA polymerases by Msh2-bound cisplatin adducts may result
in the formation of double-strand breaks, which are present after cisplatin treatment.72 This
behavior would explain why cell lines deficient in recombination repair pathways are often more
sensitive to cisplatin.72
Another possible explanation for the cytotoxicity of cisplatin lesions is that the MMR
pathway treats cisplatin adducts as mismatched bases, which would lead to cycles of excision
and resynthesis of the strand opposite the cisplatin adduct in an effort to find a base which
confers normal duplex structure to the adduct. These futile cycles could lead to apoptosis. 72 The
mechanism for the MMR-dependent response to cisplatin may also be related to cell cycle arrest
and apoptosis signaling through the tyrosine kinase, c-Abl. 73'74 Cisplatin exposure activates the c-
Abl MAPK pathway," which can stabilize p73 and lead to cell death through apoptosis in an
MMR-dependent manner.74
DNA protein kinase (DNA-PK)
DNA-PK is a heterotrimer of the proteins DNA-PKcs, Ku70 and Ku80 and is a
component of the primary nonhomologous end-joining (NHEJ) double strand break repair
pathway.76 The Ku subunits of DNA-PK will recognize DNA double-strand breaks and recruit
the catalytic subunit DNA-PKs. 76 Ku proteins do bind to cisplatin-DNA adducts, although this
binding will not activate DNA-PK.77 The lack of activity may be due to the inhibition of Ku
translocation down the DNA because it can be stalled by the cisplatin adduct. This translocation
is a necessary step in the activation of DNA-PK." A 1,2-d(GpG) cisplatin cross-link six base
pairs from a DNA terminus will inhibit NHEJ by 95%, and an adduct 15 bases pairs from the
terminus will inhibit NHEJ by 60%. 79 In these examples, Ku binding was not affected, only
DNA-PK activity. This process requires a cisplatin adduct to be located near a double-strand
break. If double-strand breaks occur near a platination site, the inhibition of NHEJ by the
cisplatin lesion could be a factor in cell-killing by cisplatin. Supporting this theory, treatment of
cells with high levels of cisplatin prior to ionizing radiation will inhibit repair of the irradiation-
induced double-strand breaks.o Treatment of the cells with lower levels of cisplatin prior to
treatment resulted in the opposite effect," most likely due to the induction of UV-damage
response proteins following cisplatin-DNA adduct processing."
3-Methyladenine DNA glycosylase (AAG)
The protein 3-methyladenine DNA glycosylase (AAG), which is responsible for repairing
methylated DNA, will bind to cisplatin-modified DNA."8 Although the protein has an affinity for
both the 1,2-d(GpG) and 1,3-d(GpTpG) intrastrand cross-links of the compound, it is unable to
excise the lesions." AAG is a base excision repair (BER) protein, a repair process not active on
cisplatin lesions. Recognition of lesions by the protein may signal the NER machinery to repair
the damaged DNA.8 2 If AAG recruits NER proteins to the damaged DNA, repair of cisplatin-
DNA cross-links could be indirectly stimulated by this protein.
Poly(ADP-ribose) polymerase I (PARP-1)
PARP-1 belongs to a family of proteins with an enzymatic activity resulting in the
addition of poly(ADP-ribose) (PAR) polymers onto itself and other proteins in a reaction that
consumes nicotinamide. 83 The affinity of this protein for platinum-damaged DNA was recently
discovered34 using methodologies described in detail in this thesis. The DNA damage-stimulated
activity of PARP proteins can lead to DNA repair or cell death through apoptosis or necrosis,
each involving an independent pathway.83 A detailed discussion of the activity of PARP-1
following exposure to platinum-damaged DNA is presented in Chapter 5.
IV. SUMMARY OF CONSEQUENCES OF PROTEINS BINDING TO PLATINUM-
MODIFIED DNA
Potentiation of repair. Cisplatin-damaged DNA is repaired by the nucleotide excision
repair (NER) pathway and this repair is necessary for survival of the cell.' In global genome
NER (GG-NER), the binding of proteins XPA and RPA to cisplatin-modified DNA signals the
repair of these adducts.36 ,38 Although the protein XPE-BF, now referred to as DDB1, is not
necessary for NER to take place in vitro, the sensitivity of patients with mutated DDB 1 to DNA
damaging agents suggests that the protein plays a role in DNA repair.84 HMG-domain proteins
can counteract NER activity by shielding cisplatin-modified DNA from repair.' The significance
of this interaction was demonstrated by inducing the expression of the HMG-domain protein
tsHMG in HeLa cells, which sensitized the cells to cisplatin.8 5 Whereas HMG-domain proteins
have been specifically implicated, the binding of any protein to cisplatin-modified DNA may
inhibit repair by blocking NER proteins from recognizing the lesion.
Proteins binding to cisplatin-damaged DNA can signal repair through interactions with
other proteins involved in DNA repair pathways. The protein AAG recognizes cisplatin-damaged
DNA, although it is involved in the base excision repair pathway and cannot excise the lesions. 8
AAG has a greater affinity for the 1,2-d(ApG) versus 1,2-d(GpG) intrastrand adduct of cisplatin.
The 1,2-d(ApG) adduct is repaired more efficiently in crude extracts but the two adducts are
repaired to a similar extent in purified NER components, suggesting that a cisplatin-DNA
binding protein, such as AAG, may recruit NER proteins to repair the lesion and account for the
repair discrepancy.82 Another example of these types of associations is YB-1, which interacts
with the proliferating cell nuclear antigen (PCNA). 17 PCNA is required for NER,86 because is
involved in the resealing of single-stranded DNA gaps formed when damaged DNA is excised
by NER.8 7
The cisplatin-damaged DNA-binding proteins HMGB1, YB-1 and mtTFA each interact
with the tumor suppressor p53 .5561,88 This protein serves a variety of roles following DNA
damage." Global genome NER (GG-NER) is dependent on BRCA1- and p53-dependent
expression of the DNA damage recognition proteins DDB2 and XPC.90 Following DNA damage,
p53 localizes to sites of NER and its activity leads to chromatin loosening through histone
acetylation, which makes the damaged DNA more accessible to repair proteins.9' This work was
performed using UV-irradiation as the DNA damaging agents, but the dependence of NER on
p53 has recently been demonstrated for cisplatin-DNA adducts. 2 Paradoxically, p53 can also
signal apoptosis, and p53-deficient cells, despite having more persistent DNA adducts, are less
sensitive to DNA damaging agents such as cisplatin.93 This result indicates that the p53-
dependence of NER is outweighed by the ability of the protein to signal cell death.
Hijacking proteins from native functions. Another possibility is that proteins with an
affinity for platinum-damaged DNA are hijacked from other responsibilities within the cell. The
hijacking of transcription factors, such as UBFI, may lead to transcription inhibition as discussed
earlier. Other proteins may also be hijacked. For instance, the sequestration of mismatch repair
proteins could compromise the ability of the cell to repair actual DNA mismatches. This is
especially significant for mismatch repair proteins, since they are expressed at low levels in
cells .9
Death signaling. Another possibility is that the proteins bound to cisplatin-damaged DNA
lead to the induction of cell death mechanisms. The tumor suppressor p53, which interacts
indirectly with these adducts, is a part of the apoptosis-signaling pathway. 95 As mentioned above,
cells deficient in functional p53 protein are more resistant to DNA damaging agents such as
cisplatin. 93 Mismatch repair (MMR) proteins bind to platinum-modified DNA, despite being
unable to repair the adducts. Futile cycles of failed attempts to repair the DNA may lead to
apoptosis signaling, a hypothesis supported by the observation that MMR-deficient cells are
often more tolerant of cisplatin adducts.62 MMR proteins may also signal apoptosis through the
tyrosine kinase, c-ABL.73'74 The protein PARP-1, which has recently been characterized as a
platinum-damaged DNA-binding protein, can lead to apoptosis or necrosis through unique
pathways." The consequences of these signaling pathways are discussed in more detail in
Chapter 5.
V. NEW PLATINUM ANTICANCER COMPOUNDS
The search for new chemotherapeutics continues to face the challenge of selectively and
efficiently killing cancer cells while allowing healthy cells to survive. Many new
chemotherapeutics agents incorporate more efficient targeting and delivery of anticancer
compounds into cancer cells. Recent work has shown the efficacy of nanotubes in the delivery of
platinum compounds to cancer cells. 97 These transport mechanisms present the cell with a
platinum(IV) compound, which will be reduced upon entry into the cellular medium, yielding
cis-diamminedichloroplatinum(II), cisplatin. 98 Improved delivery mechanisms should increase
the number of cisplatin-DNA adducts in the cell, and these adducts will be recognized by the
same proteins listed in this review. Other new strategies for improved anticancer therapeutics
involve the synthesis of platinum compounds with different ammine ligands than cisplatin. These
ligands may effect uptake of the compounds, 3 and will lead to differential recognition of the
platinum-DNA adducts.
Oxaliplatin is an FDA-approved platinum anticancer drug that contains a
diaminocyclohexane (DACH) ligand (Figure 1.4). The oxaliplatin-DNA adduct is repaired by
NER with similar efficiency to the cisplatin-DNA adduct.99 Mismatch repair proteins, however,
do not bind oxaliplatin-DNA adducts as strongly as cisplatin-DNA adducts, and mismatch repair
deficient cell lines are equally sensitive to oxaliplatin treatment. 00 Cisplatin is ineffective against
colorectal cancers, 3 a cancer type that is commonly MMR-deficient.o0  The efficacy of
oxaliplatin in colorectal cancer has recently been attributed to the expression of organic cation
transporters (OCTs), which greatly increase the uptake of oxaliplatin compared to cisplatin in
these cells.3 These data together suggest that the benefit of oxaliplatin over cisplatin in colorectal
cancer cells is due both to uptake and processing of the drugs.
Satraplatin is a platinum anticancer compound currently undergoing clinical trials for the
treatment of hormone refractory prostate cancer (Figure 1.4). The DNA bound form of this
compound is analogous to that of cisplatin with one ammine ligand replaced with a
cyclohexylamine. 102 This type of DNA adduct is repaired by NER to a similar extent as cisplatin-
DNA adducts. 99 The advantage of this compound is its oral availability.' 0 2 Both oxaliplatin and
satraplatin form similar types of DNA adducts to cisplatin. Platinum complexes with different
DNA-binding properties are more likely to be processed differently.
Multinuclear platinum compounds connected by long alkyl linkers were designed such
that they bind to DNA through long-range intra- and interstrand cross-links (Figure 1.4). These
compounds are not affected by the mismatch repair status of the celll 03 and are effective in cell
lines with both wild-type and mutant p53.1'0 4 This result is especially important because p53 is
mutated in most cancer cells. 89 The anticancer properties of these compounds may derive from
their ability to form interstrand cross-links, which account for about 20% of DNA adducts
formed. 10 5 Monofunctional platinum compounds are also under investigation for anticancer
potential. The compound [Pt(NH3)2(pyridine)Cl]Cl binds DNA monofunctionally, and exhibits
transcription inhibitory and anti-proliferative properties. 10 6 Unlike cisplatin-DNA adducts, these
lesions do not bend or unwind DNA, indicating that their recognition by nuclear proteins will be
significantly different than that of bifunctional platinum-DNA adducts. 10 6
The identification of proteins that bind to platinum-modified DNA has yielded many hits,
which may have clinical significance to the efficacy of platinum anticancer drugs. Some of these
proteins are involved in the repair of these adducts, allowing cancer cells to survive, and other
proteins block this repair or initiate signaling cascades that will lead to cell death. These
discoveries have led to clinical trials of combination therapies, such as cisplatin with ionizing
radiation or estrogen, which aim to improve the chemotherapeutic potential of the drug. The
intrinsic or acquired resistance to cisplatin that is common in many types of tumors has also led
to the development of new platinum constructs, including monofunctional and multinuclear
compounds, which are recognized differently by DNA repair proteins. The continued search for
proteins with an affinity for cisplatin-modified DNA, as well as DNA damaged with these new
types of platinum lesions, will provide mechanistic information about DNA damage processing
that will continue to foster improved strategies of chemotherapy.
VI. ORGANIZATION AND SCOPE OF THESIS
Following the success of the serendipitously discovered platinum anticancer drug
cisplatin, the mechanisms by which such a simple compound is able to selectively and
effectively kill cancer cells has been studied thoroughly! The intrinsic and acquired resistance of
certain tumors to the drug has led to the development of new platinum constructs capable of
treating resistant tumors.1o5 Resistance to cisplatin derives from a dysfunction of certain
mechanisms required for cisplatin to be effective. The uptake of cisplatin into cells can be
compromised, or the cell can have an increased ability to efflux the drug.10 7 Once aquated inside
the cell, the platinum compound can be rendered less effective by an upregulation of "decoy"
binding sites, such as glutathione. 108 This thesis focuses on another type of resistance, in which
the processing of the platinum-DNA adducts enables the cancer cell to survive.1 0 8 This resistance
mechanism is probed by the identification of proteins with an affinity for platinum-modified
DNA.
This thesis addresses the challenge of compiling a comprehensive index of nuclear
proteins that bind to platinum-modified DNA. The identification of these proteins is
accomplished by using a photoactive cisplatin analogue cis-[Pt(NH3)(N-(6-aminohexyl)-4-
benzophenonamide)C12] (PtBP6). Photo-cross-linking is advantageous over other methods for
protein identification since it allows the platinum-modified DNA to be exposed to the nuclear
milieu. Proteins can compete for binding to the probe as they would in the nucleus. Multiprotein
complexes that bind to damaged DNA can stay intact in these extracts. The presence of
multiprotein complexes is important because some proteins bind more strongly in complex with
other proteins, such as the FACT complex, comprising subunits SSRPl and SPT16.28 This
method allows for screening of nuclear extracts from different cancer cell lines to determine
whether differences in protein binding result in differences in sensitivity to cisplatin.
Chapter 2 focuses on the optimization of photo-cross-linking conditions for identification
of proteins with an affinity for a 25-bp duplex containing a 1,2-d(GpG) cross-link of the
photoactive analogue of cisplatin, PtBP6. The 25-bp duplex allows for simpler synthesis than
longer DNA probes, so that many conditions could be tested to optimize cross-linking. Once the
conditions were optimized, photo-cross-linking experiments identified several proteins with an
affinity for platinum-modified DNA, HMGB1, HMGB2, HMGB3, Ku70, Ku80, DNA-PKcs,
UBF 1, Msh2, DNA Ligase III, PARP-1. The cisplatin-damaged DNA-binding ability of many of
the proteins identified has been characterized by other methods, such as EMSAs. The
identification of PARP- 1, and the PARP-1 associating protein DNA Ligase III, was novel to this
type of photo-cross-linking experiment. In Chapter 3, these photo-cross-linking were extended to
identify nuclear proteins that bind to various constructs of a 25-bp duplex containing a site-
specific adduct of PtBP6. Preparative-scale photo-cross-linking experiments with a 25-bp duplex
containing a 1,3-d(GpTpG) cross-link of PtBP6 indicated that this type of adduct does not bind
strongly to HMG-domain proteins but does bind to the NER protein, RPA. A probe containing a
compound lesion with both a mismatched base and a 1,2-d(GpG) intrastrand adduct of PtBP6
binds more strongly to the mismatch repair protein Msh2. This finding agrees with EMSA assays
using purified Msh2 reported in the literature. 109 Photo-cross-linking experiments were also
carried out using nuclear extracts from various cancer cell lines and reveal differences in protein
expression between cell lines, but also suggest that DNA damage recognition is consistent
between cells with different sensitivity to cisplatin.
In Chapter 4, photo-cross-linking studies were extended to a longer DNA dumbbell
probe. This probe separates the platination site further from the DNA ends, making it less likely
that end-binding proteins will be photo-cross-linked. Only the first four bases of the dumbbell
ends should interact with the protein PARP-1, 110 allowing us to determine whether the protein is
able to bind to platinum-damaged DNA. All of the proteins identified by the 25-bp duplex probe
were also found using this probe. Several other proteins were also identified, Msh3, Msh6, DNA
topoisomerase I, SPT16, YB-1, DDBI as well as members of the SWI/SNF chromatin
remodeling complex. The implications of these proteins binding to platinum-modified DNA are
discussed.
The identification of PARP-1 using these photo-cross-linking methods was the first
evidence that the protein binds to platinum-modified DNA.34 PARP inhibitors have proven
effective in the potentiation of cisplatin sensitivity, although some reports show little effect."' -113
In Chapter 5, the ability of PARP inhibitors to sensitize four cell lines to cisplatin was
investigated. The effect of one of these inhibitors on photo-cross-linking experiments was
analyzed. These cells lines were then used for nuclear extract- and cell-based assays of PARP
activity following exposure to cisplatin. It was determined by this work that the sensitization of
cells to cisplatin using PARP inhibitors is cell-line dependent, however, a clear understanding of
the activity of PARP proteins following treatment with cisplatin was not attained.
In order to evaluate the proteins that bind to different types of platinum-DNA adducts, a
benzophenone-modified DNA probe was synthesized. This work, described in Appendix A, led
to the design of the DNA probe 15G-BP, which is able to photo-cross-link proteins specific to
cisplatin-damaged DNA. A longer PtBP6-modified probe was synthesized as well. The ability to
photo-cross-link proteins using a long DNA probe is important for future experiments that will
photo-cross-link proteins with an affinity for platinum-damaged nucleosomes. As described in
Appendix B, photo-cross-linking using a 157-bp duplex results in complications in resolving the
protein-platinum-DNA complexes. The binding of asymmetric cisplatin analogues to DNA will
result in orientational isomers of the lesions.1 14 ,115 Preliminary NMR studies of the binding of
PtBP6 to d(GpG) were carried out and are discussed in Appendix C.
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VIII. TABLES
Table 1.1: Proteins with an affinity for cisplatin-damaged DNA
Protein(s)
AAG
DDB1
DNA-PK
HMGB 1, HMGB2
LEF-1
Msh2
mtTFA
PARP-1
SRY
SSRP1
TBP
UBF1
XPA/RPA
YB- I
DNA-binding domain
Glycosylase-DNA binding site
DNA damage recognition domain
Ku70/Ku80 heterodimer
HMG-domain
HMG-domain
Mismatch binding domain
HMG-domain
Two zinc fingers
HMG-domain
HMG-domain
TATA-binding domain
HMG-domain
XPA minimal DNA binding domain (MBD)
Cold shock domain
Notable
interactions
NER proteins?
NER proteins
PARP-1
p5 3
MMR proteins
p 53
p53, histones
FACT subunit
RNA Pol II
RNA Pol I
NER proteins
p53, PCNA
Comments
Base excision repair protein
Nucleotide excision repair protein
Nonhomologous end joining repair
protein
Chromatin remodeling proteins
Transcription factor
Mismatch repair protein
Transcription factor
Involved in repair, death signaling,
transcription regulation
Transcription factor
Binding facilitated by FACT subunit
SPT16
Transcription factor
Transcription factor
Nucleotide excision repair proteins
Transcription factor
References
18, 82
12, 39
76-81
5, 35, 41, 42
53
14, 62-75
25, 35, 55
83
54
28
19, 57, 59
27, 49, 51
36, 38
15, 17, 61
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Figure 1.1. The four steps of cisplatin anticancer activity.
i) Cisplatin and analogous platinum complexes enter cells by passive and active diffusion mechanisms. ii) The platinum compound is
aquated due to the low intracellular chloride concentration. iii) These positively charged compounds will bind to DNA and form
several bifunctional DNA adducts. iv) The adducts must be repaired for the cell to survive, otherwise cell death mechanisms will be
initiated.
cisplatin-DNA adducts
Intrastrand Interstand
1,2d(GpG) 1,2d(ApG) 1,3-d(GpNpG) d(GpC)
d(CpG)
65% 25% 5-10% 2-3%
i~
i'l ; ... II
1,2-d(GpG)
intrastrand
1,3-d(GpTpG)
intrastrand
d(GpC)/d(CpG)
interstrand
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Figure 1.3. Methodologies developed for the characterization and identification of
proteins with an affinity for damaged DNA.
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Figure 1.4. Platinum compounds with anticancer activity.
Cisplatin (A), oxaliplatin (B) and the reduced form of satraplatin (C) form the same types
of bifunctional adducts with DNA, but contain different ammine ligands which may
influence the recognition of the adduct. The platinum-pyridine compound (D), with only
one chloride leaving group, forms monofunctional adducts with DNA. BBR 2464 (E),
which has one chloride leaving group on each outer platinum atom, forms long-range
bifunctional intrastrand and interstrand adducts.
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Following recognition of DNA damage, a series of cellular signaling pathways are
activated. These damage-response pathways can result in DNA repair or cell death. Several
repair processes have been implicated in response to platinum-damaged DNA. Chief among
these is nucleotide excision repair (NER), which removes platinum adducts from DNAl 2 and is
correlated with cisplatin resistance.13 In addition, E. coli and human cancer cells deficient in
recombination repair pathways are sensitized to cisplatin damage. 4' 15 Inhibition of the mismatch
repair (MMR) pathway correlates with increased resistance to the drugl6 . Proteins involved in
repair processes bind preferentially to cisplatin-DNA adducts, including the Ku70/80 subunits of
the mulitprotein complex DNA protein kinase (DNA-PK)17. The DNA-PK complex participates
in non-homologous end-joining (NHEJ) repair of double-strand breaks (DSB).' 8 These findings
suggest that the identification of proteins that bind to platinum-modified DNA in cells with
varying sensitivities to cisplatin may provide insight into processing of cisplatin adducts in these
different contexts. 19
Studies of the cellular proteins that interact with cisplatin-damaged DNA date back many
years. Early work applied electrophoretic mobility shift assays (EMSAs) to demonstrate that
xeroderma pigmentosum group E binding factor (XPE-BF) binds preferentially to cisplatin-
modified versus unmodified DNA.20 Using EMSAs to identify proteins with an affinity for
platinum-modified DNA would require a separate experiment for each of numerous nuclear
proteins. In another study, use of a cisplatin-modified DNA probe to screen a cDNA expression
library identified the HMG-domain protein SSRPl.10,21 Because SSRP1 contains an HMG
domain that is homologous to domains in HMGB1 (formerly HMG1), it was hypothesized that
the latter would also bind to cisplatin-modified DNA. Following isolation and purification of rat
HMGB1, gel retardation assays revealed that the protein binds to the 1,2-d(G*pG*), but not the
1,3-d(G*pG*), intrastrand cross-link of cisplatin.8 'That HMGB1 and HMGB2 have an affinity
for cisplatin-damaged DNA was also revealed by southwestern blotting methods.9'22 Despite
these successes, however, neither cDNA library screening nor southwestern blotting methods can
gauge protein binding to platinated DNA in the context of multiprotein complexes.
Globally platinated DNA immobilized onto a column treated with nuclear extracts
identified Pt-DNA-binding proteins DNA-PK, HMGBI, replication protein A (RPA), and
xeroderma pigmentosum group A protein (XPA).23 This method requires a sensitive adjustment
of salt concentration to remove proteins with different affinities for the probe. Also, the use of
globally platinated DNA does not distinguish which of many possible Pt-DNA adducts is being
recognized.
A superior method for identifying proteins that bind to platinum-modified DNA utilizes a
cisplatin analogue capable of forming a covalent bond to capture DNA-damage-response
proteins following incubation with nuclear extracts. This method is sensitive to all nuclear
proteins that bind to Pt-modified DNA, affording a more complete assessment. Photo-cross-
linking provides a convenient way to bind the proteins covalently to the platinated DNA, which
can then be isolated for identification.
To achieve this type of photo-cross-linking, we first synthesized a cisplatin analogue
containing a photo-reactive azide moiety. 24 Control experiments performed during this study
showed that cis-{Pt(NH3)2}2+-d(G*pG*) adduct itself was activated by the 302 nm irradiation
required to convert the aryl azide to a nitrene. The aryl azide-modified analogue of cisplatin did
not form photo-cross-links more effectively than the cis- {Pt(NH3)2 2+ adduct alone.24 We also
showed that the cis-{Pt(NH3)2 2+ could be more efficiently activated using a laser at 325 or 350
nm to irradiate the sample. 25 A limitation of experiments using cis- Pt(NH3)2} 2+ as the cross-
linker is that the protein must come into close contact with the platinum atom in order to form a
covalent DNA-Pt-protein linkage. This requirement make it difficult to capture DNA-damage
recognition proteins that recognize the bulge created on the undamaged DNA strand,26 where it
is unlikely to be close enough to the cis- {Pt(NH3)2}2+ adduct to be photo-cross-linked.
In order to cross-link proteins bound to Pt-DNA adducts more effectively, a photo-
reactive benzophenone moiety was tethered to a platinum center. This compound, Pt-BP6,
contains a six-carbon linker separating the platinum complex from the benzophenone (Figure
2.1), a hexamethylene chain proving to be optimal for efficient protein photo-cross-linking.2 7
With an excitation wavelength of 365 nm, benzophenone is an excellent photo-activatable cross-
linker for biological applications. The photophore excitation energy is low enough such that it
does not cause significant damage to biological samples, and benzophenone moieties are not
prohibitively sensitive to background light sources.28
In a preliminary study, we prepared a site-specifically platinated duplex containing a
single 1,2-d(GpG) PtBP6 adduct, exposed it to HeLa nuclear extracts, and irradiated the solution
to activate the benzophenone moiety (Figure 2.2). The protein-platinum-DNA complexes were
isolated using streptavidin-coated magnetic beads (Figure 2.3). Several photo-cross-linked
proteins were observed, two of which were identified as HMGB1 and poly(ADP-ribose)
polymerase-l (PARP-1). 27 Binding to HMGBI was expected, given the results of work reported
in the literature using EMSAs, but the photo-cross-linking of PARP-1 was the first evidence that
the protein has an affinity for platinum-damaged DNA. In the present study, we have optimized
the analytical and preparative photo-cross-linking conditions. We have also increased the scale
of the preparative work, which has allowed us to identify all the proteins that photo-cross-link to
this probe. These experiments were able to identify a complete panalopy of proteins with an
affinity for platinum-damaged DNA.
II. MATERIALS AND METHODS
Solvents and chemical reagents were purchased from commercial sources. Potassium
tetrachloroplatinate(II) was provided by Engelhard. DNA strands were synthesized on an
Applied Biosystems ABI 392 DNA/RNA synthesizer using solvents and reagents supplied by
Glen Research. Enzymes were purchased from New England BioLabs and Promega. UV-vis
spectra were obtained on an HP 8453 UV-visible spectrometer. Platinum analyses were
performed by flameless atomic absorption spectroscopy on a Perkin-Elmer AAnalyst 300
system. Analytical and preparative HPLC work was performed either on an HP Waters or an
Agilent 1200 HPLC system. UV irradiation was conducted in a Stratagene Stratalinker UV
Crosslinker. Protein digestion and analyses were performed by trypsin digestion-coupled LC-
MS/MS analysis at the MIT Biopolymers facility. Antibodies used in western blot experiments
were purchased from Axxora Life Sciences
Cell culture
HeLa cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) with 10%
fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 C under 5% CO 2. Once growth
reached -80% confluence, cells were trypsinized and passed or collected. Cells between
passages 4 and 18 were collected and used for preparing nuclear extracts.
Nuclear extraction
In a typical extraction, a cell pellet from 5 x 175 cm 2 plates was used. Cells were
collected and pelleted at 1000 rpm for 5 min. Cell pellets were washed with ice cold sterile PBS
(10 mM Na2HPO 4 pH 7.4, 137 mM NaC1, 2.7 mM KC1) twice at five times the pellet volume.
Pellets were resuspended in five times the pellet volume of lysis buffer (10 mM HEPES pH 7.9,
10 mM KC1, 1.5 mM MgCl 2, 1 mM DTT, 1 mM PMSF) and incubated for 15 min on ice. Pellets
were centrifuged at 450 g for 5 min and resuspended in 2X volume of lysis buffer. The cells
were lysed through a 26 3/8-gauge needle 10 times. The lysates were centrifuged at 11,000 g for
20 min and resuspended in two-thirds the cell pellet volume of extraction buffer (20 mM HEPES
pH 7.9, 25% glycerol, 400 mM NaC1, 0.5 mM EDTA, 1.5 mM MgCl 2, 1 mM DTT, 1 mM
PMSF). The pellets were lysed again with a needle. The lysate was incubated at 40C for 30 min
with gentle mixing and centrifuged at 18,4000 g for 10 min. The supernatant containing the
nuclear extracts was removed and the protein content quantified by the BCA Assay. Nuclear
extracts were stored at -80 oC. Between 0.5 - 1 mg of protein was obtained from each 175-cm 2
plate. For preparative scale photo-cross-linking experiments, 4 mg of nuclear extracts was
required; nuclear extracts from 4-8 x 175 cm2 plates were used.
Synthesis of PtBP6
The compound cis-[Pt(NH 3)(N-(6-aminohexyl)-4-benzophenonamide)C 2] (PtBP6) was
synthesized as reported previously. 27 The synthesis was repeated in this work and reported here
for completeness (Scheme 2.1).
Synthesis of cis-Diamminediiodoplatinum(II) (1)
To a stirring solution of K2PtC14 (4.00 g, 9.59 mmol) in 25 mL warm water was added KI
(6.63 g, 39.7 mmol) in 2 mL of water. The solution was stirred and heated slowly to 600 C and
NH40H (4.0 mL, 31.0 mmol) was added slowly. A yellow precipitate formed almost
immediately. The solution was filtered and dried under vacuum to give 91% yield of 1 (4.21 g,
8.72 mmol).
Synthesis of cis-Diamminedichloroplatinum(I) (2)
To a stirring suspension of 1 (2.01 g, 4.16 mmol) in 20 mL water was added AgNO 3
(1.42 g, 8.36 mmol). The solution was heated to 60 C for 10 min with gentle stirring. Solid AgI
was removed by filtration and KC1 (0.70 g, 12.0 mmol) was added to the filtrate with gentle
stirring. The solution was stirred for 10 min and 2 was removed by vacuum filtration. The yellow
solid was washed with ice-cold water, ethanol and ether and dried in air to give a 72% yield of 2
(0.89 g, 3.0 mmol).
Synthesis of (Ph4P)[PtCl3(NH3)] (3)
A portion of 2 (0.52 g, 1.7 mmol) and tetraethylammonium chloride (0.29 g, 1.8 mmol)
were dissolved in 120 mL dimethylacetamide. The solution was stirred and heated to 1000 C with
nitrogen bubbling through it for six h. Over this period, the solutionevaporated to a volume of
20 mL. Then 360 mL of 1:1 ethyl acetate/hexanes was added and a yellow precipitate formed
immediately. The solution was stored at -24oC overnight. The filtrate was decanted, and the
remaining yellow solid was dissolved in 50 mL of water. Unreacted 2 was then removed by
filtration and tetraphenylphosphonium chloride (0.65 g, 1.733 mmol) in 2 mL of water was
added to the yellow filtrate. The solution was stirred for four h, followed by vacuum filtration to
remove 3 (0.6898 g, 1.049 mmol) in a 61% yield.
Synthesis p-Benzoylbenzoic acid N-hydroxysuccinimide ester (4)
The synthesis of 4 has been previously established. 29 N-hydroxysuccinimide (0.86 g, 7.5
mmol), 4-benzoylbenzoic acid (1.68 g, 7.50 mmol) and 1,3-dicyclohexylcarbodiimide (1.64 g,
7.96 mmol) were combined in 80 mL of acetonitrile and stirred in the dark overnight. A white
solid was filtered out and the solvent was removed by rotary evaporation. Compound 4 was
collected in 51% yield and characterized by TLC (Rf = 0.35 in 1:1 ethyl acetate/hexanes).
Synthesis of [(4-Benzoyl-benzoylamino)-hexyl]-carbamic acid tert-butyl ester (5)
Tert-butyl-N-(6-aminohexyl)carbamate hydrochloride (0.60 g, 2.4 mmol) was stirred in
25 mL of dichloromethane to which 4 (0.77 g, 2.4 mmol) in 10 mL of dichloromethane was
added. Upon dissolution of these two reactants, triethylamine (1.50 mL, 10.7 mmol) was added.
The solution was stirred overnight in the dark. The solvent was removed by rotary evaporation
and the resulting white solid was purified by silica gel chromatography. Rf = 0.30 (95:5
dichloromethane/methanol). The solvent of the eluate was removed by rotary evaporation to
afford 5 in an 81% yield (0.82 g, 1.9 mmol). The product was characterized by 'H NMR
spectroscopy; (CDCl3): d7.93 (2H, d), 7.83 (4H, m), 7.60 (1H, m), 7.50 (2H, m), 6.59 (1H, t, br),
4.57 (1H, t, br), 3.47 (2H, m), 3.15 (2H, m), 1.78 - 1.25 (17H, m). The results agreed with
published data for this compound.27
Synthesis of N-Aminohexyl-4-benzoyl-benzamide (Sb)
To a solution of 5 (0.31 g, 0.72 mmol) in 5 mL chloroform was added trifluoroacetic acid
(1.00 mL, 13.0 mmol). The solution was stirred overnight in the dark. The solvent was removed
by rotary evaporation. The remaining solid was dissolved in 50 mL of ethyl acetate to which 75
mL IM NaOH was added. The solution was shaken three times in a separatory funnel and the
organic layer was removed with ethyl acetate. The solvent was removed by rotary evaporation
and the remaining white solid was purified by silica gel chromatography. Rf (impurity) = 1.0, Rf
(5b) = 0.20. The solvent was removed by rotary evaporation to give a 47% yield of product
(0.5376g, 1.657 mmol). The white solid was characterized by 1H NMR; (CDCl3): d7.90 - 7.75
(6H, m), 7.61 (1H, m), 7.50 (2H, m), 6.25 (1H, br), 3.49 (2H, m), 2.72 (2H, m), 1.79 - 1.20
(10H, m). This data agreed with previously published results.27
Synthesis of [PtC!2(NH)2(BP6)] (6)
Sodium tetraphenylborate (0.43 g, 1.3 mmol) and 3 (0.86 g, 1.3 mmol) were stirred in
100 mL of methanol for ten min. The compound (Ph4P)(BPh 4) precipitated as a white solid and
was removed by filtration. 10 mL of water was added to the yellow filtrate and the filtrate was
slowly reduced to about 10 mL by rotary evaporation. A portion of 5b (0.50 g, 1.5 mmol) was
added in 5 mL of ethanol. The solution was stirred overnight in the dark. The solvent was
decanted leaving a tan precipitate in the flask. The solid was dissolved in 5 mL
dimethylformamide to which 35 mL of water was added and the solution was put on ice for 30
minutes. The solution was then centrifuged for 30 minutes at 4000 rpm and 40 C. The solvent was
decanted and 35 mL of water was added. The suspension was then centrifuged again under the
same conditions. The water was decanted and the tan solid was dried by lyophilization. The
product (0.10 g, 0.17 mmol) was collected at 13% yield and characterized by 'H NMR; (DMF-
d-): d8.70 (IH, t), 8.13 (2H, d), 7.84 (4H, m), 7.73 (1H, m), 7.61 (2H, m), 4.85 (2H, t, br), 4.25
(3H, t, br), 3.44 (2H, m, partially buried by H20 peak), 2.78 (2H, m, buried under DMF signal),
1.80 -- 1.20 (8H, m). These data agree with previously published results.27
DNA Synthesis
5'-CCTCTCCTCTCAGGATCTTCTCTCC-3' and its complementary strand were
synthesized on ABI DNA/RNA synthesizer on a 1 jpmole scale. For preparative-scale photo-
cross-linking experiments, DNA containing a 3'-biotin-TEG moiety was synthesized and
platinated. The DNA was incubated overnight at 550 C in 30% ammonium hydroxide. DNA
strands were purified by 12% urea denaturing PAGE and visualized by UV shadowing. The
DNA was then isolated from the gel using the crush and soak method. DNA-containing gel
pieces were broken up with a spatula and incubated overnight at 370C with mixing in soaking
buffer (10 mM Tris HCI pH 7.3, 50 mM NaCl, 1 mM EDTA). The gel was then filtered from
DNA and the solution was ethanol precipitated. The DNA pellet dissolved in water and dialyzed
against water using dialysis tubing with a molecular weight cutoff of 3500.
Preparation of a 25 base DNA containing a site-specific PtBP6 adduct
To a solution of PtBP6 dissolved in 90 gL of DMF was added 1.9 molar equivalents of
AgNO 3 dissolved in 10 gL of water. The solution was protected from light and vortexed for 4 h
at room temperature. The solution was then centrifuged to separate precipitated AgCl from the
activated platinum complex. To a 10 1tL aliquot of the solution is added 1 jiL of 5 M NaCl. No
precipitate formed, demonstrating that all of the silver had been removed from the solution. The
25-bp DNA was dissolved in 10 mM Na 2HPO4 pH 6.3. To this solution was added 2 molar
equivalents of activated PtBP6. The solution was incubated overnight at 37 'C in the dark with
mixing.
The PtBP6-modified 25 base DNA was purified by IE-HPLC. The eluant was a gradient
of 40-50% B over 30 min at 45 OC, where solvent A was 90/10 water/acetonitrile, 0.025M
TEAA, pH 6.8 and solvent B was A + 1 M NaCl. The 25 base DNA containing a 1,2-d(GpG)
adduct of PtBP6 eluted at 25.4 min. The peak was collected and lyophilized. The product was
resuspended in water and dialyzed against water, MWCO 3500. In a typical purification, 5 nmol
of platinated DNA was collected, a 17% yield.
Characterization of 25 base DNA containing a 1,2-d(GpG) adduct ofPtBP6
Each collected peak was characterized by UV-visible absorbance and atomic absorption
spectroscopy to establish a 1:1 ratio of platinum per DNA strand. The collected peaks were
characterized by ESI-MS to confirm that both chloride ligands were replaced by Pt-DNA bonds.
Platination of the guanine bases was verified by enzymatic digestion of the DNA. The
digests consisted of 20 tL 100 mM NaOAc (pH 5.2), 1 gL 100 mM ZnC12 , 10 gL nuclease P1,
and 150 pmol DNA. The total reaction volumes were increased to 100 gL with ddH20. The
solutions were mixed thoroughly and incubated at 37 "C overnight. Next, 5 gL of 1.5 M Tris-
HCI (pH 8.8) and 1 gtL of calf intestinal phosphatase (CIP) was added. After a 4-h incubation at
37 "C, the samples were centrifuged at 5000 rpm for 5 min. The supernatants were analyzed by
RP-HPLC using a Supelcosil LC-18-S column. The eluant was a gradient of 5 - 15% B over 30
min, 15 - 80% B over 10 min, and 80% B for 5 min, where solvent A was 100 mM NaOAc, pH
5.2, and solvent B was methanol. PtBP6 was activated as described above and allowed to react
with deoxyguanosine overnight, followed by analysis with this HPLC methodology. This
experiment was carried out to determine the elution of the compound PtBP6-(dG) 2, a likely
product of the nuclease digestion of the platinated 25-base DNA, under these HPLC conditions.
The platination of the guanines was also verified by the four Maxam-Gilbert sequencing
reactions.
G reaction: A 1.5 jiL portion of radiolabeled DNA was combined with 14.5 gtL of water
and 200 1tL of DMS Buffer (50 mM sodium cacodylate pH 7.0, 1 mM EDTA pH 8.0). A I gL
aliquot of dimethyl sulfate was then added and the reaction was incubated at room temperature
for 5 minutes. Then a 50 [tL portion of DMS stop solution (1.5 M sodium acetate, 1 M
mercaptoethanol, 250 gg/mL salmon sperm DNA) was added.
A+G reaction: A 3 gL portion of DNA was combined with 13 tL of water and 25 gL of
formic acid. The reaction was incubated at room temperature for 5 minutes. Then a 200 tL
aliquot of stop solution #2 (0.3 M sodium acetate pH 7.0, 0.1 mM EDTA pH 8.0, 100 glg/mL
salmon sperm DNA) was added.
C+T reaction: A 16 gL aliquot of DNA was combined with 10 jtL of water and 30 tL of
hydrazine. The solution was incubated at room temperature for 15 minutes. Then a 200 gL
portion of stop solution #2 was added.
C reaction: A 9.5 tL aliquot of DNA was combined with 6.5 jiL of 5 M NaCi and 10 tL
of water. This solution was then incubated with 30 jtL of hydrazine for 15 minutes followed by
the addition of 200 gLL of stop solution #2.
All reactions: After each of these steps was completed, to each reaction was added 750
tL of ice-cold ethanol, and each was cooled on dry ice for 30 minutes. Each was then
centrifuged at 1350 rpm and -4'C for 30 minutes. Each sample was then ethanol precipitated
once more and dried in the vacufuge. To each reaction was then added 75 JiL of 1:9
piperidine/water and heated to 900 C for 30 min. The reactions were then dried in the vacufuge,
washed with 45 jtL of water and dried again twice in the vacufuge. Platinated probes were then
treated with 50 gL of 0.2 M NaCN at 370 C overnight, followed by another ethanol precipitation.
The reactions were then analyzed by 20% urea-denaturing PAGE.
Radiolabeling of 25 base DNA
In an eppendorf tube, 50 pmol of DNA was combined with 3 gtL of 10X PNK Buffer
(700 mM Tris-HC1, 100 mM MgCl 2, 50 mM DTT, pH 7.6), 3 gL of y- 32 P-ATP (Perkin-Elmer)
and 1 tL of T4 PNK (New England Biolabs). The solutions were diluted to 30 tL and incubated
at 370 C for 2 h. The solutions were then purified by Sephadex G-25 spin columns (GE
Healthcare), ethanol precipitated, and dried by vacuum centrifugation.
Synthesis of duplex probes
Equimolar amounts of PtBP6-modifed top strand and unmodified bottom strand were
combined in 50 gL of NEBuffer 3 (New England BioLabs, 50 mM Tris-HCl pH 7.9, 100 mM
NaCi, 10 mM MgC12, 1 mM DTT). For preparative-scale photo-cross-linking, 500 pmol
unradiolabeled DNA were used, and for analytical-scale photo-cross-linking, 50 pmol of
radiolabeled DNA was used. The solutions were heated to 90 'C for 5 min, cooled to 16 oC over
3 h. The solution was then ethanol precipitated and dried by vacuum centrifugation. The DNA
was then purified by 15% native PAGE and located using either audioradiography for
radiolabeled DNA or UV shadowing for unlabeled DNA. The DNA was isolated by using the
crush and soak method and the purity of the oligonucleotide was verified by 15% native PAGE.
Optimization of analytical-scale photo-cross-linking with a 1, 2-d(GpG)-PtBP6 probe
In a typical analytical-scale photo-cross-linking reaction, 1 pmol of 1,2-d(GpG)-PtBP6-
modified double-stranded radiolabeled DNA was combined with 20 jig of HeLa nuclear extracts
in 20 gL of protein binding buffer (10 mM Tris pH 7.5, 10 mM KC1, 10 mM MgCl2 , I mM
EDTA, 0.05% NP-40, 0.2 jig/mL BSA). The solution was incubated on ice and then exposed to
UV irradiation. Irradiation was performed by using NEC FL8BL 8W bulbs, which provide a
maximum at 360 nm with minimal output at 300 nm
(http:/!www.nelt.co.jp/english/iproducts/safl/). The latter wavelength could potentially labilize the
platinum-DNA bonds. The cross-linking was then analyzed by 10% SDS-PAGE with a 4%
stacking gel. The irradiation time was varied between 0, 5, 30, 60, 90 and 120 min. The
incubation time was varied between 0, 30, 60, 120, 240 and 360 min. The temperature was
varied between 4'C, 25°C and 37°C.
Optimization of preparative-scale photo-cross-linking ofprobes
Into four eppendorf tubes were added 20 tg of HeLa nuclear extracts and 28.5 jL of
binding buffer. This mixture was added to 0.5 mg of streptavidin-coated magnetic beads and the
solution was vortexed thoroughly. The tubes were placed on a magnetic rack and the supernatant
was removed. The beads were then vortexed in 100 pL of wash/binding buffer (5 mM Tris pH
7.5, 0.5 mM EDTA, 1 M NaCI) and put back on the magnetic rack to separate the supernatant
from the beads again. This washing process was repeated 0, 2, 5 or 10 times for each eppendorf
tube. After the final supernatant was removed, to each sample was added 50 jL of gel-loading
solution (125 mM Tris-HCI pH 6.8, 40% glycerol, 4% SDS, 10% 3-mercaptoethanol). The
solutions were heated to 90 oC for 10 min and then the supernatant was isolated immediately
using the magnetic test tube stand. To denature the samples, they were heated to 900 C for 5 min
and then cooled immediately on ice. The cross-links were then separated by a 4-20% BioRad
pre-cast SDS-PAGE gel. The gel was removed from the gel box and soaked for I h in destain
solution (10% methanol, 7% acetic acid, 83% water by volume). The gel was soaked in Sypro
Ruby Gel Stain (Cambrex) overnight and then soaked in destain solution for 1 h. The gel was
then wrapped in plastic wrap and analyzed by a BioRad FluorS Multimager scanner exciting at
450 nm.
Preparative scale photo-cross-linking
To 100 pmol of unradiolabeled duplex in 100 gL of binding buffer was added 2 mg of
HeLa nuclear extract. The reaction mixtures were irradiated for 2 h on ice. To each reaction
mixture was then added 5 mg of streptavidin-coated magnetic beads (Dynabeads, Invitrogen),
and the solutions were incubated with mixing for 20 min at 4 OC. To the solution was then added
400 gL of 2X elution buffer (50 mM Tris-HC1, 10 mM DTT, 1% SDS, pH 7.9) and the mixture
was incubated with agitation for 20 min at 4 oC.
The supernatant was then removed from the beads using a magnet. The beads were
washed four times with high salt buffer (5 mM Tris-HC1, 500 M EDTA, 1 M NaCl, pH 7.5),
each time the supernatant was removed using the magnet. The beads were then washed five
times with iX elution buffer, again each time removing the supernatant using the magnet. After
the fifth elution buffer wash was removed, 40 [L of 2X SDS-PAGE loading buffer (100 mM
Tris-HC1, 20 mM DTT, 2% SDS, 30% glycerol, 0.1% bromophenol blue, pH 7.9) was added to
the solution. The solution was heated to 90 'C for 10 min to dissociate the biotinylated DNA
from the beads and the supernatant was quickly removed using the magnet. The samples were
then resolved by 12% SDS-PAGE with a 4% stacking gel. Following electrophoresis, the gel was
removed from the plates and the lanes containing the preparative scale photo-cross-linking
products were separated from the rest of the gel using a blade. These lanes were then soaked in
Coomassie Blue R-250 for 1 h and destained in 10% methanol, 7% glacial acetic acid, 83%
ddH 20 2 times for I h each.
The bands were located using the results from the radioactive analytical scale cross-
linking experiment as a guide. Molecular weight ladders were run on both gels, so that the
locations of each band on the gel could be precisely estimated prior to excision. Bands were
excised from lanes containing PtBP6-platinated DNA as well as unplatinated DNA. The excised
bands were analyzed by trypsin digest-coupled LC-MS/MS. The peptide fragments were then
processed by SEQUEST protein analysis software to identify the parent proteins. 30
The proteins present in the lane containing the unplatinated DNA were eliminated from
the list of those found in the lane with the PtBP6-platinated DNA. Proteins were scored as
binding to the platinated probe only if they occurred in two repetitions of the photo-cross-linking
experiments. In accordance with suggested guidelines for the identification of proteins by trypsin
digest-coupled mass spectrometry,3 1 the proteins identified were only accepted if they met the
criteria of low probability of coincidental identification (P < 1.0 x 10-3) and/or multiple unique
matching peptides found. "Unique peptides" were defined as having entirely different sequences
from one another; two peptides differing only by a modified amino acid were scored as being
identical.
III. RESULTS
As described in a preliminary report,27 a 25-bp duplex containing a 1,2-d(GpG)
intrastrand cross-link of the photo-active cisplatin analogue PtBP6 was prepared and
characterized. This probe was used to photo-cross-link proteins with an affinity for platinum-
modified DNA (Figure 2.2). Most of the proteins that bind to this probe were previously
unidentified, and cross-linking conditions were optimized here in order to characterize them.
Synthesis and characterization of cis-[Pt(NH3)(N-(6-aminohexyl)-4-
benzophenonamide) C2] (PtBP6)
PtBP6 was synthesized in seven steps and characterized as previously reported.27 1H
NMR spectroscopic analysis of the final product indicated that the desired compound was pure
(Figure 2.4).
Synthesis and characterization of a 25 base 1, 2-d(GpG) intrastrand probe
A 25 base DNA containing a 1,2-d(GpG) intrastrand cross-link of PtBP6 was synthesized
as reported previously. 27 The purification did not afford significant separation of the orientational
isomers27'32 of PtBP6-modified DNA by RP-HPLC (Figure 2.5), and a mixture of the two isomers
was used for these studies. Following purification, the collected peak was dialyzed to remove salt
using a molecular weight cutoff of 3500. In a typical purification, 5 nmol of platinated DNA was
collected, a 17% yield. The ratio of bound platinum atoms per DNA fragment was determined to
be 0.99 _ 0.10.
Nuclease digestion analyses of the platinated probe (Figure 2.6) confirm that the platinum
atom is bound to both guanine bases. The expected ratio of C:G:T:A for the unplatinated 25 base
DNA was 12:2:9:2, and the experimental ratio was 11.9:2.1:9.1:2.0 (Figure 2.6A). For the
platinated probe, the experiment revealed 11.9:0.4:9.1:1.6 (Figure 2.6B). These data indicate
that, following nuclease digestion of the platinated DNA, the signal for guanosine is muted. The
signal for adenosine is also slightly less intense, suggesting the possibility of some d(ApG)
platination. In the digestion of cisplatin-modified DNA, described in Appendix A, the digested
platinum-nucleobase products elute during the HPLC gradient. PtBP6-nucleobase complexes
may exhibit stronger retention on the column, because no new peaks are present in the trace
(Figure 2.6B). To confirm that the platinum-containing products of this digestion should not
elute during the run, activated PtBP6 and deoxyguanosine were allowed to react and the resulting
complexes were analyzed using the same HPLC methodology (Figure 2.7). The products of the
reaction elute at about 43 min (Figure 2.7B), during the washing sequence of the HPLC run. This
is likely due to the benzophenone moiety and six-carbon chain on PtBP6 (Figure 2.1), which will
interact favorably with the C18 column. The peak for guanosine was not completely depleted by
the binding of PtBP6 to the base (Figure 2.6B), so it was necessary to ensure that the platinum
was bound to the DNA in a bifunctional manner by mass spectrometric analysis.
The purified DNA is bound to the DNA in a bifunctional manner, as indicated by ESI-
MS (Figure 2.8). The platinum-modified DNA has a calculated value of 7967.4 m/z, and ESI-MS
revealed an experimental value of 7967.2 ± 1.64 m/z. A monofunctional adduct would require
another ligand to fulfill the coordination of the platinum, which would be evident by an increase
in the molecular weight of the complex. Maxam-Gilbert analysis of the platinated DNA (Figure
2.9) confirms that the platinum is bound to the N7 of guanine, since it is able to block the
Maxam-Gilbert G reaction of dimethyl sulfate (Figure 2.9C). The ability of the Maxam-Gilbert
AG reaction to access the guanosine bases was also compromised by platination. These three
methods conclusively demonstrate that the product of the reaction is a 25-base DNA containing a
1,2-d(GpG) cross-link of PtBP6.
Duplex 25-bp probes
Radiolabeled 25-bp duplex probes were prepared in approximately 70% yield, an
estimated value since UV-vis measurements were not taken on the radioactive material. The
double-stranded constructs could be well separated from single-stranded material by native
PAGE, and the ImageQuant gel analysis program was used to determine that their purity was
approximately 100% (Figure 2.10). For preparative-scale photo-cross-linking experiments,
unradiolabeled 25-bp duplex probes were prepared. Following purification, 455 pmol of the
unplatinated 25-bp duplex and 379 pmol of the 25-bp duplex containing a 1,2-d(GpG) intrastrand
adduct of PtBP6 were isolated. These values correspond to 91% and 76% yields, respectively.
Analytical-scale photo-cross-linking of a 25-bp duplex containing a 1,2-d(GpG) adduct
of PtBP6
Analytical-scale photo-cross-linking afforded a number of bands corresponding to
protein-platinum-DNA complexes containing different covalently-bound proteins. The
parameters used for analytical-scale photo-cross-linking were analyzed. Varying the UV-
irradiation time indicates that the maximum photo-cross-linking occurs at the full 120 min
irradiation (Figure 2.11). By varying the pre-irradiation incubation time, we observed that little
incubation time was required prior to UV-irradiation to achieve maximum photo-cross-linking
(Figure 2.12). Incubation and photo-cross-linking at temperatures higher than 4oC revealed that
the proteins are degraded significantly under these conditions (Figure 2.13).
Analysis ofprotein retention on streptavidin-coated magnetic beads
Incubation of the streptavidin-coated magnetic beads with nuclear extracts revealed
significant retention of proteins onto the beads. Subsequent washing of the beads with high salt
buffer was able to remove most of these proteins (Figure 2.14). These washing conditions were
used for preparative-scale photo-cross-linking experiments. Some protein still remains even after
10 washes. These proteins are identified in the control experiments outlined below and are listed
in Table 2.2.
Preparative-scale photo-cross-linking of a 25-bp duplex containing a 1,2-d(GpG)
intrastrand PtBP6 adduct with HeLa nuclear extracts
The PtBP6-modified DNA was irradiated in the presence of HeLa nuclear extracts to
generate covalent bonds between the benzophenone moiety of the platinum compound and any
proteins in the vicinity of the damage site. The DNA-to-protein ratio was adjusted to be the same
for both preparative-scale preparative and analytical-scale experiments. After immobilization of
the biotinylated DNA-platinum-protein conjugates on streptavidin-coated magnetic beads, the
complexes were washed thoroughly with high salt and SDS-containing buffers to remove any
non-covalently bound proteins. SDS-PAGE analysis was performed on a slab gel to obtain better
separation of proteins. An analytical-scale photo-cross-linking experiment was run in parallel to
the preparative-scale experiment as a guide for excising DNA-platinum-protein complexes, as
shown in Figure 2.15. Mass spectral analysis of the preparative-scale photo-cross-linking
experiment identified a number of proteins in each of the six major bands on the analytical gel
(Table 2.1), including the DNA repair proteins PARP-1, DNA ligase III, Msh2, and all three
members of the DNA-PK heterotrimer, as well as HMG-domain proteins HMGB , HMGB2,
HMGB3 and UBF1.
A control lane containing unplatinated DNA was included in the preparative scale photo-
cross-linking experiment. Proteins identified in this control lane (Table 2.2), as well as proteins
for which the molecular weight was inconsistent with the band location, were excluded from the
list in Table 2.1, which reports the results of three repeats of preparative-scale photo-cross-
linking experiments. In the table, the "Band" column refers to the relative mobility of the
protein-platinum-DNA complex through the gel, with 1 being the fastest migrating species. The
"Unique Peptides" column reports the number of individual peptide fragments matching those
expected from the known protein sequence. Peptides differing by only one amino acid were not
considered to be unique. The "Probability" column assigns a number to each protein based on the
likelihood of a coincidental match of the best unique peptide for each protein. For example, three
unique peptides were found that correspond to the protein UBF 1. One of these peptides,
RQLQEERPELSESELTRL, produced MS/MS data with a probability of 7.96 x 10-7 , meaning
there is a 0.0000796% probability that this identification is an artifact due to background.
Peptides with probabilities of 1.0 x 10-3 or higher were not accepted.
IV. DISCUSSION
Since the discovery that cisplatin targets DNA, much effort has been expended to identify
proteins with an affinity for the platinated duplex. In the present study, we prepared and
characterized a site-specifically modified 25-bp duplex containing a 1,2-d(GpG) intrastrand
cross-link bearing a pendent photo-activatable benzophenone. Upon irradiation, these probes
form covalent bonds between the platinated DNA and any proteins in a nuclear extract with an
affinity for the adduct. Isolation of the DNA-platinum-protein complexes followed by trypsin
digestion and mass spectrometric analysis allowed the proteins to be identified. Unlike
southwestern blotting and other techniques, the present approach exposes the platinated DNA to
multiprotein complexes. The method requires proteins to compete for binding to the probe, thus
providing a more realistic assessment of the cellular milieu. Although cisplatin itself can cross-
link proteins, in order to form such a covalent bond a protein would have to be in very close
proximity to the adduct. 24 ,33 PtBP6 probes utilize a photo-reactive moiety with a six-carbon atom
linker chain, allowing for a larger number of DNA-bound proteins to be captured. Our probes
also can carry site-specific platinum adducts such that proteins having an affinity for a specific
cross-link can be analyzed.
Optimization ofphoto-cross-linking experiments
The parameters for photo-cross-linking were optimized. UV-irradiation time-dependent
experiments (Figures 2.10) revealed that the samples should be irradiated for 2 h prior to
resolving them by SDS-PAGE. Incubation time-dependent experiments (Figure 2.12) indicated
that a pre-irradiation incubation is unnecessary, and samples can be irradiated immediately after
the DNA and proteins are combined. Temperature-dependent experiments (Figure 2.13)
emphasized the need to keep the samples on ice throughout processing, otherwise the proteins
will degrade significantly.
Preparative-scale experiments were optimized to ensure the removal of non-covalently
bound proteins from the streptavidin-coated magnetic beads. This was achieved by washing the
beads with high salt (Figure 2.14) and SDS-containing buffers prior to resolution by SDS-PAGE.
Control experiments using unplatinated DNA are able to identify many proteins (Table 2.2).
These proteins are present because of binding to the streptavidin-coated magnetic beads that is
not compromised using our washing methods, or as background signal from the LTQ mass
spectrometry instrument. This could be due to a phenomenon known as carryover, described
below. The protein-to-DNA ratio was kept constant between the analytical and preparative-scale
experiments to ensure the same protein-platinum-DNA complexes that can be visualized in
analytical-scale experiments (Figures 2.14) were formed in both types of experiment.
Protein carryover
Many of the proteins identified in the photo-cross-linking experiments conducted in this
study (Table 2.1) appear in more than one band. This phenomenon occurs for a number of
reasons. During photo-cross-linking and subsequent work-up steps, the samples were kept at low
temperatures whenever possible. Despite these efforts, some protein degradation is inevitable.
Degraded proteins travel down the gel more rapidly and the fragments appear in faster eluting
bands. The nature of trypsin-digest coupled mass spectrometric analysis does not distinguish
between full-length proteins and protein fragments. For example, a small amount of DNA-PKcs, a
protein that is clearly identified in the slowest eluting band (Figure 2.15, Band 6), also occurs to
a lesser degree in the three bands just below. Another common problem with trypsin-digest
coupled mass spectrometry is a phenomenon known as carry-over. The instrumentation is
extremely sensitive, able to detect attamole quantities of peptides, and very small amounts of
protein from one run can be carried over into the next.
Even with 2 mg of nuclear extracts used for photo-cross-linking, only the band containing
DNA-PKCs is distinctly visible by Coomassie staining. Since the analytical-scale photo-cross-
linking must be used as a guide to excise bands that run extremely close together on the gel,
some overlap of excised bands is inevitable. The methodology was able to isolate and identify a
band containing DNA-PKcs and one containing HMGB 1, HMGB2, and HMGB3. The other
bands were labeled based on molecular weight and experiments carried out on Chapter 3.
Detection limits ofphoto-cross-linking
The instrument used to detect proteins is a Thermo Electron Model LTQ Ion Trap mass
spectrometer connected to an Agilent Model 1100 Nanoflow HPLC system. This type of
instrument should be able to detect peptides at an attamole range. One attamole is 6.022 x [10
molecules. Each reaction in these experiments contains 2 mg of nuclear extracts. This amount of
extracts are prepared from approximately 6 x 107 HeLa cells. Even if a protein is expressed at
one copy per cell, there would be 100 times the detection limit present in the reaction. The
binding of proteins to DNA is an equilibrium, however, the equilibrium is disturbed by photo-
cross-linking, since a covalently bound protein will no longer be able to dissociate from the
probe. Any protein bound to the DNA, no matter what the abundance, will be permanently
photo-cross-linked. Even a protein with very low abundance should be above the detection limit
of the instrument. These calculations indicate that this method is able to detect the complete
panoply of proteins that bind to platinum-modified DNA.
Consideration qf the end effect
One concern of this present study is that proteins that recognize the ends of the 25-bp
duplex may be photo-cross-linked together with those that bind specifically to the platinum
lesion. The DNA-PK heterotrimer, for example, is involved in the repair of DNA double strand
breaks through the nonhomologous end-joining pathway.34 Although the Ku proteins, which
comprise two thirds of the DNA-PK heterotrimer, have previously been associated with cisplatin
adducts,"7 Ku-binding to DNA ends would probably extend far enough down the duplex to reach
the platination site. 35 Another photo-cross-linked protein that may be involved in double-strand
break repair is PARP-1. Evidence that this protein is bound to the platinum adduct and not the
DNA ends is discussed in Chapters 3 and 4.
PtBP6 versus cisplatin adducts
All of the proteins cross-linked, with the exceptions of PARP-1, DNA ligase III, and
HMGB3, have been previously associated with cisplatin-damaged DNA. This finding is
consistent with the notion that cis- {Pt(NH 3)(N-(6-aminohexyl)-4-benzophenonamide)} 2 -DNA
cross-links are being processed in a manner identical to that of the cis-[Pt(NH 3)2]2+-DNA
adducts. HMGB3 contains two tandem HMG domains,36 similar to HMGB1 and HMGB2, and
its affinity for platinum-modified DNA was not unexpected. The fact that the ammine/alkyl
amine platinum complex PtBP6 behaves like cisplatin is relevant to the mechanism of the orally
available platinum(IV) compound cis,trans,cis- [Pt(NH3)(cyclohexylamine)(acetato) 2C1, ,
satraplatin, which is undergoing clinical trials for hormone resistant prostate cancer. Satraplatin
is reduced to platinum(II) in blood, and in cells the cis-{Pt(NH3)(cyclohexylamine)}1 + cation is
expected to be the DNA-binding moiety.3237 DNA adducts made by satraplatin are apparently not
recognized by mismatch repair proteins.38 Our present results suggest that its adducts, containing
a pendent cyclohexylamine similar to the BP6 ligand, may be processed by the cell in a manner
comparable to that of cisplatin.
DNA repair proteins
Proteins involved in DNA repair processes were identified by these photo-cross-linking
experiments. Included are the nonhomologous end-joining heterotrimer DNA-PK, mismatch
repair protein Msh2, PARP-1, and DNA Ligase III, which have been implicated in base excision
repair and nonhomologous end-joining. The DNA-PK heterotrimer and Msh2 have been
previously reported to bind to cisplatin-modified DNA and the significance of this affinity has
been discussed in the literature and in Chapter 1.1739'40 The affinity of PARP-1 for platinum-
modified DNA was not established prior to these experiments,27 and the importance of this
interaction will be discussed further in Chapter 5. DNA Ligase III was most likely photo-cross-
linked in these experiments due to a close association with PARP- 1.4
HMG-domain proteins
HMG-domain proteins HMGBI, HMGB2, HIMGB3, and UBF1 were also identified
using this methodology. The interaction of UBFI with platinated DNA has been reported" and is
discussed in Chapter 1. Detailed studies of the binding of HMGBI to cisplatin-modified DNA
are available in the literature42 and are discussed in greater detail in Chapter 1. HMGB3,
originally named HMG4, contains two HMG domains and an acidic C-terminal tail shorter than
those of HMGB 1 and HMGB2.36 The platinated DNA-binding properties of HMGB3 have not
been investigated previously. Due to its homology with HMGB 1 and 2, the affinity of HMGB3
for platinum-damaged DNA is not surprising. HMGB3 is expressed at high levels during
embryonic development, and adult tissues often have little or no expressed protein.36 HMGB3 is
differentially expressed, though not to a significant degree, in platinum-resistant versus sensitive
ovarian tumors.4 3 Based on these data and the results of the photo-cross-linking experiment,
HMGB3 most likely plays a very small role, if any, in cisplatin cytotoxicity since its structure
and activity is nearly identical to the more abundant HMGB 1 and HMGB2 proteins.
V. CONCLUSIONS
Methodology for the photo-cross-linking and identification of proteins with an affinity
for platinum-modified DNA has been established. These studies were able to identify several
nuclear proteins. The binding of the nuclear protein PARP-I to platinum-modified DNA had not
been previously established and has led to more detailed research into the mechanism of this
protein as a mediator of cisplatin cytotoxicity, detailed in Chapter 5. This research also provides
a basis for using this photo-active cisplatin analogue to study other types of platinum-DNA
adducts, detailed in Chapter 3.
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VII. TABLES
Table 2.1: Proteins identified by preparative scale photo-cross-linking of a 25-bp duplex containing a 1,2-d(GpG) intrastrand PtBP6 adduct.
Banda
1
Proteinb
HMGB1
HMGB2
HMGB3
2 Ku70
Ku80
PARP-1
3 Ku80
Ku70
PARP-1
4 Ku80
Ku70
UBF1
PARP-1
DNA-PKcs
DNA ligase III
Msh2
5 PARP-1
DNA-PKcs
Probabilityc
3.50E-10
3.12E-07
4.14E-08
4.47E- 11
2.50E-09
7.01E-11
4.44E-15
1.11E-15
1.35E-10
2.22E-15
1.26E-12
7.96E-07
9.88E-10
4.01E-11
3.91E-08
8.53E-06
2.63E-13
4.26E-11
MW (Da)
24977.3
24018.7
22849
69829.2
82652.4
113012.4
82652.4
69829.2
113012.4
82652.4
69829.2
89350
113012.4
468786.9
112834.9
104676.8
113012.4
468786.9
Unique
Peptidesd
5
5
Protein Function
HMGB 1 shields cisplatin-DNA adducts from excision repair 44
Analysis of the NCI library of cancer cell lines reveals a correlation
between cells expressing high levels of HMGB1 and cisplatin sensitivity
45,46
HMGB 1, HMGB2 and HMGB3 are chromatin architectural proteins 47
Ku70 and Ku8O are members of the DNA-PK complex involved in
nonhomologous end-joining repair of double-strand breaks 34
See Chapter 5 for more information.
HMG-domain protein responsible for initiation of RNA polymerase 1 11
See text
Protein involved in the recognition of base pair mismatches 48
Member of the DNA-PK complex involved in nonhomologous end-joining
repair of double-strand breaks 34
DNA ligase III 8.10E-14 112834.9 11
Msh2 7.57E-12 104676.8 5
6 DNA-PKcs 8.73E-15 468786.9 146
aThe LC-MS/MS analysis was carried out on six gel slices corresponding to the bands form the analytical-scale experiment (Figure 2.15). The
proteins found in each band are listed here. bProteins identified as described in the Materials and Methods section. cProbability of the peptide
identification being an artifact of background signal from the LC-MS/MS instrument. For example, a probability of 1.0E-4 indicates that there is a
0.01% chance that the identified peptide is not actually present in the sample. The values listed correspond to the peptide most likely to be present
for each protein. dThe number of peptides identified for each protein. Peptides differing by only one amino acid were not considered to be unique.
Table 2.2: Proteins identified by preparative-scale photo-cross-linking of an unplatinated 25-bp duplex.
, , ll ll ilia
Banda Proteina
1 60 kDa heat shock protein, mitochondrial precursor
Transmembrane emp24 domain-containing protein 9 precursor
L-lactate dehydrogenase A chain
Tubulin alpha-i A chain
Heterogeneous nuclear ribonucleoprotein K
Homerin
Creatine kinase, ubiquitous mitochondrial precursor
Alpha-enolase
Pyruvate kinase isozymes M1/ iM2
Nucleolin
Protein disulfide-isomerase A3 precursor
Heterogeneous nuclear ribonucleoprotein Al
Tubulin, beta, 4
14-3-3 protein epsilon
60S ribosomal protein L 10a
Transmembrane emp24 domain-containing protein 7 precursor
TUBB protein
TUBB6 protein
UMP-CMP kinase
Caspase- 14 precursor
Protein S 00-A8
Hypothetical protein DKFZp686PO3159
Uncharacterized protein C7ort24
2 60 kDa heat shock protein, mitochondrial precursor
Probablility a
8.65E-13
8.10E-12
7.38E-10
9.29E-09
1.01E-08
1.17E-08
1.91E-08
2.29E-08
2.50E-08
3.40E-08
5.04E-08
7.06E-08
7.87E-08
2.19E-07
3.28E-07
7.66E-07
4.23E-06
5.17E-05
7.76E-05
6.25E-07
5.99E-06
3.52E-04
8.25E-04
8.29E-13
MW (Da)
61016.5
25088.9
36665.4
50103.7
47527.7
282225.7
47007.3
47139.4
57900.2
76568.5
56746.8
38822.1
88324.5
29155.4
24815.5
25155.6
14407.6
50058.2
22208.3
27662.0
10827.7
40327.7
20994.3
61016.5
Unique
Peptidesa
6
1
3
5
2
2
1
1
1
4
1
2
3
1
1
1
1
1
2
1
1
1
3
Complement component 1 Q subcomponent-binding protein, mitochondrial precursor 1.22E-12 31342.6 1
L-lactate dehydrogenase A chain 3.21E-09 36665.4 2
Trypsin-3 precursor 2.85E-07 32478.0 1
Heterogeneous nuclear ribonucleoproteins A2/B 1 3.61E-07 37406.7 1
Nucleolin 2.69E-06 76568.5 1
FASN variant protein 5.96E-06 277192.9 1
Heterogeneous nuclear ribonucleoprotein Al 1.79E-05 38822.1 1
Transmembrane emp24 domain-containing protein 9 precursor 3.02E-05 25088.9 1
Tubulin, beta, 4 4.16E-05 88324.5 1
Alpha-enolase 5.82E-05 47139.4 1
Pyruvate carboxylase, mitochondrial precursor 6.06E-07 129551.6 2
Serum albumin precursor 1.48E-06 69321.6 1
3 Pyruvate carboxylase, mitochondrial precursor 7.98E-09 129551.6 10
Serum albumin precursor 3.73E-06 69321.6 2
G-protein signalling modulator 2 2.26E-04 76614.3 1
UTP--glucose- 1-phosphate uridylyltransferase 6.97E-04 56904.8 1
60 kDa heat shock protein, mitochondrial precursor 1.05E-09 61016.5 1
Pyruvate carboxylase, mitochondrial precursor 4.92E-09 129551.6 8
Heterogeneous nuclear ribonucleoprotein K 9.35E-06 47527.7 1
RRP l-like protein B 6.10E-05 84359.2 1
4 Serum albumin precursor 1.24E-08 69321.6 2
RRP l-like protein B 1.71E-06 84359.2 4
Propionyl Coenzyme A carboxylase, alpha polypeptide 1.60E-04 11872.0 1
5 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial precursor 2.26E-07 80422.0 3
HSPA5 protein 2.39E-07 72377.6 1
6 Serum albumin precursor 2.73E-05 69321.6 1
aHeadings discussed in Table 2.1.
VIII. SCHEMES
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DCC = 1,3-dicyclohexylcarbodiimide
TFA = trifluoroacetic acid
Scheme 2.1. Synthesis of cis-[Pt(NH 3)(N-(6-aminohexyl)-4-benzophenonamide)C1 2],
PtBP6 (6).
Products are numbered and yields are reported.
5b, 47%
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IX. FIGURES
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Figure 2.1. Chemical structures of cisplatin and PtBP6.
The structure of cis-diamminedichloroplatinum (A), cisplatin and the photoactive
analogue cis-[Pt(NH3)(N-(6-aminohexyl)-4-benzophenonamide)Cl 2], PtBP6 (B).
PtBP6-modified
DNA
HN, pf H2
PtMM
Exposed to
nuclear proteins
HJN p
Photo-induced
cross-linking
Analyzed by
SDS-PAGE
Mo.--
DRP, damage-response protein
Figure 2.2. Photo-cross-linking with a PtBP6-modified DNA probe.
Radiolabeled duplex DNA that is site-specifically platinated with PtBP6 is incubated
with nuclear extracts, allowing nuclear proteins to bind to the damaged DNA. The
mixture is then UV irradiated, creating protein-platinum-DNA complexes that can be
resolved by SDS-PAGE. DRP = damage response protein.
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Figure 2.3. Isolation of photo-cross-linked proteins using streptavidin-coated magnetic
beads.
After photo-cross-linking, many nuclear proteins will be bound to the DNA that are not
the protein of interest (marked with an *). The protein-DNA complexes are incubated
with streptavidin-coated magnetic beads. The strong affinity of biotin for streptavidin
holds the protein-DNA complex to the bead. The beads are then held in place using a
magnetic test tube stand. The complex is subjected to several denaturing washes to
disrupt protein-DNA interactions. The only protein that will remain is the photo-cross-
linked protein. The complex is then heated in sodium dodecyl sulfate (SDS) to dissociate
the biotin from the streptavidin and the purified DNA-platinum-protein complex can be
analyzed by SDS-PAGE.
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benzophenonamide)C12]
6.61
spectroscopic analysis of cis-[Pt(NH3)(N-(6-aminohexyl)-4-
(PtBP6) in DMF.
The compound cis-[Pt(NH3)(N-(6-aminohexyl)-4-benzophenonamide)C1 2] was
synthesized as indicated in Scheme 2.1 in 13% yield.
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Figure 2.5. RP-HPLC purification of platinated 25 base DNA.
This method was able to separate unplatinated DNA (1) from PtBP6-modified DNA (2).
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Figure 2.6. Nuclease digestion of 25 base DNA.
Unplatinated 25 base DNA (A) and 25 base DNA containing a 1,2-d(GpG) adduct of
PtBP6 (B). The signal for the guanosine peak is decreased due to platination of the base.
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Figure 2.7. Analysis of the reaction between activated PtBP6 and deoxyguanosine.
Deoxyguanosine (A) and the reaction between deoxyguanosine and activated PtBP6 (B)
were analyzed by RP-HPLC under the same conditions as the analysis of a nuclease
digestion. The deoxyguanosine elutes at 12.2 min, and the reaction products elute at
about 43 min.
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Figure 2.8. ESI-MS analysis of 25-base DNA containing a 1,2-d(GpG) adduct of PtBP6.
The PtBP6-modified DNA has a calculated value of 7967.4 m/z, and an experimental
value of 7967.2 + 1.64 m/z. This spectrum indicates that some unplatinated DNA is
present, and the platinated DNA contains PtBP6 bound in a bifunctional manner. A
monofunctional adduct would require another ligand to satisfy the coordination
environment of the platinum, and the mass of the complex would be increased. The
analysis was performed by the staff of the MIT Biopolymers facility.
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Figure 2.9. Maxam-Gilbert analysis of 25 base probe.
Each gel and a graphical representation of the bands are presented. (A) C+T reaction of
unplatinated DNA. All bases except for the two bases on the 5'-end of the DNA were
sequenced using this method. (B) A+G reaction of unplatinated DNA. (C) A+G reaction
of platinated DNA. The platination reaction significantly decreases the intensity of the
bands for the G reaction, and decreases the intensity of the G bands in the A+G reaction
as well.
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Figure 2.10. Native PAGE analysis of 25-bp duplexes.
Lane 1: 25 base ssDNA. Lane 2: 25-bp duplex. Lane 3: PtBP6-modified 25-bp duplex.
Lane 4: PtBP6-modified 25 base ssDNA. The single-stranded (ss) DNA migrates faster
down the gel than the duplex (ds) DNA.
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Figure 2.11. Effect of varying the UV
modified 25-bp duplex.
irradiation time on photo-cross-linking of PtBP6-
The photo-cross-linking is maximized at 2 h.
10 -
Figure 2.12. Effect of varying the pre-irradiation incubation time on photo-cross-linking
of PtBP6-modified 25-bp duplex.
No incubation is necessary for maximum photo-cross-linking, and an incubation of
longer than 60 minutes results in less photo-cross-linking, most likely due to degradation
of the proteins.
1 2 3
Figure 2.13. Effect of temperature on photo-cross-linking.
Lane 1: Reaction kept on ice. Lane 2: Reaction kept at room temperature. Lane 3:
Reaction incubated at 37C and irradiated at room temperature. Elevated temperatures
lead to protein degradation.
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Figure 2.14. Analysis of washing conditions of the streptavidin-coated magnetic beads.
The beads were incubated with nuclear proteins and washed using a high salt containing
buffer. The gel was stained using Sypro Ruby protein stain. The well containing the "5
washes" sample leaked into the lane to the left. The beads retain proteins which need to
be washed 5 times to sufficiently remove background for the photo-cross-linking
experiments.
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Figure 2.15. Analytical-scale photo-cross-linking of 25-bp duplex containing a 1,2-
d(GpG) adduct of PtBP6.
The bands indicated were used as a guide to excise protein-platinum-DNA adducts from
the preparative-scale experiments.
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Chapter 3: Photo-cross-linking and identification of nuclear proteins that
bind to constructs of a 25-bp probe containing a site-specific adduct of PtBP6.
*Work from this chapter was submitted for publication; Guggenheim, E. R., Xu, D., Zhang, C.
Z., Chang, P. V., Lippard, S. J., "Photo-Affinity Isolation and Identification of Proteins in Cancer
Cell Extracts that Bind to Platinum-Modified DNA."
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I. INTRODUCTION
Results from Chapter 2 indicate that we have developed a powerful tool to analyze
proteins that bind to platinum-damaged DNA. The methodology was used to address several
other questions regarding platinum-damaged DNA. Beside the 1,2-d(GpG) intrastrand adduct,
cisplatin also forms 1,3-d(GpNpG) intrastrand adducts on DNA. L Photo-cross-linking
experiments were therefore extended to include a DNA duplex probe containing a PtBP6 1,3-
d(GpTpG) intrastrand adduct to identify proteins with an affinity for this type of adduct. Bypass
of cisplatin adducts by polymerases could result in a compound lesion containing a
d(G*pG*)/d(CpT) mismatched intrastrand cisplatin adduct, where G* denotes the platinated
guanine. 2 These compound lesions bind more strongly to the mismatch repair (MMR) protein
Msh2.3 A probe containing a mismatched 1,2-d(GpG)/d(CpT) adduct of PtBP6 was synthesized
to determine whether this behavior extended to nuclear extracts, where all nuclear proteins can
compete for binding to the damaged DNA. We also applied the methodology to investigate
nuclear proteins from cancer cells with varying degrees of sensitivity to cisplatin. Photo-cross-
linking experiments were carried out using nuclear extracts from testicular, cervical, bone and
pancreatic cancer cells. The results provide a comprehensive knowledge of nuclear proteins that
contact the major cisplatin adducts in cancer cells.
I1. MATERIALS AND METHODS
All solvents and most chemical reagents were purchased from commercial sources. DNA
strands were synthesized on an Applied Biosystems ABI 392 DNA/RNA synthesizer using
solvents and reagents supplied by Glen Research. Enzymes were purchased from New England
BioLabs and Promega. UV-vis spectra were obtained on an HP 8453 UV-visible spectrometer.
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Platinum analyses were performed by flameless atomic absorption spectroscopy on a Perkin-
Elmer AAnalyst 300 system. ESI-MS was performed by staff at the MIT Biopolymers
instrumentation facility on a Sciex Model API 365 triple stage mass spectrometer. Analytical and
preparative HPLC work was performed either on an HP Waters or an Agilent 1200 HPLC
system. UV irradiation was conducted in a Stratagene Stratalinker UV Crosslinker. Protein
digestion and analyses were performed by trypsin digestion-coupled LC-MS/MS analysis at the
MIT Biopolymers facility.
Cell culture
Cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal
bovine serum (FBS) and 1% penicillin-streptomycin at 37 'C under 5% CO 2. Once growth
reached ~80% confluence, cells were trypsinized and passed or collected. Cells between
passages 4 and 18 were collected and used for preparing nuclear extracts. Testicular (NTera2),
cervical (HeLa), bone (U2OS), pancreatic (BxPC3), and HeLa cells in which PARP-1 was
silenced by RNAi were used for these experiments.
Short hairpin RNA (shRNA)-induced RNAi on PARP-1 in HeLa cells
The silencing of PARP-1 in HeLa cells was performed by Dong Xu. He designed several
DNA sequences that transcribe to shRNAs for silencing PARP-1 in HeLa cells. These DNA
constructs were cloned into the plasmid vector pcDNA3.1-Zeo (-) -U6. This plasmid, derived
from the Invitrogen pcDNA3.1-Zeo (-), has the human U6 promoter inserted upstream of the
cloning site to drive shRNA transcription. The transfected HeLa cells were selected in DMEM
with 100 gg/ml Zeocin. After the Zeocin selection, cells were collected by trypsin digestion and
their nuclear extracts were prepared as previously reported.4 The total protein concentrations of
the extracts were estimated by bicinchoninic acid solution (BCA) assay. For each sample,
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extracts with 20 tg of total protein were analyzed by western blot. With the use of a MoFlo high-
performance cell sorter (DakoCytomation), HeLa cells transfected with the plasmid were sorted
into wells of two 96-well plates. The instrument set up allows only 0.1 tl of diluted culture with
no more than one cell being added to each well. The single clones were incubated at 37 C for
two weeks. During this time, the medium was changed every four d. These cells were collected
by trypsin digestion and grown in 6-well plates. The nuclear extracts of surviving clones were
analyzed by western blot to evaluate the expression level of PARP- 1.
Nuclear extraction
Nuclear extracts were prepared as described in Chapter 2.
Cytotoxicity assays
Cells were plated at 500 - 1000 cells/well in a 96-well plate. On day 2, the cells were
treated with varying concentrations of cisplatin. On day 6, cellular survival was measured by the
MTT assay. Cells were treated with 1 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) for 4 h. The media was removed from each well and
replaced with 100 gL of DMSO. The absorbance of each cell at 562 nm was measured using a
plate reader.
Synthesis ojf a 25-base single stranded DNA containing a 1,3-d(GpTpG) intrastrand
PtBP6 cross-link
In a method similar to that used to prepare a DNA strand containing the 1,2-d(GpG)
adduct, cis-ammine(BP6)dichloroplatinum(II) was activated with AgNO3. To a solution of 35
nmol of a 25-base DNA containing one d(GpTpG) site, 5'-
CCTCTCCTCTCGTGATCTTCTCTCC-desthiobiotin-TEG-3', in 10 mM NaH2PO 4 (pH 6.3)
was added 70 nmol of activated PtBP6. The reaction was incubated overnight at 37 'C with
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mixing. The singly-platinated 25-base DNA was then isolated by reverse-phase HPLC on an
Agilent C18 300-SB column. The method used was 0 - 12% B over 5 min, followed by 12-25%
over 25 min, where solvent A contained 95:5 water:acetonitrile, 0.1% trifluoroacetic acid, and
solvent B contained 90:10 acetonitrile:water, 0.1% trifluoroacetic acid. The collected fractions
were neutralized and lyophilized. The samples were then reconstituted in water and dialyzed to
remove salt.
Characterization of 1, 3-d(GpTpG) intrastrand PtBP6-modified 25-base DNA probes
Each collected peak was characterized by UV-visible absorbance and atomic absorption
spectroscopy to establish a 1:1 ratio of platinum per DNA. The collected peaks were
characterized by ESI-MS to confirm that both chloride ligands were replaced by Pt-DNA bonds.
Platination of the guanine bases was verified by enzymatic digestion of the DNA. The
digests consisted of 20 gL 100 mM NaOAc (pH 5.2), 1 jpL 100 mM ZnC12, 10 tL nuclease P1,
and 150 pmol DNA. The total reaction volumes were increased to 100 jtL with ddH20. The
solutions were mixed thoroughly and incubated at 37 'C overnight. Next, 5 tL of 1.5 M Tris-
HCI (pH 8.8) and I jtL of calf intestinal phosphatase (CIP) was added. After a 4-h incubation at
37 'C, the samples were centrifuged at 5000 rpm for 5 min. The supernatants were analyzed by
RP-HPLC using a Supelcosil LC-18-S column. The method was 5 - 15% B over 30 min, 15 -
80% B over 10 min, and 80% B for 5 min, where solvent A was 100 mM NaOAc, pH 5.2 and
solvent B was methanol.
Synthesis of duplex DNA
A single-stranded 25-base DNA of the sequence 5'-GGAGAGAAGATCTTGAGAGG-
AGAGG-3' was prepared on a DNA synthesizer using standard phosphoramidite methods. The
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DNA was heated to 55 'C for 14 h and then purified by 12% denaturing PAGE. The DNA was
located using UV shadowing and then extracted from the gel and dialyzed as described above.
The 25-base DNA containing a 1,2-d(GpG) adduct were prepared and characterized as
described in Chapter 1. For analytical-scale experiments, 50 pmol of each DNA was annealed in
NEBuffer 3 (New England BioLabs, 50 mM Tris-HCI pH 7.9, 100 mM NaCl, 10 mM MgCl 2, 1
mM DTT). Three types of DNA were prepared, a 25-base DNA containing a 1,3-d(GpTpG)
adduct of PtBP6 and the complementary bottom strand a 25-base DNA containing a 1,2-d(GpG)
adduct of PtBP6 and the complementary bottom strand, and a 25-base DNA containing a 1,2-
d(GpG) adduct of PtBP6 and the mismatched bottom strand.
In an eppendorf tube, 50 pmol of duplex DNA was combined with 3 pL of 10X PNK
Buffer (700 mM Tris-HC1, 100 mM MgC12, 50 mM dithiothreitol, pH 7.6), 3 pL y-32P-ATP
(Perkin-Elmer) and 1 pL polynucleotide kinase (New England Biolabs). The solutions were
diluted to 30 tL and incubated at 37 'C for 2 h. The solutions were then purified by Sephadex G-
25 spin columns (GE Healthcare), ethanol precipitated, and dried by vacuum centrifugation. The
purity of the DNA was evaluated by 15% native PAGE.
For preparative-scale experiments, 500 pmol of each DNA was annealed in NEBuffer 3
(New England BioLabs, 50 mM Tris-HCI pH 7.9, 100 mM NaC1, 10 mM MgCI2, 1 mM DTT).
Duplex DNA was synthesized containing a 1,3-d(GpTpG) adduct or an unplatinated top strand.
The DNA was purified by 15% native PAGE. The duplexes were visualized by UV shadowing
and isolated from the gel using the crush and soak method. The absorbance of the solutions at
260 nm was measured by UV-vis spectroscopy and the DNA concentration was determined.
Analytical-scale photo-cross-linking
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Analytical-scale photo-cross-linking experiments were carried out using a methodology
identical to that for the analytical-scale photo-cross-linking of the 25-bp duplex containing a 1,2-
d(GpG) adduct of PtBP6, as described in Chapter 2. These experiments were carried out for the
25-bp duplex containing a 1,3-d(GpTpG) adduct of PtBP6 and 25-bp duplex containing a
mismatched 1,2-d(GpG) adduct of PtBP6. Analytical-scale photo-cross-linking experiments were
also performed for the 25-bp duplex containing a 1,3-d(GpTpG) or a 1,2-d(GpG) intrastrand
adduct of PtBP6 with nuclear extracts from HeLa, NTera2, U20S, BxPC3 and HeLa cells in
which PARP-1 was silenced (HeLa YS).
Preparative-scale photo-cross-linking of 25-bp duplex containing a 1,3-d(GpTpG)
adduct of PtBP6
The photo-cross-linking was carried out using identical methodology to that applied in
the preparative-scale photo-cross-linking of the 25-bp duplex containing a 1,2-d(GpG) adduct of
PtBP6, as described in Chapter 2.
Western blot for PARP-1 in HeLa and NTera2 nuclear extracts
For each cell line, 50 jtg of nuclear extracts were resolved by 10% SDS-PAGE. The
proteins were then transferred to PVDF using a BioRad Semi Dry Transfer Cell. The membrane
was cut at 80 kDa to isolate PARP-1 from B-actin. Each membrane was soaked in t-PBS (10 mM
Na2HPO4 pH 7.4, 137 mM NaCl, 2.7 mM KC1, 0.1% Tween-20) with 5% milk for one h. The
membranes were washed with t-PBS and incubated in t-PBS with 1/1000X dilution of mouse
anti-PARP-1 or rabbit anti-B-actin antibodies for two h. The membranes were again washed with
t-PBS and incubated in t-PBS with 1/2000X dilution of HRP anti-mouse or anti-rabbit for one h.
The membranes were washed thoroughly with t-PBS and exposed to luminol-containing imaging
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reagent (Pierce) for one min. Each membrane was then exposed to Kodak MR audioradiography
film, which was developed.
III. RESULTS
Photo-cross-linking experiments detailed in Chapter 1 were carried out using two new
probes. A 25-bp duplex containing a 1,3-d(GpTpG) intrastrand adduct of PtBP6 was synthesized
and characterized. This type of adduct is the second most common in patients treated with
cisplatin.1 Several proteins were photo-cross-linked to this probe, with some differences from the
set obtained with the probe containing a 1,2-d(GpG) intrastrand adduct Chapter 2. The other new
probe contained a mismatched 1,2-d(GpG)-d(CpT) adduct, such that there was both a mismatch
and a platinum lesion. The 1,2-d(GpG) and 1,3-d(GpTpG) probes were employed in analytical-
scale photo-cross-linking experiments with nuclear extracts from cell lines having varying
sensitivities to cisplatin. In one cell line from HeLa, PARP- was silenced by RNAi technology.
Preparation of nuclear extracts
Nuclear extracts were prepared from HeLa, NTera2, BxPC3, U20S and HeLa YS cells at
concentrations between 6 and 12 mg/mL. These extracts were frozen in liquid nitrogen stored at -
80 oC.
Cytotoxicity assays
The cytotoxicity of cisplatin toward each cell line was determined by the MTT assay.
Figure 3.1 contains graphical representations of cellular survival versus cisplatin concentration
for each cell line. The calculated IC 50 values for HeLa, NTera2, BxPC3, U20S and HeLa YS
cells were 0.80, 0.040, 1.5, 3.3 and 0.35 gM, respectively.
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Preparation and characterization of 25-base DNA containing a 1,3-d(GpTpG) adduct of
PtBP6
Platinated and unplatinated DNA were separated using RP-HPLC (Figure 3.2). Three
peaks were collected and dialyzed. In a typical 60 nmol synthesis, 5 nmol of platinated DNA was
isolated, a 17% yield. It was determined by UV-vis and atomic absorption spectroscopy that the
collected peak 1 did not contain platinum and peaks 2 and 3 contained 0.90 _ 0.16 and 0.96 -
0.09 Pt atoms per DNA strand, respectively.
Nuclease digestion analysis was able to cut the DNA into individual nucleosides, which
were resolved by RP-HPLC (Figure 3.3). The expected ratio C:G:T:A was 12:2:10:1 for the 25-
base DNA used in these experiments. For unplatinated DNA the ratio was 12.0:1.9:9.9:1.0. For
peak 2 the ratio was 12.0:0.8:9.8:0.9 and for peak 3 the ratio was 12.0:0.6:10.0:0.9. This
confirms that the platinum was bound to the guanine residues, since the guanosine peak was the
only one muted in these experiments. The guanosine peaks do not completely disappear in these
analyses, similar to results from Chapter 2. This suggests that the platinum may be bound ot the
DNA in a monofunctional manner. This possibility was investigated by ESI-MS. For DNA
containing a bifunctional adduct of PtBP6, the expected mass would be 7956.3 m/z. For peaks 2
and 3, the experimental values were 7955.7 ± 0.6 m/z and 7955.8 ± 0.7 m/z, respectively (Figure
3.4). From these data, it is evident that both of these peaks contain a 25-base DNA with PtBP6
bound in a bifunctional manner.
Synthesis of duplex DNA
The platinated and unplatinated DNA was annealed to the complementary strand and the
duplexes were purified by 15% native PAGE. For analytical-scale experiments, the radiolabeled
DNA was analyzed by 15% native PAGE, demonstrating that both the 25-bp duplex containing
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a 1,3-d(GpTpG) adduct and mismatched 1,2-d(GpG) adduct of PtBP6 were 100% pure (Figure
3.5).
Silencing of PARP-i in HeLa cells
The silencing of PARP-1 in HeLa cells, carried out by Dong Xu, successfully eliminated
the desired protein, as determined by western blotting (Figure 3.6).
Photo-cross-linking of 25-bp duplex containing a 1,3-d(GpTpG) adduct of PtBP6
The 25-bp duplex containing a 1,3-d(GpTpG) adduct of PtBP6 photo-cross-linked to
several proteins. In analytical-scale photo-cross-linking experiments, several proteins appear to
be identical to those of the 1,2-d(GpG) adduct, although there are differences (Figure 3.7A). The
cross-linking experiments identified several proteins that bind to this probe (Table 3.1). Unlike
the probe containing a 1,2-d(GpG) PtBP6 adduct, this probe exhibited only weak affinity for
HMGB1 and HMGB3, and no affinity at all for HMGB2 or UBF1. The probe formed photo-
cross-links to DNA repair proteins PARP-1, DNA ligase III, Msh2, all three members of the
DNA-PK heterotrimer, and RPA1, which was not photo-cross-linked by the 1,2-d(GpG) adduct.
Analytical-scale photo-cross-linking using nuclear extracts from HeLa cells in which
PARP-1 was silenced by RNAi
Nuclear extracts from HeLa cells in which PARP-1 was silenced by RNAi were used in
photo-cross-linking experiments with the probe containing a 1,2-d(GpG) intrastrand PtBP6
adduct (Figure 3.7B). The band identified as PARP-1 by preparative-scale photo-cross-linking
was completely abolished when using nuclear extracts from the PARP-1 silenced cells.
Analytical-scale photo-cross-linking of a 25-bp duplex containing a mismatched 1,2-
d(GpG) intrastrand adduct
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A 25-bp duplex containing a mismatched 1,2-d(GpG) intrastrand cross-link was
synthesized and purified. The duplex was constructed such that the platinated guanine on the 3'-
side of the top strand was mismatched against a thymine residue on the bottom strand. Photo-
cross-linking experiments using this probe and NTera2 nuclear extracts were performed (Figure
3.7C). The main result was formation of a band containing the protein Msh2 that appears with
much greater intensity in lane 2. The increase in affinity of Msh2 for the compound lesion
competes other proteins that bind to the platinum adduct (Table 3.2). In particular, the HMG-
domain proteins and PARP-1 are photo-cross-linked less effectively, and proteins that comprise
the DNA-PK heterotrimer are also somewhat less competed.
Analytical-scale photo-cross-linking using nuclear extracts from different cancer cell
lines
Nuclear extracts from cervical (HeLa), bone (U20S), testicular (NTera2) and pancreatic
(BxPC3) cancer cells were used in photo-cross-linking experiments with both the 1,2-d(GpG)
and 1,3-d(GpTpG) adducts of PtBP6 (Figure 3.8). The proteins cross-linked to each probe appear
to be the same for nuclear extracts from the four different cell lines, but with varying quantities.
The most dramatic difference occurs for PARP-1, the band for which is strong using nuclear
extracts from NTera2 cells, but very weak for nuclear extracts from BxPC3 cells.
Western blot of analysis PARP-1 in HeLa and NTera2 cells
Western blot analyses of HeLa and NTera2 nuclear extracts reveal that PARP-1
expression is significantly higher in the latter (Figure 3.9). This result indicates that the greater
amount of photo-cross-linking to PARP-1 in NTera2 nuclear extracts is a consequence of its
higher expression level.
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IV. DISCUSSION
Since the discovery that cisplatin targets DNA, much effort has been expended to identify
proteins with an affinity for the platinated duplex. In the present study, we prepared and
characterized site-specifically modified 25-bp duplex containing a 1,3-d(GpTpG) intrastrand
cross-link bearing a pendent photo-activatable benzophenone. Upon irradiation, this probe forms
covalent bonds between the platinated DNA and any proteins in a nuclear extract with an affinity
for the adduct. Isolation of the DNA-platinum-protein complexes followed by trypsin digestion
and mass spectrometric analysis allowed the proteins to be identified. Photo-cross-linking using
a probe containing a mismatched 1,2-d(GpG) PtBP6 adduct was also performed. Analytical-scale
photo-cross-linking experiments were conducted using both the 1,2-d(GpG) and 1,3-d(GpTpG)
adducts in nuclear extracts from various cancer cell lines with different sensitivity to cisplatin.
Protein identification
Many of the proteins identified in the photo-cross-linking experiments conducted in this
study (Table 3.1) appear in more than one band. This phenomenon is discussed in detail in
Chapter 2. The work in this chapter confirmed the identity of the bands containing PARP-1 and
Msh2. As described below, the band containing PARP-1 was identified by photo-cross-linking
using nuclear extracts from HeLa cells in which PARP-1 was silenced with RNAi (Figure 3.7B).
Also, the band that contains Msh2 was identified by photo-cross-linking with a DNA duplex
containing a combination of a platinum adduct and a mismatched base (Figure 3.7C). The
identification of the remaining bands is in accord with the molecular weights of the individual
proteins, Ku70, Ku80, and UBF I.
Consideration of the end effect
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One concern of this present study is that proteins that recognize the ends of the 25-bp
duplex may be photo-cross-linked together with those that bind specifically to the platinum
lesion. The DNA-PK heterotrimer, for example, is involved in the repair of DNA double strand
breaks through the nonhomologous end-joining pathway.5 Although the Ku proteins, which
comprise two thirds of the DNA-PK heterotrimer, have previously been associated with cisplatin
adducts, 6 Ku-binding to DNA ends would probably extend far enough down the duplex to reach
the platination site.7 Another photo-cross-linked protein that may be involved in double-strand
break repair is PARP-1. Evidence that this protein is bound to the platinum adduct and not the
DNA ends is presented below.
Photo-cross-linking with nuclear extracts from different cancer cell lines
The photo-cross-linking experiments were extended to include nuclear extracts from a
variety of cancer cell lines with varying sensitivity to cisplatin (Figures 3.1 and 3.8). The
proteins photo-cross-linked by the platinated probe are generally consistent among all cell lines
tested, although their relative amounts differ. The fact that extracts from a variety of cells exhibit
an identical array of platinated DNA-binding proteins is consistent with recent work indicating
that the success of oxaliplatin, by comparison to cisplatin or carboplatin, to treat colorectal
cancer is a consequence of increased cellular uptake8 and not differential processing of the Pt-
DNA adducts. The photo-cross-linking of PARP-1 between the different extracts varies greatly,
with the greatest levels appearing in extracts from NTera2 testicular cancer cells (Figure 3.8).
The significance of PARP-1 as a DNA-damage sensor is discussed below.
HMG-domain proteins and the 1,3-d(GpTpG) adduct
A difference between the 1,2-d(GpG) and 1,3-d(GpTpG)-intrastrand Pt cross-links is that
the former are recognized by HMG-domain proteins.9 These chromosomal proteins bind to
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distorted DNA structures such as four-way junctions and induce further bending of the DNA.'0
The present results indicate that, in cell extracts, HMGB 1 and HMGB3 bind weakly to the 1,3-
d(GpG) adduct (Table 3.1), whereas HMGB 1, HMGB2, HMGB3, and UBFI all bind strongly to
the 1,2-d(GpG) cross-link (Figure 3.7A), as described in Chapter 2. This finding supports
previous work utilizing electrophoretic mobility shift assays (EMSAs) and isolated HMGB1,
revealing that the protein binds to the 1,2-d(GpG) but not the 1,3-d(GpTpG) adduct.9 Here we
provide conclusive evidence that this behavior occurs in a nuclear milieu, where many other
proteins can compete for binding to the platinum adduct, supporting the conclusion that cis-
{Pt(NH 3)(N-(6-aminohexyl)-4-benzophenonamide)} 2' and cis-{Pt(NH3)2}2' DNA cross-links are
processed in an identical manner.
Nucleotide excision repair protein, RPA 1
Replication protein Al (RPAI) is a component of the nucleotide excision repair
apparatus, the major machinery for removing cisplatin adducts from DNA.' We observe this
protein to be photo-cross-linked only to the 1,3-d(GpTpG) intrastrand adduct of PtBP6. EMSA
studies using purified RPA1 indicate that the protein has a 1.5-2-fold stronger affinity for the
1,3-d(GpTpG) than the 1,2-d(GpG) cisplatin cross-link." The 1,3-d(GpTpG) adduct is repaired
more efficiently by NER than the 1,2-d(GpG) adduct, and the repair is further inhibited,
exclusively for the 1,2-d(GpG) cross-link, by the binding of HMG-domain proteins." The
affinity of HMG-domain proteins for the 1,2-d(GpG) intrastrand adduct has been confirmed in
the present experiments, as discussed earlier. Our results indicate that RPA1 binds with greater
affinity to the 1,3-d(GpTpG) intrastrand cross-link of PtBP6 in the nuclear milieu, where other
proteins such as HMGB 1 are available to compete for binding. That RPA does not bind to the
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1,2-d(GpG) intrastrand adduct of PtBP6 most likely reflects lower affinity for the lesion in
addition to competition for binding from HMG-domain proteins.
Nucleotide excision repair of cisplatin adducts results in excised DNA fragments of
approximately 28-32 base pairs, 12 only 3-7 bp longer than the probe used in these experiments.
Use of a longer DNA probe modified with PtBP6 will most likely increase the ability of
nucleotide excision repair proteins to bind and become activated, possibly providing a more
complete account of proteins that compete for binding with platinated DNA. Given the present
results using a 25-bp duplex, work with longer platinated photo-cross-linkable DNA duplexes is
clearly warranted.
Platinum-modified DNA containing a mismatch
Previous work using EMSAs indicates that the mismatch repair protein, Msh2, has a
greater affinity for a 1,2-d(GpG) cisplatin cross-link in which the unplatinated DNA strand
contains a mismatched thymine opposite the 3'-guanosine. 3 This result nicely correlates with the
finding in the present study that the cross-linking efficiency is enhanced in the mismatched probe
(Figure 3.7C). The increased affinity of Msh2 for DNA containing the mismatched Pt adduct is
accompanied by diminished photo-cross-linking to the other proteins (Table 3.2). If a DNA
polymerase were able to bypass a cisplatin adduct, the resulting duplex could incorporate a
mismatched base 2 and become a better binding site for mismatch repair proteins, inducing futile
attempts to repair the compound lesion and eventually signaling apoptosis. 3
PARP-1 and DNA ligase III
Photo-cross-linking experiments identified PARP-1 binding to both the 1,2-d(GpG) and
1,3-d(GpTpG) intrastrand PtBP6 cross-links. Using nuclear extracts from HeLa cells in which
PARP-1 was silenced by RNAi, the identification of the band containing the protein could be
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confirmed (Figure 3.7B). PARP-I has been associated with base excision repair 4 and a backup
system of nonhomologous end joining (NHEJ); this process repairs double strand breaks when
the DNA-PK heterotrimer is compromised. 1""6 In both of these processes, PARP-1 recruits DNA
ligase III to the damage site, 4 which we propose to be the reason for DNA ligase III photo-cross-
linking by our probes. Since PARP-1 recognizes double strand breaks, we considered the
possibility that the protein binds to the ends of our probe and not to the platinum cross-links. The
present work provides three strong pieces of evidence that PARP-1 binds to DNA at the platinum
adduct and not the duplex ends.
The first line of evidence stems from the fact that PARP-1 and the Ku proteins of the
DNA-PK heterotrimer compete for binding to DNA double-strand breaks. 15 19 Photo-cross-
linking experiments using nuclear extracts from NTera2 cells, which express high levels of
PARP-1 (Figure 3.9), reveal much greater PARP-1 cross-linking compared to extracts from
HeLa cells (Figure 3.8). Using ImageQuant data analysis software, we determined the photo-
cross-linking of PARP-1 to be 3.1-fold higher in NTera2 extracts, whereas the relative photo-
cross-linking of the Ku proteins and DNA-PK,, was almost unchanged, being 1.1-fold and 0.9-
fold, respectively.
The second piece of evidence stems from photo-cross-linking using HeLa nuclear
extracts from cells in which PARP-1 had been silenced, which revealed comparable photo-cross-
linking to the DNA-PK heterotrimer (Figure 3.7B). Despite the absence of PARP-1, the Ku
proteins and DNA-PKcs were photo-cross-linked 0.9-fold and 1.1-fold as efficiently, respectively,
in PARP-I silenced HeLa nuclear extracts compared to normal HeLa nuclear extracts. These
results indicate that the binding of PARP-I to this probe is independent of the DNA ends and
requires the platinum lesion itself. If PARP- 1 were competing with the DNA-PK heterotrimer for
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binding to the DNA ends, differences in expression of the protein should affect the binding of the
DNA-PK heterotrimer.
The third line of evidence derives from photo-cross-linking experiments using the
mismatched DNA probe. Table 3.2 lists the relative photo-cross-linking efficiency of each
protein for the mismatched versus correctly matched probes. Since the mismatched repair protein
Msh2 has a greater affinity for the mismatched probe, photo-cross-linking of other proteins is
decreased. The photo-cross-linking of HMG-domain proteins, which bind to the platination site,
is competed efficiently, being 18% for HMGB1, HMGB2 and HMGB3 and 38% for UBF1
compared to the matched probe. Photo-cross-linking of DNA end-binding proteins Ku70, Ku80
and DNA-PKcs is less efficiently competed, being 82%, 65% and 55%, respectively. The photo-
cross-linking of PARP-1 and DNA ligase III is competed to 33%, suggesting that the proteins are
bound in a similar fashion as the HMG-domain proteins and not the DNA-PK heterotrimer.
Given the sensitivity of NTera2 cells to cisplatin, the high levels of PARP-1 expression in
this context (Figure 3.9) suggest a role of this protein in mediating the anticancer activity of the
drug. The catalytic domain of PARP-I is commonly mutated in germ cells,20 which may account
for the increase in expression of the protein necessary for the cells to function. PARP proteins
can lead to DNA repair or conversely, cell death signaling through distinct pathways.21 It is
possible that the binding of PARP-1 to platinum-damaged DNA has different consequences
depending on the cell line. A number of studies indicate that PARP-1 inhibition by 3-
aminobenzamide in ovarian and cervical cell lines leads to cisplatin sensitization,2 2-25 although
there are conflicting results indicating no effect.26 A newly developed inhibitor for PARP-1 and
PARP-2 revealed that PARP inhibition sensitizes a non-small cell lung carcinoma line to
cisplatin. 27 These data suggest that PARP-1 may facilitate repair of Pt-DNA adducts, since its
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inhibition sensitizes cells to cisplatin. PARP inhibitors are currently being evaluated in several
clinical trials, including those applied in combination with carboplatin.28 The present work
demonstrates that the activity of PARP-1 following exposure to cisplatin most likely arises from
an enhanced ability of the protein to bind to platinated DNA. The role of PARPs following
cisplatin exposure in cancer cells is investigated further in Chapter 5.
V. CONCLUSIONS
A platinated 25-bp DNA duplex containing a cisplatin analog with an amino ligand
bearing a pendent photo-activatable moiety, PtBP6, was prepared to photo-cross-link proteins
with an affinity for Pt-modified DNA. Differences in photo-cross-linking between 1,2-d(GpG)
and 1,3d(GpTpG) intrastrand cross-linked probes reflected preferences previously reported for
DNA adducts of cisplatin studied in isolation. For example, HMG-domain proteins strongly
favor the 1,2-d(GpG) intrastrand cross-link whereas the nucleotide excision repair protein RPA1
prefers the 1,3-d(GpTpG) adduct. Similarly, a duplex containing the 1,2-d(GpG) adduct of
PtBP6 carrying a mismatched base opposite the platination site has a greater affinity for the
mismatch repair protein, Msh2. These results indicate that the PtBP6-DNA lesion is processed in
manner analogous to cisplatin-DNA lesions. The PtBP6-DNA probe allowed us to identify
PARP-I binding specificity to Pt-modified DNA. This protein is currently a subject of much
scrutiny by cancer biologists, and the discovery that it binds to platinum-modified DNA warrants
further attention. This protein is differentially expressed among the sampling of cancer cell lines
routinely investigated in our laboratory and high levels of expression in testicular cancer cells
lead to greater photo-cross-linking. The significance of PARP-1 binding to platinated DNA
remains under investigation.
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VII. TABLES
Table 3.1: Proteins identified by preparative scale photo-cross-linking of a 25-bp duplex containing a 1,3-d(GpTpG) intrastrand PtBP6 adduct.
Unique
Banda Proteinb Probabilityc MW (Da) Peptidesd Protein Function
Analysis of the NCI library of cancer cell lines reveals a correlation between cells
1 HMGBI 2.57E-04 24878.2 1 expressing high levels of HMGB 1 and cisplatin sensitivity 29,30
HMGB 1I and HMGB3 are chromatin architectural proteins 10
HMGB3 4.97E-04 14597.2 1 HMGB1 shields cisplatin-DNA adducts from excision repair 12
2 PARP-1 1.61E-07 113012.4 2 See Chapter 5 for more information.
RPA1 2.13E-06 68095.4 1
Member of the DNA-PK complex (Ku70, Ku80 and DNA-PKcs) involved in
Ku70 1.30E-05 69799.2 1 nonhomologous end-joining repair of double-strand breaks 5
3 Ku80 7.72E-13 82652.4 13
PARP-1 1.20E-08 113012.4 5
RPA1 8.47E-07 68095.4 1 RPA1 is involved in DNA-damage recognition of NER. It has a 2-fold greater
affinity for cisplatin 1,3-d(GpNpG) vs 1,2-d(GpG) intrastrand adducts 11
DNA ligase 11I 1.36E-06 112834.9 4
Msh2 1.5 1 E-05 104676.8 3 Protein involved in the recognition of base pair mismatches 31
Ku70 2.21E-05 69799.2 3
4 PARP-1 8.47E-10 113012.4 14
DNA ligase 11I 8.51E-07 112834.9 6 See Chapter 5 for more information.
5 PARP-1 2.44E-07 113012.4 7
DNA ligase III 4.46E-07 112834.9 3
6 DNA-PKcs 4.94E-09 468786.9 8
aThe LC-MS/MS analysis was carried out on six gel slices corresponding to the bands from the analytical-scale photo-cross-linking experiment. The proteins
found in each band are listed here. bProteins identified as described in the Materials and Methods section. cProbability of the peptide identification being an
artifact of background signal from the LC-MS/MS instrument. For example, a probability of 1.0E-4 indicates that there is a 0.01% chance that the identified
peptide is not actually present in the sample. The values listed correspond to the peptide most likely to be present for each protein. dThe number of peptides
identified for each protein. Peptides differing by only one amino acid were not considered to be unique.
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Table 3.2: Ratios of normalizeda intensities of photo-
cross-linking using a mismatched 1,2-d(GpG)
intrastrand adduct of PtBP6 to a correctly matched
1,2-d(GpG) intrastrand adduct of PtBP6.
Mismatched/
Protein Matched
DNA-PYI., 0.55
PARP- 1/DNA ligase III 0.33
Msh2 1.32
UBF1 0.38
Ku80 0.65
Ku70 0.82
HMGB 1, HMGB2, HMGB3 0.18
aThe intensity of each band was normalized to total
signal in the lane.
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VIII. FIGURES
Kill Curve: HeLa cells treated wiA
120%
1 10%
(N0'/.100%
90%
80%
40%
30%
I(r%
C
1200,
1100/
1000 '
90/o
80"%
700.
S60%
500'.
400%
300%
200.
10%
00,;
E
120%
100/0
700,
600.
1 500'.
S400
30/0
200%0
100o
00,10.
th cDDP B Kill Curve: NTera2 cells treated with cDDP
1000%
800
40%
200.
20%
2 2.5 3 0
1
D
1200.
100%0
900
8060
70%
600
50,
40@0
300.
200.
100,o
0 I 2 3 4 5
cDDP (plM)
Kill Curve: HeLa YS cells treated with cDDP
0 0.2 0.4 0.6 08
cDDP (pM)
I 12 14 l6
0.1 0.2 0.3
cDDP (pM)
0.4 0.5 0,6
Kill Curve: U2OS cells treated with cDDP
0 1 2 3 4 5 6
cDDP (pM)
Cell line
HeLa
NTera2
BxPC3
U20S
HeLa YS
7 8
IC50o (pM)
1.0
0.040
1.5
3.3
0.40
Figure 3.1. Cytotoxicity assays of HeLa, NTera2, BxPC3, U20S and HeLa YS cancer
cell lines with increasing concentrations of cisplatin.
Various cancer cell lines were treated with cisplatin and the survival was measured using
the MTT assay. Error bars represent one standard deviation. The cell lines tested were
(A) HeLa, (B) NTera2, (C) BxPC3, (D) U20S and (E) HeLa YS in which PARP-1 was
silenced by RNAi. The IC5o for each cell line is tabulated (F).
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Figure 3.2. RP-HPLC purification of the reaction between a 25-base DNA fragment and
the activated form of PtBP6.
This reaction yields three major peaks. Peak I is the starting material, and peaks 2 and 3
are platinated DNA.
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Figure 3.3. Nuclease digestion analysis of products from the reaction of PtBP6 with DNA
containing a 1,3-d(GpTpG) site.
The analysis indicates that the platinum atom is bound to guanosine. The signal for this
base is muted after the platination reaction (Peaks 2 and 3) compared to starting material
(Peak 1).
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Figure 3.4. ESI-MS analysis of 25-base DNA containing a 1,2-d(GpTpG) adduct of
PtBP6.
The PtBP6-modified DNA has a calculated value of 7956.3 m/z. For peaks 2 and 3, the
experimental values were 7955.7 ± 0.6 m/z and 7955.8 + 0.7 m/z. This spectrum
indicates that the platinated DNA contains PtBP6 bound in a bifunctional manner. A
monofunctional adduct would require another ligand to satisfy the coordination
environment of the platinum, and the mass of the complex would be increased. No
unplatinated DNA is detected. The analysis was performed by the staff of the MIT
Biopolymers facility.
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Figure 3.5. Native PAGE analysis of 25-bp duplexes.
Lane 1: duplex containing a 1,3-d(GpTpG) adduct of PtBP6. Lane 2: duplex containing a
1,2-d(GpG) adduct of PtBP6. Lane 3: duplex containing a mismatched 1,2-d(GpG)
adduct of PtBP6.
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Figure 3.6. Western blot analysis of single clones of HeLa cells transfected with the
plasmid for RNAi of PARP-1.
The nuclear extracts of clones #4, #5, #11 and #13 were loaded in lanes 3 to 6,
respectively. Untransfected HeLa cells (lane 1) and transfected but unsorted cells (lane 2)
were used as controls. The cells from lane 5 were used for subsequent experiments.
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Figure 3.7. Analytical-scale photo-cross-linking results of the 1,2-d(GpG), 1,3~d(GpTpG)
and mismatched 1,2-d(GpG) intrastrand adduct-containing probes, and photo-cross-
linking using nuclear extracts from HeLa YS cells.
(A) 10% SDS-PAGE analysis of photo-cross-linking of HeLa nuclear extracts using a 25-
bp duplex containing a 1,2-d(GpG) (lane 1) or 1,3-d(GpTpG) (lane 2) cross-link of
PtBP6. (B) 120/0 SDS-PAGE analysis of photo-cross-linking using a 25-bp duplex
containing a 1,2-d(GpG) cross-link of PtBP6 incubated with HeLa nuclear extracts (lane
1) or nuclear extracts from HeLa cells in which PARP-l has been silenced using RNAi
(lane 2). Lane 1 was used as a guide to excise six bands from preparative scale photo-
cross-linking experiments for analysis by LC-MS/MS. (C) 10% SDS-PAGE analysis of
photo-cross-linking of NTera2 nuclear extracts using a 25-bp duplex containing a 1,2-
d(GpG) cross-link of PtBP6 (lane 1) or a 25-bp duplex containing a mismatched 1,2-
d(GpG)/d(CpT) cross-link of PtBP6 (lane 2).
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Figure 3.8. Photo-cross-linking of 25-bp PtBP6 probes with nuclear extracts from various
cell lines.
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Figure 3.9. Western blot analysis of PARP-1 expression using HeLa and NTera2 nuclear
extracts.
NTera2 cells (lane 2) express much higher levels of PARP-1 than HeLa cells (lane 1).
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Chapter 4: Photo-Cross-Linking and Identification of Nuclear Proteins that
Bind to a PtBP6-Modified 90-base DNA Dumbbell Probe.
*Work from this chapter was submitted for publication; Guggenheim, E. R., Xu, D., Zhang, C.
Z., Chang, P. V., Lippard, S. J., "Photo-Affinity Isolation and Identification of Proteins in Cancer
Cell Extracts that Bind to Platinum-Modified DNA."
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I. INTRODUCTION
In Chapters 2 and 3, a photoactive analogue of cisplatin, cis-[Pt(NH3)(N-(6-aminohexyl)-
4-benzophenonamide)C2] (PtBP6), was used to photo-cross-link proteins with an affinity for
platinum-damaged. In the work, PtBP6-modified 25-bp duplexes containing a site-specific
adducts were synthesized. This DNA was used to photo-cross-link and identify a number of
proteins with an affinity for platinum-modified DNA. The proteins identified for the 1,2-d(GpG)
intrastrand adduct were HMGBI, HMGB2, HMGB3, Ku70, Ku80, UBF1, Msh2, DNA Ligase
III, PARP-1 and DNA-PKs. These photo-cross-linking studies provide several advantages over
previous methodologies. Since nuclear extracts are used for these experiments, the entire
proteome can be surveyed in each experiment. These assays also identify the proteins that will
bind to platinum-modified DNA in the context of the nuclear milieu, in which all nuclear
proteins are able to compete for binding to the lesion.
In this chapter, a longer 90-base dumbbell DNA probe is used in these photo-cross-
linking studies. This probe is superior to the 25-bp duplex because the platination site if further
from the DNA ends (Figure 4.1). DNA end-binding proteins that make contacts deep into the
DNA, such as the Ku proteins, 1 could potentially be photo-cross-linked without binding to the
platinum lesion. Eliminating this possibility is important because the protein poly(ADP-ribose)
polymerase-1 (PARP-1), which will binds to DNA ends, 2 was photo-cross-linked by the 25-bp
probe. This type of study was the first evidence that PARP-1 has an affinity for platinum-
modified DNA. 3,4 The 90-base dumbbell probe contains two loops instead of blunt ends (Figure
4.1). PARP-1 will bind to these loops, but only come in contact with the first four base pairs of
the DNA.5 In this manner, proteins with an affinity for the loops are isolated from the platination
site. The proteins with an affinity for the PtBP6-modified 90-base dumbbell probe were
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identified, and photo-cross-linking studies were carried out using nuclear extracts from several
cancer cell lines with different sensitivities to cisplatin.
II. MATERIALS AND METHODS
Solvents and chemical reagents were purchased from commercial sources. DNA strands
were synthesized on an Applied Biosystems ABI 392 DNA/RNA synthesizer using solvents and
reagents supplied by Glen Research. Enzymes were purchased from New England BioLabs and
Promega. UV-vis spectra were obtained on an HP 8453 UV-visible spectrometer. Platinum
analyses were performed by flameless atomic absorption spectroscopy on a Perkin-Elmer
AAnalyst 300 system. Analytical and preparative HPLC work was performed on an Agilent 1200
HPLC system. UV irradiation was conducted in a Stratagene Stratalinker UV Crosslinker.
Protein digestion and analyses were performed by trypsin digestion-coupled LC-MS/MS analysis
at the MIT Biopolymers facility.
Cell culture
Cells were grown and nuclear extracts prepared as described in Chapters 2 and 3.
Testicular (NTera2), cervical (HeLa), bone (U20S), pancreatic (BxPC3), and HeLa cells in
which PARP-l was silenced by RNAi (HeLa YS) were used for these experiments.
Synthesis and characterization of a site-specifically platinated 25-base DNA
Synthesis and characterization of a 25-base DNA containing a 1,2-d(GpG) adduct of
PtBP6 was carried out as described in Chapter 2.
Synthesis of a biotinylated 65-base DNA
DNA having the sequence 5'-CCACACCCTTTTGGGTGTGGGGAGAGAAGATCCT-
GAGAGGAGAGGGCCGAGTT(biotin-T)TTTAACTCGGC-3' (see also Figure 4.1) was
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prepared at a 1 jtmole scale. Biotin-T represents a commercially available biotin-modified
thymine phosphoramidite (Glen Research). The DNA was purified by 6% urea-PAGE and
visualized by UV shadowing and excised. The DNA was extracted from the gel using the crush
and soak method, and dialyzed versus water using dialysis tubing with a molecular weight cutoff
of 3500 (Pierce).
Synthesis ofsite-specifically modified 90-base probe
For analytical-scale experiments, 100 pmol each of 25-PtBP6 and 65-biotin were
radiolabeled using T4 PNK (New England Biolabs) and a mixture of unradiolabeled and y-_32p_
ATP. The radiolabeled DNA was annealed in 100 gL of NEBuffer 3 (New England BioLabs, 50
mM Tris-HCI pH 7.9, 100 mM NaCl, 10 mM MgCl 2, 1 mM DTT) from 90 oC to 16 oC over 4 h.
The DNA was ligated by the addition of 100 piL of T4 DNA ligase reaction buffer (50 mM Tris-
HC1, 10 mM MgCl 2, 1 mM ATP, 10 mM DTT pH 7.5, 400 units T4 DNA ligase) and incubated
at 16 'C overnight. The ligated DNA was analyzed and then purified by 6% urea-PAGE. The
bands were isolated by audioradiography, followed by DNA extraction by the crush and soak
method. The DNA was then re-annealed and ethanol precipitated.
For preparative-scale experiments, 2 nmol 65-biotin and 1 nmol each of platinated and
unplatinated 25-base DNA were phosphorylated using T4 PNK and 10 mM ATP. The DNA was
annealed and ligated in a method analogous to that used for the analytical-scale probes. The
ligated DNA was purified by 6% urea-PAGE and the band was isolated by UV shadowing. The
DNA was extracted from the gel using the crush and soak method. The 90-base DNA was then
reannealed and ethanol precipitated.
Characterization of site-specifically modified 90-base probe
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To ensure that the collected product contained one 65-base DNA and one 25-base DNA,
the preparative-scale probe was analyzed by nuclease digestion. Each digestion used 75 pmol of
purified DNA. The DNA was digested with exonuclease III, T7 exonuclease and mung bean
nuclease for 1 h at 30 'C in 60 p.L of NEBuffer 4 (50 mM potassium acetate, 20 mM tris-acetate,
10 mM magnesium acetate, 1 mM DTT pH 7.9). To the solution was then added 10 gpL of 10X
SI nuclease buffer (500 mM sodium acetate pH 4.5, 2.8 M NaCI, 45 mM ZnSO 4) and 10 L of
nuclease S t (Promega). The solutions were mixed thoroughly and incubated at 37 OC overnight.
Next, 5 [tL of 1.5 M Tris-HCl (pH 8.8) and 1 gtL of calf intestinal phosphatase (CIP) were added.
After a 4-h incubation at 37 °C, the samples were centrifuged at 5000 rpm for 5 min. The
supernatants were analyzed by RP-HPLC using a Supelcosil LC-18-S column. The eluant was a
gradient of 5 - 15% B over 30 min, 15 - 80% B over 10 min, and 80% B for 5 min, where
solvent A was 100 mM NaOAc, pH 5.2 and solvent B was methanol.
To examine whether the DNA was fully ligated, the analytical-scale probe was
determined by digestion with mung bean nuclease, which cleaves the looped ends. The purity of
the DNA was first analyzed by 6% urea-PAGE. As a control, a singly ligated 90-base probe was
synthesized on the DNA synthesizer, purified, and radiolabeled as above. In an eppendorf tube, I
pmol of DNA was incubated in MBN reaction buffer (50 mM sodium acetate, 150 mM NaC1, I
mM ZnSO 4, 5 units mung bean nuclease, pH 5.0) for 30 min at room temperature. The reactions
were analyzed by 8% or 12% urea-PAGE.
Analytical-scale photo-cross-linking of 90-base probe
A 1 pmol quantity of DNA was incubated in 20 1tL of binding buffer (10 mM Tris pH
7.5, 10 mM KC1, 10 mM MgCl2, 1 mM EDTA, 0.05% NP-40, 0.2 jtg/mL BSA) with 20 gpg of
nuclear extracts from HeLa, NTera2, BxPC3, U20S, and HeLa YS cells. The reactions were UV
138
irradiated for 2 h on ice and the photo-cross-links were resolved by 7.5% SDS-PAGE with a 4%
stacking gel.
90-base probe repair assay
A 1 pmol quantity of DNA was incubated in 20 pL of binding buffer with 20 ptg of
nuclear extracts from HeLa, NTera2, BxPC3 U20S, and HeLa YS cells. The reactions were
incubated on ice for 2 h. A sample containing U20S nuclear extracts was exposed to UV
irradiation for 2 h to assess whether irradiation effects the stability of the DNA. The samples
were phenol extracted and ethanol precipitated to remove proteins and concentrate the DNA. The
samples were analyzed by 8% urea-PAGE.
Preparative-scale photo-cross-linking of 90-base probe
Preparative-scale experiments were carried out using methodology analogous to
preparative-scale photo-cross-linking of 25-bp probe described in Chapter 2, except using 7.5%
SDS-PAGE with a 4% stacking gel.
III. RESULTS
A 90-base dumbbell probe containing a site-specific 1,2-d(GpG) intrastrand adduct of
cis-[Pt(NH3)(N-(6-aminohexyl)-4-benzophenonamide)Cl2] (PtBP6) was synthesized and
characterized. This probe was used in photo-cross-linking experiments to identify proteins with
an affinity for the platinum-modified DNA.
Synthesis of a site-specifically platinated 90-base probe
Biotinylated 65-base DNA was synthesized on the DNA synthesizer and purified by 6%
urea-PAGE. A total of 12.4 nmol was collected. The 65-base DNA and a PtBP6-modified 25-
base DNA were phosphorylated, annealed, and ligated to make a 90-base dumbbell probe
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(Figure 4.1). Formation of the 90-base probe was confirmed by 6% urea-PAGE analysis (Figure
4.2). The 90-base probe was isolated by 6% urea-PAGE and visualized by audioradiography. For
the preparative-scale probe, the DNA was visualized by UV shadowing. UV shadowing detected
a band migrating the same distance through the gel as the radiolabeled 90-base DNA product.
The DNA was excised from the gel and isolated by the crush and soak method. Following
extraction of the DNA from the gel, 630 pmol of preparative-scale 90-base probe was obtained.
Characterization of the site-specifically platinated 90-base probe
To determine whether the excised DNA contained the desired 90-base probe, the
preparative-scale sample was analyzed by nuclease digestion. The digestion was altered from
that in Chapters 2 and 3 by addition of an initial step with exonuclease III, T7 exonuclease, and
mung bean nuclease. This step is necessary to digest the dumbbell and duplex DNA prior to
incubation with the single-stranded exonuclease S 1. An additional peak outside of the four base
peaks is visible at 19.5 minutes (Figure 4.3). The ratios of optical bands, at 280 nm:260 nm for
cytosine, thymine, guanine and adenine are expected to be 1.03, 0.66, 0.78 and 0.16,
respectively. 6 Experimentally, these ratios were 1.06, 0.66, 0.79 and 0.20, in very good
agreement with theoretical values. For the peak at 19.5 min, this ratio was 2.14, indicating that
this peak is unlikely to contain a DNA base. RP-HPLC analysis of the buffers and enzymes alone
(without DNA) indicates that this peak is an artifact and not the 90-base DNA (Figure 4.3A).
If the probe contained only 65-base DNA, the C:G:T:A ratio would be 13:23:15:14; for
25-base DNA, 12:2:9:2; and for 90-base DNA, 25:25:24:16. For the unplatinated probe (Figure
4.3B), the experimental ratio was 23.1:26.5:23.7:15.7 and for the platinated probe (Figure 4.3C)
it was 24.1:25.9:23.6:15:4. These ratios compare well to the expected ratios of a 90-base probe,
indicating that the DNA contains one of each 25- and 65-base DNA. The presence of a 90-base
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DNA was demonstrated using these experiments; the structure of the 90-base DNA was
investigated using mung bean nuclease digestion.
To determine whether the DNA was in the completely ligated dumbbell form, a
radiolabeled sample was analyzed by digestion with mung bean nuclease (MBN, Figure 4.4).
The purity of the DNA was first determined as 100% by 6% urea-PAGE analysis (Figure 4.5A).
MBN digestion of 90-base dumbbell probes produced a radiolabeled DNA fragment of 41 basess
(Figure 4.5B). MBN digestion of a 90-base DNA that is only singly ligated produces a
radiolabeled DNA fragment of 33 bases (Figure 4.5C).
90-base probe repair assay
The 90-base probe remains intact following exposure to nuclear extracts from various cell
lines or after UV irradiation (Figure 4.6). DNA exposed to nuclear extracts shows no difference
from untreated DNA. The lane labeled "U20S + UV" indicates that exposure to UV light also
does effect the probe. If the dumbbell ends were severed from the probe, as was demonstrated by
incubation with mung bean nuclease (Figure 4.5), a digestion product of 41 bases would be
present. If the platinum adduct were excised by NER proteins, a DNA fragment of 28-32 bases
would be seen on the gel.7
Analytical-scale photo-cross-linking of 90-base probe
Photo-cross-linking using a radiolabeled 90-base probe containing a site-specific 1,2-
d(GpG) adduct of PtBP6 and nuclear extracts from various cancer cell lines yielded several
protein-platinum-DNA complexes (Figure 4.7). The complexes appear to be consistent between
nuclear extracts from cell lines with different sensitivities to cisplatin.
Preparative-scale photo-cross-linking of 90-base probe
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Preparative-scale photo-cross-linking experiments using the 90-base dumbbell probe and
HeLa nuclear extracts led to the identification of many nuclear proteins with an affinity for this
DNA (Table 4.1). All of the proteins identified using the 25-bp probe in ,chapter 2 were detected
with the 90-base probe. The transcription factor YB-1, mismatch repair proteins Msh3 and Msh6,
excision repair proteins DDB1, RFCI and RFC2, and the chromatin remodeling proteins
SMARCA3, DNA topoisomerase 1, protein polybromo-1 (PB-1), SMARCA4, SMARCC2 and
FACT subunit SPT 16 were also photo-cross-linked.
IV. DISCUSSION
Proteins photo-cross-linked by a 25-bp probe containing a site-specific 1,2-d(GpG)
intrastrand adduct of PtBP6 also bind a PtBP6-modified 90-base dumbbell probe. This result
assures that photo-cross-linking is not simply a consequence of affinity of certain proteins for
DNA ends. Several other proteins were also photo-cross-linked by this probe.
Mung bean nuclease analysis of 90-base dumbbell probe
A radiolabeled 90-base DNA was synthesized from a PtBP6-modified 25-base DNA and
a biotin-modified 65-base DNA (Figure 4.1). Purified DNA was analyzed by digestion with
mung bean nuclease (MBN). Completely and partially ligated DNA result in different digestion
products, so the assay is able to distinguish the product obtained in our synthesis (Figure 4.4).
MBN can also slowly digest double-stranded DNA ends, resulting in a pattern of digested DNA
demonstrated in Figure 4.5B and 4.5C. A singly-ligated 90-base probe was used as a control; the
resulting digested DNA migrates as a 33-base DNA (Figure 4.5C). This assay was able to
determine that the 90-base probe synthesized for photo-cross-linking experiments was fully
ligated.
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The photo-cross-linking of PARP-1 is not due to an affinity for DNA ends
The affinity of PARP-1 for platinum-damaged DNA was first established by photo-cross-
linking experiments using PtBP6.3 PARP-1 has an affinity for DNA ends,2 and protein binding to
the ends of the 25-bp probe could allow it to be photo-cross-linked. PARP-1 will also bind to
DNA loops, but it only interacts with the four base pairs adjacent to the loop,5 making it unlikely
to be photo-cross-linked by the 90-base probe if bound in this manner. The photo-cross-linking
of PARP- 1 by the 90-base DNA probe demonstrates that the protein has an affinity for platinum-
damaged DNA.
PARP-1 contains two zinc finger DNA-binding domains, a catalytic domain and a BRCT
domain responsible for mediating protein-protein interactions.2 Although the zinc fingers of
certain proteins, such the Wilms tumor suppressor protein (WT1), bind in the major groove of
DNA,8 such is not the case for PARP-1. A solution structure of the zinc finger of DNA ligase
IIIa, which is homologous to those in PARP-1, indicates that major groove-binding of these zinc
fingers would not be possible due to steric interactions. 9 In cisplatin-modified DNA, the
platinum adduct causes the DNA to bend toward the major groove, resulting in a wide shallow
minor groove.10 A zinc finger is unlikely to bind to the distorted major groove of platinum-
modified DNA, suggesting that the distorted helical structure of damaged DNA creates a
recognition site for zinc fingers of PARP- 1.9,11
The DNA-end binding proteins Ku70 and Ku80 were photo-cross-linked by the 90-base
probe. These proteins bind to DNA double-strand breaks as well as loops, 12 and they form a
complex that translocates along the DNA duplex.13 The DNA-bound Ku proteins recruit DNA-
PKCs1.4 Due to this activity, photo-cross-linking of these proteins to the 90-base probe was
expected. Investigating the specificity of the Ku proteins for cisplatin-modified DNA remains a
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challenge due to the affinity of these proteins for various DNA structures, such as loops and
blunt ends.
Mismatch repair recognition complexes Nh2/Msh3 and Msh2/Msh6 both bind to
platinum-modified DNA
The binding of mismatch proteins to cisplatin-damaged DNA is relevant to the anti-
proliferative effects of the drug and is discussed in detail in the literature. 5-21 The affinity of
MMR protein Msh2 for various constructs of cisplatin-modified DNA has been
demonstrated. 15 ,22 Msh2 forms a complex with either Msh3 or Msh6 when it binds to
mismatched DNA. These two distinct mismatch repair recognition complexes have different
affinities for certain types of mismatched bases and nucleotide insertions or deletions.23 The
current study establishes that both protein complexes Msh2/Msh3 and Msh2/Msh6 will bind to
platinum-modified DNA.
The photo-cross-linking of SPT16 gives structural information about the binding of the
FACT complex to platinum-modified DNA
Facilitates chromatin transcription (FACT) complex subunit SPT16 increases the affinity
of the other subunit of FACT, the HMG-domain protein SSRP1, for cisplatin-modified DNA.4
Structural analysis of the HMG-domains of HMGBI indicate that these domains bind to the
widened minor groove of cisplatin-modified DNA, opposite the lesion itself.2 4' 25 The photo-
cross-linking of the SPT 16 subunit but not SSRP 1 suggests that SSRP 1 binds to the opposite side
of the DNA with SPT16 directed toward the platinum adduct. The photo-cross-linking of this
protein demonstrates that the protein will bind to platinum-modified DNA in the context of the
nuclear milieu and is relevant to the processing of these adducts.
Proteins implicated in nucleotide excision repair bind to PtBP6-modified DNA
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The DNA damage binding protein-i (DDB-1), which is the 142 kDa subunit of the
complex DDB, originally known as xeroderma pigmentosum complementation group E protein
binding factor (XPE-BF), was photo-cross-linked by the 90-base probe. The cisplatin-modified
DNA-binding ability of this protein was demonstrated by using electrophoretic mobility shift
assays (EMSAs) with extracts from XPE cells, which contain mutated DDB-1.2627 This protein
stimulates nucleotide excision repair (NER) of UV-damaged DNA,28 although it is not necessary
for the repair of the 1,3-d(GpTpG) intrastrand adduct of cisplatin.29 The role of this protein in
cisplatin-damaged DNA repair is not well understood; it may be one of the first NER proteins to
bind to damaged DNA.30
The transcription factor YB-1, which was photo-cross-linked by the 90-base probe, binds
to cisplatin-modified DNA.31 The consequences of this binding may derive from the interaction
of YB-1 with proliferating cell nuclear antigen (PCNA), a protein necessary for NER.10' 32
Another PCNA-interacting protein photo-cross-linked by our probe is replication factor C
(RFC). 30 Five RFC proteins are involved in DNA replication and repair. 33 RFC1 binds to double-
stranded DNA and interacts with PCNA to initiate transcription. 33 A role for RFC in DNA
repair is supported by experiments demonstrating that the protein is necessary to promote cell
survival following cisplatin or UV exposure. 34 The protein RFC2 was also photo-cross-linked.
RFC2 binds to damaged DNA downstream of damage recognition in the nucleotide excision
repair pathway following excision of the damaged bases.35'36 It may be responsible for keeping
the damage response activated until repair is completed.37
Since RFC2 binds to damaged DNA following excision of the lesion, the nature of the
90-base probe following incubation with nuclear extracts was investigated. After incubation with
nuclear extracts, the DNA was analyzed by PAGE, which indicated that the platinum lesion was
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not excised during the incubation period (Figure 4.6). This result indicates that RFC2 can bind to
platinum-damaged DNA prior to excision of the lesion. The experiment also demonstrates that
the dumbbell DNA structure is stable in nuclear extracts, consistent with other studies of this
type of DNA. 38 The stability of dumbbell DNA structures in biological media has led to an
investigation of their therapeutic potential as decoys for transcription factors.39
Chromatin remodeling proteins bind to platinum-modified dumbbell DNA
'The binding of DNA topoisomerase I (topo 1) to closed circular DNA and DNA-histone
complexes containing cisplatin adducts indicates that this protein may be important in processing
the adducts.4 0,'41 Topo I relaxes superhelical DNA by severing one strand, crossing the unbroken
strand through the break, and then re-ligating the broken strand. This function is necessary for
transcription.42 The stalling of topo I at DNA damage sites can interfere with repair, an effect
blocked by poly(ADP-ribosyl)ation of topo I by PARP-1 and PARP-2, which dissociates the
protein from DNA.43 The combination of cisplatin and topo I poisons, such as camptothecin, has
showed improved response in clinical trials.44 The synergistic cell-killing by these two drugs is
not well understood, but the effect only occurs in cells with a functional homologous
recombination repair pathway. 45 The ability of topo I to bind non-nucleosomal platinum-
modified DNA has not been established, but the current study demonstrates that the interaction
will occur in nuclear extracts.
The SWI/SNF family proteins SMARCA3, SMARCA4, SMARCC2 and protein
polybromo-1 (PB-1) were photo-cross-linked by the 90-base dumbbell probe. The acronym
SMARC stands for SWI/SNF-related matrix-associated actin-dependent regulators of chromatin.
These proteins are responsible for chromatin remodeling, which allows the transcription
machinery to processes DNA that is tightly wrapped around histones. 46 One member of this
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family, PB-1, contains an HMG-domain, 47 which may bind to the platinum site and recruit the
other SWI/SNF proteins. The affinity of PB-1 and the SWI/SNF family of proteins for platinum-
modified DNA has not been demonstrated prior to the present work. The ability of these proteins
to bind to platinum-modified DNA may inhibit excision of the adduct by NER proteins or hijack
the proteins from their native functions.
PtBP6-modified DNA is able to photo-cross-link proteins with low cellular abundance
The binding of proteins to DNA is an equilibrium process, but photo-cross-linking
creates a covalent bond, which prevents proteins from dissociation. Due to this covalent linkage,
any protein with an affinity for platinum-modified DNA will be photo-cross-linked by the probe.
As few as 500 zeptomoles of trypsin-digested peptides can be detected by the Thermo Electron
Model LTQ Ion Trap mass spectrometer used in our experiments.48 In practice, the instrument
used in these studies will detect sub-femptomolar amounts of peptide in complex mixtures,49
corresponding to fewer than 6.02 x 108 molecules. We used 2 mg of nuclear extracts for each
experiment, obtained from approximately 6 x 107 cells. These considerations indicate that
proteins expressed at a level as low as ten copies per cell should be detectable by our methods.
Several highly abundant proteins present at upwards of 105 molecules per cell were
identified using Pt-BP6-modified DNA, including PARP-150 and the Ku proteins.51 Other
proteins identified are not nearly as abundant, such as the MMR proteins Msh2, Msh3, and
Msh6, as well as the SWI/SNF family proteins, for which there are only 100-200 molecules per
cell,52,53 and DDB 1, which is present at 8,000 molecules per cell.54 The expression of HMGB3 in
adult tissues was undetectable by RT-PCR,5 5 but was identified using our methodology. The
identification of these proteins demonstrates that these photo-cross-linking experiments provide a
very sensitive method for detection of platinum-damaged DNA-binding proteins. It is likely that
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most if not all of the cisplatin-DNA binding proteins expressed in the cancer cells investigated
have been identified in this study.
Recognition ofplatinum-modified DNA is consistent between cancer cell lines
Analytical-scale photo-cross-linking using nuclear extracts from various cell lines
indicated that, similar to the results with the 25-bp probe described in Chapter 3, the same
proteins are photo-cross-linked in each extract (Figure 4.7). Photo-cross-linking with nuclear
extracts from PARP-1 silenced HeLa cells (Figure 4.7, lane 5) demonstrates that the band
consisting of a PARP-1-platinum-DNA complex overlaps with other complexes and was not
resolved. These data suggest that recognition of the damaged DNA is not responsible for the
varying sensitivities of these cell lines to cisplatin.
V. CONCLUSIONS
Using a 90-base dumbbell probe, proteins binding to a 1,2-d(GpG) intrastrand platinum
lesion were identified. This probe is superior to previous work using a 25-bp probe, discussed in
Chapters 2 and 3, because a longer DNA was used that does not contain blunt ends. The proteins
identified by the 25-bp probe were also photo-cross-linked by the 90-base dumbbell probe.
Additional proteins were identified as well, including members of the SWI/SNF family, such as
the HMG-domain protein PB-1. The affinity of these proteins, and the protein DNA
topoisomerase I, for platinum-damaged DNA could provide new insight into the processing of
platinum-DNA adducts. The 90-base probe also photo-cross-linked to the proteins FACT, DDB 1
and YB-1, which have an affinity for cisplatin-modified DNA. Although the affinity of the
mismatch repair protein Msh2 for cisplatin-damaged DNA has been studied extensively, this
work was able to demonstrate that both mismatch repair recognition complexes Msh2/Msh3 and
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Msh2/Msh6 bind to platinum-modified DNA. Given the number of proteins that bind to this
longer probe, it is remarkable that the same families of proteins that have been implicated
binding to cisplatin-modified DNA for years are identified by this photo-cross-linking method.
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VII. TABLES
Table 4.1. Proteins identified by preparative scale photo-cross-linking of a 90-base DNA containing a 1,2-d(GpG) intrastrand PtBP6 adduct.
Banda Protein b
1 HMGB1 I
HMGB2
HMGB3
2 YB-1
RFC2
3 Ku70
4 Msh2
Ku70
Ku80
UBF1
Msh3
DNA topo I
5 PARP-1
RFC1
PB- I
Msh3
SMARCA4
SMARCA3
DNA Ligase III
DDB1
6 PARP-1
SMARCC2
DNA Ligase III
Probabilityc
2.36E-05
Unique
Peptidesd
1
M.
3.80E-08
8.64E-08
8.32E-07
3.31E-05
7.29E-08
1.70E-07
3.72E-07
3.89E-07
7.21E-07
5.72E-06
1.05E-05
1.61E-11
2.67E-10
2.02E-09
4.04E-06
2.14E-09
1.31E-08
1.91E-08
7.71E-05
6.32E-08
2.69E-06
7.68E-07
1
W. (Da) Comments
24878.2 HMGB1 shields cisplatin-DNA adducts from excision repair56
Analysis of the NCI library of cancer cell lines reveals a correlation between cells
24018.7 expressing high levels of HMGB 1 and cisplatin sensitivity57,5 8
22980.0 HMGB1, HMGB2 and HMGB3 are chromatin architectural proteins59
Y-box binding protein-i (YB-1) is a transcription factor containing a cold-shock
35902.7 domain (CSD) that binds to cisplatin-modified DNA 3 1
39132.1 Involved in intermediate steps of nucleotide excision repair 3 3
Ku70 and Ku80 are members of the DNA-PK complex (Ku70, Ku80, DNA-PKcs)
69799.2 involved in nonhomologous end-joining repair of double-strand breaks60
12834.9 Protein involved in the recognition of base pair mismatches 7
69799.2
82652.4
89350
127376.1
90668.9
113012.4
128175
192823.9
127376.1
184529.4
113856.7
112834.9
126887.4
113012.4
132796.8
112834.9
HMG-domain protein responsible for initiation of RNA polymerase 161
Protein involved in the recognition of base pair mismatches17
Chromatin remodeling protein involved in relaxing superhelical DNA42
DNA damage-binding protein involved in repair and apoptosis signaling62
Binds to double-stranded DNA and interacts with PCNA to initiate transcription.33
SWI/SNF chromatin remodeling protein containing an HMG-domain 47
SWI/SNF chromatin remodeling protein 46
SWI/SNF chromatin remodeling protein 46
DNA repair protein that associates with PARP-1 63
Nucleotide excision repair protein that binds to cisplatin-modified DNA.10,
26
,'
27
,
32
SWI/SNF chromatin remodeling protein 46
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Msh6 2.44E-07 1 152688.4 Protein involved in the recognition of base pair mismatches1 7
Msh2 2.75E-06 3 104676.8
FACT complex subunit that increases the affinity of the HMG-domain protein
SPT16 4.93E-05 2 119838.3 SSRP1 for cisplatin-modified DNA.4
7 DNA-PKcs 1.48E-08 15 468786.9
aThe LC-MS/MS analysis was carried out on six gel slices corresponding to the bands indicated in Figure 4.7. The proteins found in each band are listed
here. bProteins identified as described in the Materials and Methods section. CProbability of the peptide identification being an artifact of background
signal from the LC-MS/MS instrument. For example, a probability of 1.OE-4 indicates that there is a 0.01% chance that the identified peptide is not
actually present in the sample. The values listed correspond to the peptide most likely to be present for each protein. dThe number of peptides identified
for each protein. Peptides differing by only one amino acid were not considered to be unique.
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VIII. FIGURES
25 base DNA
65 base DNA
90 base dumbbell DNA
NH 3 BP6
5 '-CCTCTCCTCTCAGGATCTTCTCTCC-3'
TTAACTCGGC-3' 5'-CCACACCCT T
TT TTGAGCCGGGAGAGGAGAGTCCTAGAAGAGAGGGGTGTGGGT Tbiotin
NH3 BP6
TTAACTCGGCCCTCTCCTCTCAGGATCTTCTCTCCCCACACCCT T
TT TTGAGCCGGGAGAGGAGAGTCCTAGAAGAGAGGGGTGTGGGT Tbiotin
'biotin
Figure 4.1. Synthesis of 90-base dumbbell DNA from a PtBP6-modified 25-base DNA
and biotinylated 65-base DNA.
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Figure 4.2. 6% urea-PAGE analysis of synthesis of 90-base DNA.
Lane 1: 90-base DNA reaction. Lane 2: 100 base DNA ladder.
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Figure 4.3. Nuclease digestion of the 90-base DNA probe.
(A) No DNA. (B) 90-base probe. (C) PtBP6-modified 90-base probe.
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Figure 4.4. Mung bean nuclease digestion of 90-base DNA.
Digestion with this nuclease can differentiate fully and partially ligated 90-base DNA
strands.
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Figure 4.5. Analysis of purified 90-base DNA probe.
(A) 6% urea-PAGE analysis of purified 90-base DNA. (B) 8% urea-PAGE analysis of
MBN-digested 90-base DNA probe. (C) 8% urea-PAGE analysis of MBN-digested 90-
base DNA probe and control with nicked 90-base DNA. The 41 bases DNA digestion
product indicates that the 90-base DNA is doubly ligated, and the 33-base DNA digestion
product indicates that the 90-base DNA contains a nick. This is illustrated in figure 3.
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Figure 4.6.90base probe repair assay.
Figure 4.6. 90-base probe repair assay.
90-base dumbbell probe was incubated with nuclear extracts for 2 h and analyzed by 6%
urea-PAGE. The DNA was stable in all nuclear extracts, even after UV irradiation.
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Figure 4.7. Photo-cross-linking 
with 90-base DNA probe using 
nuclear extracts from
various cancer cell lines.
The numbers represent the 
bands from Table 4.1. The 
proteins photo-cross-linked
between different nuclear extracts 
are consistent. The proteins in 
Table 4.1 match well to
the approximate molecular weight 
marker; each protein is tethered 
to a 29 kDa platinated
DNA.
161
6)
A*W"
Chapter 5: The activity of PARP proteins following cisplatin exposure
in cancer cells is cell line-dependent.
* Work from this chapter was submitted for publication; Guggenheim, E. R., Ondrus, A.
E., Movassaghi, M., Lippard, S. J., "Poly(ADP-ribose) Polymerase-1 Activity Facilitates
the Dissociation of Nuclear Proteins from Platinum-Damaged DNA."
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I. INTRODUCTION
In Chapters 3 and 4, the protein poly(ADP-ribose) polymerase-1 (PARP-1) was
identified as a possible mediator of cisplatin cytotoxicity in NTera2 cells, a testicular
cancer cell line with an exceptional sensitivity to cisplatin. These cells express high levels
of PARP-1, which binds to platinum-modified DNA. PARP-1 is a 113 kDa DNA-binding
protein that catalyzes the addition of poly(ADP-ribose) (PAR) chains onto acceptor
proteins (Figure 5.1), including PARP-1 itself. The activity of the PARP family of
proteins has been implicated in DNA repair, chromatin remodeling, transcriptional
control, and inflammation.' PARP-1 has a DNA-binding domain with two zinc fingers,
an automodification domain, and a catalytic domain. The catalytic domain binds
nicotinamide adenine dinucleotide (NAD ) and creates long, branched PAR chains in
which each unit contain two negatively charged phosphate linkers (Figure 5.1A). These
polymers can be digested by poly(ADP-ribose) glycohydrolase (PARG) which can
restore proteins to their unmodified form.'
Upon exposure of cells to DNA-damaging agents, PARP proteins are strongly
activated. PARP can activate three different pathways (Figure 5.2).2 Under mild
conditions, PARP proteins mediate DNA damage repair. PARP-1 is involved in base
excision repair (BER)3 and a backup pathway for nonhomologous end-joining (NHEJ)
repair of double-strand breaks.4'5 When DNA damage is too severe to be repaired
efficiently, the PAR polymers created by PARP proteins signal the release of apoptosis-
inducing factor (AIF) from mitochondria, which initiates apoptosis.6 Apoptosis induced
by cisplatin is due to both caspase- and AIF-dependent signaling mechanisms. 7 Under
severe DNA damage conditions, the activity of PARP proteins depletes cellular reservoirs
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of NAD+. The depletion of NAD+ leads to shutdown of glycolysis, and since cancer cells
rely on glycolysis for ATP production, the cells die by necrosis.8
The attachment of PAR polymers to proteins is an important biochemical
mechanism. Automodified PARP-1 interacts with XRCC 1, which may be responsible for
the initiation of the base excision repair pathway.' A PAR-binding motif has been
identified in DNA repair proteins, and this type of domain is present in core histones,
p53, DNA topoisomerase 1, Ku70, XPA, Msh6, DNA Ligase III, and XRCC1. 9-11
Negatively charged PAR polymers create an electrostatic repulsion between modified
proteins and polyanionic DNA (Figure 5.1 B). For example, the poly(ADP-ribosyl)ation
of histones contributes to chromatin relaxation, making damaged DNA more accessible
to repair proteins.' The C-terminal domain of the chromatin remodeling protein HMGB 1
is poly(ADP-ribosyl)ated by PARP-1, causing it to dissociate from chromatin and
translocate to the cytosol. 12,13 PARP inhibitors show promise for treating tumors with
mutations in BRCAI and BRCA2 genes, a feature of certain types of breast cancer.
Inhibition of PARPs may lead to the inability of the cells to repair single-strand breaks at
replication forks, causing the formation of double-strand breaks (DSBs). These DSBs
cannot be repaired efficiently in BRCA-defective cells, which are intrinsically defective
in homologous recombination (HR). 14
Detailed studies to understand PARP activity following DNA damage have
focused on DNA methylating agents, such as N-methyl-N-nitro-N-nitrosoguanidine
(MNNG).6, 15-17 The activity of PARP proteins following cisplatin exposure is less well
understood. One study revealed increased levels of PAR polymers following cisplatin
treatment in rat and monkey tumor cells.18 Another report demonstrated that PARP
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activity is strongly upregulated following exposure of renal tubular cells to cisplatin, and
ATP levels within these cells decreased significantly.1 9 In this work, extremely high
concentrations of cisplatin (500 pM) were required to induce PARP activity. Recently,
HT29 colon carcinoma cells were used to show a mild increase in PARP activity 24 h
after a four h treatment with 10 pM cDDP.20 Only one cell line was tested using the
assay, however, providing little information about the importance of PARP activity in
cisplatin sensitivity. HeLa cervical cancer cells were also studied in the work, but PARP
activity following cisplatin treatment was not reported. 20 Further investigations using
cisplatin concentrations more relevant to human cancer are clearly warranted.
Although the activity of PARP proteins following cisplatin treatment is not well
characterized, PARP inhibitors have been used to sensitize cells to cisplatin. Cotreatment
of cisplatin and the NAD+ analogue 6-aminonicotinamide sensitizes cells to cisplatin.21
The increased cytotoxicity was due to greater uptake of cisplatin, however, and not a
decrease in repair of platinum-DNA adducts or PARP-dependent cell death signaling.
More recent work indicates that a potent PARP inhibitor, CEP-6800 (Figure 5.3),
sensitizes non-small cell lung carcinoma cells to cisplatin in both culture and in
xenografts.22 Another newly developed PARP inhibitor, ABT-888, substantially
improves tumor response to cisplatin and carboplatin.23 The anticancer potential of PARP
inhibitors and platinum drugs in combination therapies is currently being investigated in
phase I and II clinical trials.24
In the present work, the role of PARP proteins in mediating cisplatin cytotoxicity
has been investigated in a number of cell lines with varying sensitivity to cisplatin,
namely, cervical (HeLa), testicular (NTera2), pancreatic (BxPC3) and osteosarcoma
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(U20S). The potentiation of cisplatin cytotoxicity by PARP inhibitors was investigated in
these cancer cell lines. Photo-cross-linking studies, outlined in Chapters 2 and 3, were
carried out in the presence of a PARP inhibitor to determine its effect on the binding of
nuclear proteins to platinum-damaged DNA. In order to assess PARP activity, cells were
treated with cisplatin and the PAR-modification of proteins was analyzed. To achieve a
good signal in this type of assay, confluent cells were treated with cisplatin for one hour
prior to analysis. In most of our previous cytotoxicity assays, cells at low confluence are
treated with cisplatin for 96 h to assess the effect on growth. Here we report a new
cytotoxicity assay designed to be compatible with the conditions of the PARP activity
measurements. In this assay, confluent cells are treated with cisplatin for one hour and
then re-plated at low confluence to allow for cell proliferation analysis. The cytotoxicity
of cisplatin can be enhanced in cells at high versus low density due to intercellular
signaling. 25 Following determination of IC 50 values, PARP activity assays were
performed. Cells were treated with cisplatin and nuclear extracts were then analyzed for
PAR-modified proteins. The assay was repeated using a dounce homogenizer instead of
nuclear extraction methods to limit the processing time of the cells following cisplatin
exposure. A quick extraction method is necessary due to the transient nature of PAR
polymers.26
II. MATERIALS AND METHODS
Solvents and most chemical reagents were purchased from commercial sources.
Enzymes were obtained from New England BioLabs and Promega. Antibodies were
purchased from Axxora Life Sciences. NMR spectroscopy and high-resolution mass
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spectrometry were performed at the MIT department of chemistry instrumentation facility
(DCIF).
Synthesis of CEP-A and CEP-6800
CEP-A and CEP-6800 were prepared by co-author Alison Ondrus of the
Movassaghi Lab, adapted from published synthetic strategies.
2 7"29
Cell culture
HeLa, NTera2, BxPC3, and U20S cells were grown in DMEM with 10% FBS at
37 oC in an atmosphere of 5% CO2. HeLa YS and HeLa pcDNA cells were prepared as
described in Chapter 3 and were grown in DMEM with 10% FBS supplemented with 100
p.g/mL zeocin selection reagent (Invitrogen).
MTT assays
MTT assays carried out as described in Chapter 3. Cells were treated with varying
concentrations of PARP inhibitors CEP-A, CEP-6800, and 4-amino- 1,8-naphthalimide
(4-ANI) to determine the maximum tolerated dose of inhibitor in each cell line. The
cytotoxicity assays were then repeated with the maximum tolerated dose of PARP
inhibitor plus varying concentrations of cisplatin.
Density-dependent cytotoxicity assay
Cells were plated at either 1.0 x 105 or 1.0 x 104 cells/well in six-well plates. On
day two, cells were treated with varying concentrations of cisplatin and incubated for one
h. The cells were then trypsinized and replated at 1000 cells/well in a 96-well plates. On
day six, the cells were treated with one mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) for four h. The medium was removed from each
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well and replaced with 100 gL of DMSO. The absorbance of each well at 562 nm was
measured using a plate reader.
Photo-cross-linking in the presence ofPARP inhibitors
Analytical-scale photo-cross-linking experiments were carried out as described in
Chapters 2 and 3 for a 25-bp DNA containing a site-specific 1,2-d(GpG) or 1,3-
d(GpTpG) adduct of PtBP6 and HeLa nuclear extracts in the presence of 0, 0.01, 0.05,
0.1, 0.3, or 1.0 gM CEP-A. The inhibitor was dissolved in DMF and diluted to the
desired concentration with the final solution containing 0.02% DMF. Photo-cross-linking
was also performed without DMF as a control. Photo-cross-linking experiments were
then repeated using nuclear extracts from NTera2, BxPC3, U20S, and HeLa YS cell
lines, with or without 1.0 gM CEP-A, for both types of PtBP6 cross-link.
Preparation of nuclear extracts from cisplatin-treated cells
Cells were treated with a concentration of cisplatin equal to the IC 50 value of the
cell line as determined by the MTT assay for 0, 1, 4, 8, or 24 h. Nuclear extracts of these
cells were prepared as described in Chapter 2.
Preparation of cisplatin-treated cell lysates
Cells were treated for one h with a concentration of cisplatin equal to their IC50
value as determined by the density-dependent cytotoxicity assay. Cells were pelleted by
centrifugation at 450 x g for five min. Each pellet was resuspended in 750 pL of ice cold
20% trichloroacetic acid (TCA) and lysed using a Dounce homogenizer. The homogenate
was centrifuged at 3000 x g for 10 min, and the supernatant was removed. The pellet was
resuspended in 750 jL 20% of TCA and centrifuged again three times. The pellet was
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then resuspended in 750 gL of ice-cold ethanol and pelleted by centrifugation. The
pellets were dried briefly by vacuum centrifugation and stored at -80 oC.
Nuclear extract-based PARP activity assay
For each experiment, 100 jig of nuclear extracts were resolved by 10% SDS-
PAGE. The gel was transferred to PVDF membrane using a BioRad semi dry transfer cell
and subjected to western blot analysis for PAR polymers as described below.
Lysed cell-based PARP activity assay
The cell lysate was dissolved in 100 gL of 2X SDS-PAGE loading buffer (100
mM Tris-HC1, 20 mM DTT, 2% SDS, 30% glycerol, and 0.1% bromophenol blue, pH
7.9) to solubilize the proteins and resolved by 10% SDS-PAGE with a 4% stacking gel.
The proteins on the gel were transferred to a PVDF membrane and subjected to western
blot analysis for P-actin as described in Chapter 2. The images were analyzed using
ImageJ software (NIH) and the relative intensities of the 3-actin loading control were
determined. These values were used to load equal amounts of each lysate onto a second
gel. The proteins on the gel were then transferred to a PVDF membrane and subjected to
western blot analysis for poly(ADP-ribose) (PAR) polymers described below.
Western blot for PAR
The PVDF membrane was soaked in t-PBS (10 mM Na2HPO4 pH 7.4, 137 mM
NaCl, 2.7 mM KCI, 0.1% Tween-20) with 5% milk for one h. The membrane was then
washed with t-PBS and incubated in t-PBS with 1/1000X dilution of rabbit anti-PAR
antibodies for two h. Next, the membrane was washed with t-PBS and incubated in t-PBS
with 1/2000X dilution of HRP anti-rabbit for one h. The membrane was washed
thoroughly with t-PBS and treated with luminol-containing imaging reagent (Pierce) for
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one min. The blots were then exposed to Kodak MR audioradiography film, which was
developed.
III. RESULTS
Synthesis of CEP-A and CEP-6800
PARP inhibitors CEP-A and CEP-6800 (Figure 5.3) were synthesized by Alison
Ondrus of the Movassaghi lab. CEP-A was analyzed by 'H NMR spectroscopy (Figure
5.4) and CEP-6800 was analyzed by 'H NMR (Figure 5.5) and high resolution mass
spectrometry. The theoretical [M+Na] was 328.1056 m/z, and the experimental value,
328.1050 m/z.
Cytotoxicity assays
The toxicity of PARP inhibitors was investigated for each cell line to determine
the maximum tolerated dose. These MTT assays are presented in Figure 5.6 and the
results are summarized in Table 5.1. Cells were treated with the maximum tolerated dose
of each PARP inhibitor and varying concentrations of cisplatin. The MTT assays are
presented in Figure 5.7 and the results are summarized in Table 5.2. The sensitivity of
HeLa and NTera2 cells to cisplatin was unchanged by addition of PARP inhibitors, but
BxPC3 and U20S cells were sensitized to cisplatin by factors of 1.6 and 2.3,
respectively.
Cells were treated with varying concentrations of cisplatin at high and low density
in six-well plates. The cells were then transferred to 96-well plates for analysis by the
MTT assay. There were some differences in IC 50 values between the high and low-
density cells (Table 5.3), but the curves (Figure 5.8) indicate little effect, if any, on cell
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density in these cytotoxicity assays. The IC 50 values at high density of HeLa cells in
which PARP-1 has been silenced by RNAi (HeLa YS), as well as HeLa cells transfected
with a control plasmid (HeLa pcDNA), were determined using this assay (Figure 5.9).
The IC 50 values for HeLa YS and HeLa pcDNA cells were 12 and 36 JiM, respectively.
These cells must be grown in 100 gpg/mL zeocin selection reagent, so a control cell line
was evaluated to determine the effect of zeocin on these cytotoxicity assays. The HeLa
pcDNA cells are more resistant to cisplatin than untransfected HeLa cells, indicating that
the presence of zeocin in the media interferes with the antiproliferative effects of
cisplatin. This interference is possibly due to the direct interaction of cisplatin with
zeocin, a large molecule containing several nitrogen atoms that may coordinate to
cisplatin (Figure 5.10).
Photo-cross-linking in the presence of the PARP inhibitor CEP-A
For the 25-bp DNA duplex containing a 1,2-d(GpG) adduct of PtBP6, increasing
amounts of CEP-A in the photo-cross-linking experiment resulted in a decrease in
intensity of high-molecular weight band 2, and band 1 directly below increases in
intensity (Figure 5.11A). The intensities of these bands were quantitated (Figure 5.11B),
indicating that the overall photo-cross-linking of these two bands increases by a factor of
1.6 with the addition of CEP-A. For the 25-bp DNA containing a PtBP6 1,3-d(GpTpG)
cross-link, there was no effect by PARP inhibition on these bands (Figure 5.1 IA).
These experiments were repeated with 1 pM CEP-A using nuclear extracts from
HeLa, NTera2, BxPC3, U20S, and HeLa YS cells (Figures 5.11 and 5.12). The behavior
of the high-molecular weight band for the duplex containing a I,2-d(GpG) intrastrand
cross-link with HeLa nuclear extracts was consistent with the foregoing results (Figures
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5.10 and 5.11), but not for nuclear extracts from any other cell line (Figure 5.12). For
duplexes containing the 1,2-d(GpG) intrastrand cross-link, the total amount of photo-
cross-linking was increased with the addition of the PARP inhibitor for all cell lines
tested by 20 to 100% of the original intensity. Consistent with the experiment using HeLa
nuclear extracts presented in Figure 5.11, addition of CEP-A did not significantly affect
the photo-cross-linking of the duplex containing a 1,3-d(GpTpG) intrastrand cross-link in
nuclear extracts from any of the cell lines tested (Figure 5.13). The total amount of photo-
cross-linking by the 1,3-d(GpTpG) probe increased only slightly upon addition of the
PARP inhibitor for all cell lines tested except BxPC3, which was increased by almost
50%. These results are presented graphically in Figure 5.14.
PARP activity assay with nuclear extracts
HeLa and NTera2 cells were treated with cisplatin for various time points and
nuclear extracts were prepared. The extracts were resolved by SDS-PAGE and analyzed
for the presence of PAR-modified proteins using an antibody for the polymer. These
experiments indicated that several proteins are modified both with and without cisplatin
exposure (Figure 5.15). In NTera2 cells, there is a slight increase in poly(ADP-
ribosyl)ation after one and four h of platinum treatment. After eight h, the amount of
PAR-modified proteins decreases significantly (Figure 5.15A). In HeLa cells, there is no
increase in poly(ADP-ribosyl)ation after cisplatin exposure (Figure 5.15B).
Cell-based PARP activity assay
Due to the nature of the nuclear extraction process, which can activate PARP
proteins upon cellular fragmentation or allow degradation of PAR polymers by PARG, a
quicker lysis method is required. Cells were therefore homogenized in 20%
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trichloroacetic acid, a process that preserves these modifications. 26 Cells were treated
with their IC50 concentration of cisplatin for one h. Using the lysis method, no significant
increase in poly(ADP-ribosyl)ation following cisplatin treatment was evident for any cell
line (Figure 5.16).
IV. DISCUSSION
Poly(ADP-ribose) polymerase-1 (PARP-1) and the PARP family catalyze the
addition of poly(ADP-ribose) (PAR) polymers onto acceptor proteins in a reaction that
consumes NAD+ (Figure 5.1A).9 Each unit of the polymer contains two negatively
charged phosphate moieties, which electrostatically repel DNA molecules from the PAR-
modified protein (Figure 5.1B).' PARP-1 automodification leads to dissociation of the
enzyme from DNA. PARP-1 can also can modify other proteins, including histones,
which relaxes histone-DNA interactions.9 The activity of PARP proteins in the presence
of DNA damage may lead to repair, or conversely, signal cell death (Figure 5.2).
The cell lines tested do not show density-dependent cytotoxicity
In order to develop an assay for the analysis of PARP activity following exposure
to cisplatin, it was necessary to determine the ICso0 values for cells at high confluence
treated for a short exposure time. Cells were plated at high density to ensure that enough
nuclear extracts are collected to get a strong signal from western blot analysis of the
isolated proteins, as discussed below. The MTT assay requires that cells be treated at low
confluence, however, so that their subsequent differences in growth can be assessed. To
achieve both objectives, cells were first treated with various cisplatin concentrations for
one hour at high confluence, and then re-plated into 96-well plates at lower density to
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monitor their growth. With this modified procedure, we tested HeLa, NTera2, BxPC3,
and U20S cell lines for density-dependent sensitivity to cisplatin.
Our assay was adapted from a paper demonstrating density-dependent sensitivity
to cisplatin of cells with functional gap junctions and the DNA-PK heterotrimer. 25 Mouse
fibroblast cell lines MEF and SCID, as well as Chinese hamster ovary (CHO) cells were
used. Knocking down Ku80 in these lines eliminated the density-dependent effect.
Human breast adenocarcinoma (MCF-7) cells only showed density-dependent sensitivity
when supplemented with a vector expressing connexin43, a protein necessary to form gap
junctions. The cell lines tested in the present study were not significantly more sensitive
at high density (Table 5.3, Figure 5.8). This result suggests that these cells may not form
gap junctions at high density, because photo-cross-linking experiments from Chapter 3
indicate that they express all three components of the DNA-PK heterotrimer.
The IC50 values are much higher for this assay than the continuous MTT assay,
described in Chapter 3, where the cells are exposed to cisplatin for 96 h. Here the
cisplatin treatment was only one h. Under these conditions, the BxPC3 cells are the most
cisplatin-resistant of the lines tested (Table 5.3).
NTera2 cells are sensitive to PARP inhibition
The toxicity of three PARP inhibitors (Figure 5.3) was determined for the cell
lines tested to obtain the maximum tolerated dose that could be used to potentiate the
cell-killing ability of cisplatin (Table 5.1, Figure 5.6). NTera2 cells are extremely
sensitive to PARP inhibitors, which hampers our ability to assess their capacity to
enhance cisplatin sensitivity. This result is perplexing given that NTera2 cells express
high levels of PARP-1, as demonstrated in Chapter 3. PARP-1 is commonly mutated in
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germ cells, specific variants being Va1762Ala and Lys940Arg, two residues in the
catalytic domain of the protein.30 Compromised activity of the protein by these mutations
may render it especially sensitive to PARP inhibitors. The reliance of NTera2 cells on
PARP activity, even without the addition of DNA-damaging agents, warrants further
investigation.
PARP inhibitors potentiate the cytotoxicity of cisplatin in certain cancer cell lines
The potentiation of cisplatin sensitivity by PARP inhibitors was assessed in four
cancer cell lines. Testicular (NTera2) and cervical (HeLa) cancer cells were unaffected,
but pancreatic (BxPC3) and osteosarcoma (U20S) cancer cells are sensitized to cisplatin
by PARP inhibition (Table 5.2, Figure 5.7). This finding is consistent with reports in the
literature demonstrating that certain cell lines are unaffected by the presence of PARP
inhibitors, whereas others are sensitized to cisplatin. For example, PARP inhibitors were
unable to sensitize human ovarian tumor cell lines SK-OV-3, OAW-42, and the rat
ovarian tumor cell line 0-342 to cisplatin,31 but could sensitize B16F10 murine
melanoma, 9L rat glioma, HCT-116 human colon carcinoma, DOHH-2 human B-cell
lymphoma, MX-1 human breast carcinoma, and Calu-6 human non-small cell lung
carcinoma cells to the drug. 22' 23 The use of new PARP inhibitors CEP-6800 and ABT-888
(Figure 5.3C and 5.3D) for experiments involving the Bl6F10, 9L, HCT-116, DOHH-2,
MX-1, and Calu-6 cell lines is one reason for this discrepancy, because these compounds
are more water soluble and are able to enter cells and inhibit PARP proteins more
efficiently.22'23 The present work demonstrates that there is also a cell line dependence to
this effect. The sensitization of certain cell lines to cisplatin by PARP inhibitors may be
caused by differences in the processing of platinum-DNA adducts in the absence of
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PARP activity. This possibility was investigated by performing photo-cross-linking
studies in the presence of the PARP inhibitor, CEP-A, as described in the next section.
PARP-1 activity dissociates proteins from platinum-modified DNA in nuclear
extracts
The activity of poly(ADP-ribose) polymerase (PARP) proteins in the presence of
DNA damage can lead to repair or, conversely, signal cell death (Figure 5.2). It was
recently discovered that PARP-1 binds to platinum-modified DNA.3 2 33 PARP-1 and the
PARP family catalyze the addition of poly(ADP-ribose) (PAR) polymers onto acceptor
proteins in a reaction that consumes NAD' (Figure 5.1A). 9 Each unit of the polymer
contains two negatively charged phosphate moieties, which can electrostatically repel
DNA molecules from PAR-modified proteins (Figure 5.1B).' PARP-1 automodification
leads to dissociation of the enzyme from DNA, and the protein can also catalyze the
modification other proteins, including histones, which relaxes histone-DNA interactions. 9
In the present work, we studied the consequences of PARP activity upon exposure of
nuclear proteins to platinum-modified DNA using photo-cross-linking experiments.
The method utilizes DNA containing a site-specific adduct of a benzophenone-
modified cisplatin analogue Pt-BP6. Photo-cross-linking with such probes enables the
study of nuclear proteins that bind to platinum-modified DNA. Several platinum-
modified DNA-binding proteins have been identified in this manner, as discussed
elsewhere. 32 33 Here we performed photo-cross-linking experiments in the presence of the
PARP inhibitor CEP-A (Figure 5.3B). The addition of CEP-A to nuclear extracts prior to
photo-cross-linking generally increased the amount of proteins photo-cross-linked to Pt-
BP6-modified DNA (Figures 5.12-14). This result is consistent with a model in which
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PARP activity stimulated by platinum-DNA cross-links results in the PAR-modification
of DNA-binding proteins, causing them to dissociate from the duplex (Figure 5.1B).'
Inhibition of PARP activity by CEP-A eliminates this effect, resulting in more stable
protein-DNA interactions and, consequently, increased amounts of photo-cross-linking.
Our experiments indicate that the addition of PARP inhibitor significantly
increases the photo-cross-linking of proteins to the platinum-modified DNA containing a
1,2-d(GpG) intrastrand adduct of Pt-BP6 in each type of nuclear extract examined except
for HeLa (Figures 5.12-14). Nuclear extracts from HeLa cells exhibited only a modest
increase in photo-cross-linking following addition of the PARP inhibitor (Figures 5.11,
5.12, 5.14). In these nuclear extracts exclusively, a high molecular weight band decreases
in intensity with the addition of PARP inhibitor (Figure 5.11, band 7). This result
indicates that PARP-1 activity in HeLa extracts following exposure to platinum-damaged
DNA is unique.
Photo-cross-linking was more significantly affected for the 1,2-d(GpG) than the
1,3-d(GpTpG) intrastrand cross-link (Figures 5.12-14). This effect was consistent across
all cell lines tested, although to a lesser degree for BxPC3 extracts, indicating that the
1,2-d(GpG) intrastrand cross-link more efficiently activates the protein. Experiments
using extracts from HeLa cells in which PARP-1 has been silenced with RNAi (HeLa
YS) reveal an increase in photo-cross-linking, similar to the behavior of NTera2, BxPC3
and U20S cellular extracts. This result most likely indicates that, in the PARP-l-silenced
cell line, other PARP isoforms are present having the same activity as PARP-1.
There is no significant change in poly(ADP-ribosyl)ation following cisplatin
treatment of the cell lines tested
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Two methods were used to monitor poly(ADP-ribosyl)ation following exposure
to cisplatin. Using nuclear extracts from cisplatin-treated cells, a small increase in PAR
modification was evident in NTera2 but not in HeLa cells (Figure 5.15). Several
distinctly modified proteins are present in treated as well as untreated extracts. PAR-
modification of proteins can be effected by the nuclear extraction process, so a rapid cell
lysis procedure was employed. 26 Using this methodology, we observed no significant
change in poly(ADP-ribosyl)ation (Figure 5.16). There were fewer distinct bands by this
method, however, a large diffuse higher molecular weight signal was present. This
feature is characteristic of proteins containing various degrees of PAR modification, as
demonstrated by a similar assay for EM9 cells treated with a methylating agent.15 This
type of assay was also used to show a mild increase in PAR-modified proteins in HT29
colon cancer cells treated with 10 M cisplatin, but only 24 h after exposure.20 If PARP
proteins are activated upon binding to cisplatin-DNA adducts, this response would occur
more quickly. Only HT29 cells were used in that experiment, so the importance of PARP
activity in cisplatin sensitivity cannot be determined. Although HeLa cells were used for
part of the study, the authors did not present PARP activity assays for the cell line. 20 The
present results indicate either that PARP proteins are not significantly activated
immediately following cisplatin exposure in the four cell lines tested, or that such
modification is not revealed by our assay.
V. CONCLUSIONS
Several studies in the literature report varying degrees of sensitization of cancer
cells to cisplatin by PARP inhibitors. It has thus far been difficult to determine whether
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these inconsistencies are due to the cell lines or the inhibitors used, since both are varied.
We present here the finding that PARP inhibitors sensitize cells to cisplatin in a manner
that is cell line dependent. In our work, PARP inhibition resulted in the greatest increase
in cisplatin sensitivity for U20S osteosarcoma cells. NTera2 testicular carcinoma cells do
not show this effect, but are very sensitive to PARP inhibitor themselves. This effect may
be due to PARP-1 mutations, which are common in germ cells. Photo-cross-linking
studies in the presence of a PARP inhibitor indicate that the activity of PARP proteins
bound to platinum-damaged DNA leads to dissociation of PARP- I1 itself, as well as other
proteins, from the damaged duplex. We also discovered that PARPs are more activated in
nuclear extracts by a 1,2-d(GpG) than a 1,3-d(GpTpG) PtBP6 cross-link. Upon treating
cells with cisplatin, we found no increase in PAR-modified proteins. Our assay was
unable to resolve the activation of PARP proteins following cisplatin treatment even in
U20S cells, for which PARP inhibitors sensitized the cells to cisplatin by a factor of 3.6.
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VII. TABLES
Table 5.1: Maximum tolerated dose of three PARP inhibitors in four
cancer cell lines
Cell line
HeLa
NTera2
BxPC3
U20S
4-ANI (iM) CEP-A (jtM) CEP-6800 (IM)
2.0
0.1
2.0
1.0
3.0
0.1
3.0
1.0
Table 5.2: IC 50 values for cDDP co-treated with maximum tolerated dose of three PARP inhibitors in four
cancer cell lines
Cell line
HeLa
NTera2
BxPC3
U2OS
cDDP alone (jM) + 4-ANI (tM) + CEP-A (jIM) + CEP-6800 (pM) Sensitization
1.0
0.04
1.5
3.3
1.1
0.04
0.9
1.4
0.8
0.04
1.0
1.1
0.04
1.0
none
none
1.6-fold
2.3-fold
Table 5.3: Density-dependent IC 50 values for cDDP in
four cancer cell lines
Cell line
HeLa
NTera2
BxPC3
U20S
High density (jtM) Low density (pM)
16
0.94
24
20
11
1.70
24
18
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Figure 5.1. The catalytic activity of PARP proteins.
PARP proteins catalyze the addition of negatively charged poly(ADP-ribose) polymers to
acceptor proteins using NAD+ as a substrate (A). This modification is important for DNA
repair because the modified proteins will be electrostatically repelled from the DNA (B).
This activity can be eliminated by the addition of PARP inhibitors.
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Figure 5.2. Three pathways of PARP activity.
The activity of PARP proteins following DNA damage can lead to DNA repair, apoptosis
or necrosis through independent mechanisms.
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Figure 5.3. Chemical structures of four PARP inhibitors.
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Figure 5.4. 'H NMR of PARP inhibitor CEP-A.
This compound was synthesized and characterized by Alison Ondrus of the Movassaghi
lab.
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Figure 5.7. Cytotoxicity assays of cisplatin co-treated with PARP inhibitors in HeLa,
NTera2, BxPC3, and U20S cells.
Cells were treated with cisplatin alone (*) or co-treated with maximum tolerated dose of
4-ANI (U), CEP-A (&) or CEP-6800 (0). These results are summarized in Table 5.2.
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Figure 5.8. Density-dependent cytotoxicity assays for cisplatin in four cell lines.
Each cell line was tested against increasing concentrations of cisplatin. Cells were treated
at high ( ) or low (*) density with cisplatin for one h and replated into a 96-well plate
suitable for the MTT assay. These results are summarized in Table 5.3.
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High density cytotoxicity assays for cisplatin in HeLa YS and HeLa pcDNA
HeLa cells with PARP-1 silenced (*) cells are significantly more sensitive to cisplatin
than HeLa cells transfected with a control plasmid (m) using the high density
cytotoxicity assay.
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Figure 5.10. Structure of zeocin selection reagent.
This image was taken
http://tools.invitrogen.com/content/sfs/manuals/zeocinman.pdf.
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Figure 5.11. Photo-cross-linking of PtBP6-modified 25-bp
concentrations of the PARP inhibitor, CEP-A.
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For the 1,2-d(GpG) adduct, the intensity of Band 1 increases and the intensity of Band 2
decreases at increasing concentrations of CEP-A. The photo-cross-linking of the 1,3-
d(GpTpG) is unaffected by the inhibitor.
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Figure 5.12. Photo-cross-linking of 25-bp duplex containing a 1,2-d(GpG) adduct of
PtBP6 in various cancer cell extracts in the presence of the PARP inhibitor, CEP-A.
The inhibitor increases the intensity of photo-cross-linking in each cell line.
194
Cell Type HeLa NTera2 BxPC3 U20S HeLa YS
CEP-A -+ + - + + +
o.... .... o0
~~2
I_
_~~_ ~__ ___I__~__~~___~___~~__~_ ~~_~_~_
Figure 5.13. Photo-cross-linking of 25-bp duplex containing a 1,3-d(GpTpG) adduct of
PtBP6 in various cancer cell extracts in the presence of the PARP inhibitor, CEP-A.
The inhibitor does not have a significant effect in any of the cell lines.
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Figure 5.14. Intensity of total photo-cross-linking for site-specifically platinated DNA,
with or without addition of the PARP inhibitor CEP-A.
The effect of PARP inhibitor CEP-A in photo-cross-linking experiments, revealing an
increase in total intensity of photo-cross-linking. The effect is greater for the 1,2-d(GpG)
than the 1,3-d(GpTpG) intrastrand cross-link. The effect is also cell-line dependent, with
HeLa cells exhibiting the smallest increase.
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Figure 5.15. Nuclear extract-based PARP activity assay for HeLa and NTera2 cells.
Nuclear extracts from HeLa (A) and NTera2 (B) cells were prepared from cells treated
with the IC50 value of cisplatin for various time points. The extracts were used in a
western blot for PAR polymers. Cytosolic extracts from NTera2 cells were also used, but
yielded no signal. The membrane was blotted for 13-actin as a loading control.
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Figure 5.16. Cell lysis-based PARP activity assay.
Cells were treated with the IC 50 concentration of cisplatin for 1 h, and then collected and
lysed. The lysates were analyzed by western blot for the product of PARP activity, PAR
polymers. No major differences exist between cisplatin treated and untreated cells or
between the various cancer cell lines tested.
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Appendix A: Synthesis and characterization of a benzophenone-
modified DNA probe.
*Some of the work discussed in this chapter was conducted by UROP students Cindy
Yuan and Noel Lee.
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I. INTRODUCTION
Chapters 2-4 describe the synthesis of DNA containing site-specific adducts of a
photo-activatable analogue of cisplatin, PtBP6. Photo-cross-linking experiments using
PtBP6-modified DNA are limited to identifying proteins that bind to this type of platinum
adduct. By tethering the benzophenone moiety directly to the DNA, photo-cross-linking
experiments can be carried out using other DNA-damaging agents, as well as undamaged
DNA (Figure A.1). As described in Chapter 2, PtBP6-modified DNA photo-cross-links
the mismatch repair protein Msh2. This protein does not have an affinity for oxaliplatin-
modified DNA,1 demonstrating that there may be important differences in the recognition
of these types of adducts. In Chapter 1, some new types of platinum compounds that
display anticancer activity are discussed. Using a probe containing benzophenone-
modified DNA, it would be possible to determine the proteins that bind to DNA lesions
of these new complexes. The bulge created on the DNA strand opposite an intrastrand
adduct is important for DNA damage recogition. 2 Placing a photo-cross-linking moiety
on this strand may uncover new damage recognition proteins that are not positioned
favorably to photo-cross-link to the PtBP6-modified probe.
Using commercially available amino-modified phosphoramidites (Figure A.2),
benzophenone-modified DNA can be accessed in a one-step reaction (Scheme A.1).
Three different probes were synthesized to optimize the location of the benzophenone
unit along the DNA (Figure A.3). Analytical-scale photo-cross-linking experiments using
one of these probes yielded unique protein-DNA complexes for cisplatin-modified versus
unmodified DNA.
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II. MATERIALS AND METHODS
Solvents and chemical reagents were purchased from commercial sources. DNA
strands were prepared on an Applied Biosystems ABI 392 DNA/RNA synthesizer using
solvents and reagents supplied by Glen Research. Enzymes were purchased from New
England BioLabs and Promega. UV-vis spectra were obtained on an HP 8453 UV-visible
spectrometer. Platinum analyses were performed by flameless atomic absorption
spectroscopy on a Perkin-Elmer AAnalyst 300 system. Analytical and preparative HPLC
work was performed on an Agilent 1200 HPLC system. UV irradiation was conducted in
a Stratagene Stratalinker UV Crosslinker.
Synthesis of amino-modified DNA
Three 25-base DNA fragments were synthesized on the DNA synthesizer.
a. 16A: 5'-GGAGAGAAG(A-am)TCCTGAGAGGAGAGG-3', in which (A-
am) is an amino-modifier C6 dA phosphoramidite (Glen Research)
b. 11T: 5'-GGAGAGAAGATCC(T-am)GAGAGGAGAGG-3', in which (T-am)
is an amino-modifier C6 dT phosphoramidite (Glen Research)
c. 15G: 5'-GGAGAGAA(G-am)ATCCTGAGAGGAGAGG-3', in which (G-
am) is an amino-modifier C6 dT phosphoramidite (Glen Research)
The DNA was incubated overnight at 37 'C in 2 mL of 30% ammonium
hydroxide. DNA strands were purified by 12% urea denaturing PAGE and visualized by
UV shadowing. The DNA was then excised from the gel and isolated using the crush and
soak method. The crushed gel was filtered and the purified DNA was ethanol
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precipitated. The DNA pellet was then dissolved in water and dialyzed against water,
using dialysis tubing with a MWCO of 3500.
Synthesis of a benzophenone-modified DNA strand
The synthesis of benzophenone-modified DNA was adapted from similar work
with DNA modifications (Scheme A.1). 3,4 Amino-modified DNA was allowed to react
with 200 molar equivalents of the N-hydroxysuccinimidyl ester of p-benzoylbenzoic acid
(Invitrogen). The NHS ester of p-benzoylbenzoic acid was dissolved in 200 tL of DMF,
and a 50 ttL aliquot was added to the amino-modified DNA every 30 min for two h. The
reaction was stirred overnight in the dark. The solution was filtered and the product was
purified by RP-HPLC. The RP-HPLC method employed a gradient of 5-50% B over 30
min on an Agilent 300SB-C18 column where solvent A was 0.1 M ammonium acetate
and solvent B was 0.1 M ammonium acetate in 50% water and 50% acetonitrile. Peaks
were collected and lyophilized. The lyophilized DNA was dissolved in water and
dialyzed against water, using dialysis tubing with a MWCO of 3500.
Characterization of benzophenone-modified DNA
The 25-base 16A-BP DNA was analyzed by ESI-TOF mass spectrometry,
performed by Jim Delaney of the Essigmann lab. The 25-base 1 1T-BP DNA was
analyzed by the Maxam-Gilbert sequencing reactions following the protocol outlined in
Chapter 2. Enzymatic DNA digestion was used to characterize all three benzophenone-
modified probes following the protocol outlined in Chapter 2.
Synthesis of cisplatin-modified 25-base top strand
A 25-base DNA of the sequence 5'-CCTCTCCTCTCAGGATCTTCTCTCC-3'
was synthesized and purified as described previously for the amino-modified DNA. The
202
DNA was then incubated with cisplatin, which had been activated using the same
methodology as reported for PtBP6 in Chapter 2. The reaction was purified by IE-HPLC
using a gradient of 40-60% B over 30 min on an Agilent Zorbax Oligo column, where
solvent A was 25 mM TEAA in 90% water and 10% acetonitrile and solvent B was
solvent A with I M NaCi. The peak eluting at 16.3 min was collected and lyophilized.
The lyophilized DNA was dissolved in water and dialyzed against water to remove salts,
using dialysis tubing with a MWCO of 3500.
Characterization of cisplatin-modified 25-base top strand
The collected peak was characterized by UV-visible absorbance and atomic
absorption spectroscopy to establish a 1:1 ratio of platinum per DNA. The DNA was also
characterized by nuclease digestion analysis as described in Chapter 2.
Preparation of double-stranded probes
Each benzophenone-modified DNA fragment was radiolabeled as described in
Chapter 2 and then combined with an equimolar amount of the complementary platinum-
modified or unmodified strand in annealing buffer (50 mM Tris-HCl pH 7.9, 100 mM
NaC1, 10 mM MgCl 2, 1 mM DTT). The solution was heated to 90 C for 5 min and
cooled to 16 oC over 3 h. The DNA was then ethanol precipitated, dried by vacuum
centrifugation, purified by 15% native PAGE, and located using audioradiography. The
DNA was extracted using the crush and soak method and the purity of the duplex was
verified by 15% native PAGE.
Analytical-scale photo-cross-linking experiments
In an eppendorf tube, 1 pmol of benzophenone-modified double-stranded
radiolabeled DNA was combined with 20 /g of HeLa nuclear extracts in 20 uL of protein
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binding buffer (10 mM Tris pH 7.5, 10 mM KC1, 10 mM MgC12, 1 mM EDTA, 0.05%
NP-40, 0.2 yg/mL BSA). The solution was exposed to UV irradiation for two h on ice.
The cross-linked products were then analyzed by 10% SDS-PAGE with a 4% stacking
gel.
III. RESULTS
Synthesis and characterization of benzophenone-modified DNA
Commercially available amino-modified bases (Figure A.2) were incorporated
into 25-base DNA strands. Three 25-base DNA probes (Figure A.3) containing
benzophenone modifications were purified by RP-HPLC (Figure A.4). The analysis
described below indicates that peak 1 for each reaction contains the amino-modified
starting material, and peak 2 contains the benzophenone-modified product. Following
dialysis at a MWCO of 3500, no UV-vis signal was present for peaks 3 and 4, indicating
that they contain reaction byproducts of low molecular weight.
DNA strands 16A-BP, I T-BP and 15G-BP were purified with 22%, 30% and
8% yields, respectively. ESI-TOF analysis of the 16A-BP DNA displayed a peak at
1642.0270 m/z corresponding to the -5 charged species, computed to have m/z = 1642.3
for a 25-base DNA with a benzophenone-modified adenine. Nuclease digestion of
unmodified 25-base DNA, with theoretical values of 2:12:2:9 for C:G:T:A, indicated an
experimental ratio of 1.9:12.0:2.0:9.1 (Figure A.5A). The I1 T-BP DNA, which is
expected to have one fewer thymine than the unmodified DNA, was 2.1:12.4:0.9:8.7
(Figure A.5B). The 15G-BP DNA was 2.2:10.7:2.0:9.0 (Figure A.5C) and the 16A-BP
DNA, 2.1:11.8:2.0:8.1 (Figure A.5D). All of these ratios are consistent with a
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modification at the expected base. Maxam-Gilbert analysis of the 11T-BP DNA indicates
that the modified base is the expected thymine (Figure A.6). Digested DNA containing
this base is slightly retarded in the gel compared to DNA containing the amino-modified
base (Figure A.6).
Synthesis and characterization of cisplatin-modified DNA
A 25-base DNA fragment containing a 1,2-d(GpG) adduct of cisplatin was
purified by IE-HPLC. The purification yielded 1.7 nmol of platinated DNA, a 2.4% yield.
UV-vis and AAS analysis showed that the collected DNA had a 1.04 -+ 0.16 platinum
atoms per 25-base DNA. Nuclease digestion of the unplatinated DNA, with a theoretical
C:G:T:A ratio of 12:2:9:2, provided values of 12.0:2.1:9.0:2.0 (Figure A.7A). The
platinated DNA returned a 12.0:0.2:9.0:1.8 ratio, indicating that the guanine bases were
platinated (Figure A.7B). Peaks at 15.0 and 19.5 min appear in the nuclease digestion of
the cisplatin-modified DNA (Figure A.7B). These peaks likely contain digestion products
[cis-Pt(NH3)2{d(GpG)}] , [cis-Pt(NH3)2{d(pGpG)}], [cis-Pt(NH3)2(d(G))2]2 , or [cis-
Pt(NH3)2(d(G))(d(pG))]*.
Synthesis of 25-bp duplexes
Each of the benzophenone-modified DNA probes was annealed to cisplatin-
modified and unmodified DNA. The duplexes were purified by 15% native PAGE.
Analytical-scale photo-cross-linking of benzophenone-modified DNA
Analytical-scale photo-cross-linking indicated that all three probes were able to
photo-cross-link to proteins (Figure A.8). Only photo-cross-linking using the 15G-BP
probe yielded unique proteins for platinated versus unplatinated DNA (Figure A.8C).
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IV. DISCUSSION
The success of PtBP6-modified DNA in identifying proteins that bind to
platinum-modified DNA, described in Chapters 2-4, had stimulated interest in photo-
cross-linking methodologies that can identify proteins that bind to other types of platinum
adducts and DNA-damaging agents. In this work, the benzophenone modification has
been moved from the platinum atom to the DNA. Three benzophenone-modified DNA
strands were synthesized. These strands were then annealed to cisplatin-modified and
unmodified complementary DNA. The 11T-BP and 16A-BP (Figure A.3) probes photo-
cross-linked to proteins, but the results from the undamaged or cisplatin-modified were
identical (Figures A.8A and A.8B). Only the 15G-BP probe (Figure A.3) yielded
cisplatin-specific photo-cross-linking (Figure A.8C). This result indicates that a
modification at this base does not interfere with recognition of the platinum adduct and
that it is positioned favorably for photo-cross-linking of proteins bound to the damage
site. Preparative-scale photo-cross-linking experiments need to be completed for the 15G-
BP probe to identify these proteins. Moreover, the complementary strand to 15G-BP
should be synthesized with different platinum compounds, such as oxaliplatin, to
determine whether the nature of the platinum compound dictates the binding of damage
recognition proteins.
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VI. SCHEMES
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Scheme A.I. Synthesis of benzophenone-modified DNA form commercially available
starting materials.
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Figure A.1. Photo-cross-linking using benzophenone-modified DNA.
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Figure A.3. The sites of benzophenone attachment used in these experiments.
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Figure A.4. RP-HPLC purification of benzophenone-modified DNA.
The RP-HPLC purification of the 11T-BP (A), 15G-BP (B) , andl6A-BP (C) reactions.
In each trace, peak 1 contains amino-modified starting material (Figure A.2), peak 2
contains the benzophenone-modified product. Following dialysis at a MWCO of 3500, no
UV-vis signal was present for peaks 3 and 4, indicating that these peaks contain reaction
byproducts of low molecular weight.
212
j B
140*J 3
10-00 I
2
i i H
a to0 20 30 40 . 40
K
40 40 ' I~ii " 94 9 0 iP . .................
\~i t- ---- -'
?m ~ao
A
A G
C
;i i i I"
*1i0
.j
S i C T
Base Expected Unmodified
1.9
12.0
2.0
9.1
llT-BP
2.1
12.4
0.9
8.7
15G-BP
2.2
10.7
2.0
9.0
16A-BP
2.1
11.8
8.2
8.1
Figure A.5. Nuclease digestion analysis of unmodified and benzophenone-modified DNA
probe.
Unmodified (A), 1l T-BP (B), 15G-BP (C), and 16A-BP (D) DNA. The table indicates
the calculated values for each modified DNA.
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Figure A.6. Maxam-Gilbert analysis of amino- versus benzophenone-modified DNA.
A) 20% urea-PAGE analysis of the Maxam-Gilbert sequencing reactions. The
benzophenone-modified probe contains a larger modification, which slightly retards the
gel mobility of the digested DNA containing the modification. The DNA that does not
contain the modified base migrates through the gel with equal mobility. A graphical
representation of the gel (B) illustrates the difference in gel mobility between a band
containing the benzophenone-modification (1) and one that does not (2).
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Figure A.7. Nuclease digestion analysis of cisplatin-modified DNA.
The digestion of the unplatinated strand (A) matched the expected peak areas for each
base. The digestion of the platinated probe (B) indicated that the two guanines of the
DNA were bound by platinum.
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Figure A.8. Photo-cross-linking of DNA-BP duplexes.
The photo-cross-linking of the 11T-BP (A), 16A-BP (B), and 15G-BP (C) probes are
presented. Lane 1: Probe annealed to unplatinated DNA. Lane 2: Probe annealed to
cisplatin-modified DNA. The arrows in C indicate protein-DNA complexes containing
proteins photo-cross-linked exclusively by either the unplatinated or platinated DNA. The
differences between lanes 1 and 2 in C indicate that the 15G-BP probe is able to photo-
cross-link to cisplatin-damaged DNA-binding proteins.
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Appendix B: Synthesis and characterization of a benzophenone-
modified 157-base pair probe.
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1. INTRODUCTION
The success of the 25-bp duplex and 90-base probes for photo-cross-linking and
identification of proteins that bind to platinum-modified DNA, described in Chapters 2-4,
led us to investigate an even longer DNA probe. Such a probe would increase the
distance between DNA end-binding proteins and the photo-cross-linker, perhaps
providing a more realistic environment of damaged DNA in cells. Work from our lab has
demonstrated our ability to use 146-bp site-specifically platinated duplex probes to
reconstitute nucleosomes from both native and recombinant histones.-4 The synthesis of
such a long PtBP6-modified duplex would therefore allow photo-cross-linking
experiments to take place on nucleosomal DNA in the future. In the present work, a
PtBP6-modified 157-bp probe was synthesized. Analytical-scale photo-cross-linking
experiments using this DNA were carried out.
II. MATERIALS AND METHODS
All solvents and chemical reagents were purchased from commercial sources.
DNA strands were synthesized on an Applied Biosystems ABI 392 DNA/RNA
synthesizer using solvents and reagents supplied by Glen Research. Enzymes were
purchased from New England BioLabs and Promega. UV-vis spectra were obtained on an
HP 8453 UV-visible spectrometer. UV irradiation was conducted in a Stratagene
Stratalinker UV Crosslinker.
Synthesis and characterization of'a site-specifically platinated 25-base DNA
Synthesis and characterization of a 25-base DNA containing a 1,2-d(GpG) adduct
of PtBP6 were carried out as described in Chapter 2.
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Synthesis of other DNA strands. A set of 48-, 49-, 60-, 63-, and 69-base DNA
strands of the desired sequence, shown in Figure B.1, were prepared on the DNA
synthesizer and purified by 6% urea-PAGE as described for the 65-base DNA in Chapter
4.
Synthesis of a 157-bp duplex containing a 1,2-d(GpG) intrastrand adduct of
PtBP6
PtBP6-platinated or unplatinated 25-base DNA was radiolabeled using T4 PNK
and y-32P-ATP as described in Chapter 2. The 48-, 49-, and 69-base DNA strands were
phosphorylated using standard T4 PNK protocols in 10 mM ATP. In an eppendorf tube,
100 pmol of radiolabeled 25-base DNA, phosphorylated 48-, 49-, and 69-base DNAs and
unmodified 60- and 63-base DNAs were combined in 100 jiL of NEBuffer 3 (New
England BioLabs, 50 mM Tris-HCl pH 7.9, 100 mM NaCI, 10 mM MgCI2, I mM DTT).
The DNA was heated to 90 oC for 5 min and cooled to 16 oC over 4 h. To each tube was
added 100 L of ligation reaction buffer (50 mM Tris-HC1, 10 mM MgC12, 1 mM ATP,
10 mM DTT pH 7.5, 400 units T4 DNA ligase). The solutions were incubated at 16 oC
overnight. The DNA was then ethanol precipitated, dried by vacuum centrifugation, and
analyzed and subsequently purified by 6% urea-PAGE. The DNA was visualized by
audioradiography and extracted from the gel by the crush and soak method. Following
purification, the DNA strands were reannealed.
Analytical-scale photo-cross-linking of 157-bp duplex containing a 1,2-d(GpG)
intrastrand adduct of PtBP6
To 1 pmol of a 157-bp duplex was added 20 tg of HeLa nuclear extracts in 20 gL
of protein binding buffer (10 mM Tris pH 7.5, 10 mM KC1, 10 mM MgC12, 1 mM EDTA,
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0.05% NP-40, 0.2 ig/mL BSA). The solution was incubated on ice for 30 min and then
exposed to UV irradiation for 2 h on ice. The cross-linking was analyzed by 5% SDS-
PAGE with a 4% stacking gel.
Exonuclease digestion of 157-bp duplex
To each of four eppendorf tubes containing 20 iL of binding buffer was added 2
pmol of radiolabeled PtBP6-platinated or unplatinated 157-bp duplex. Next, 0.5 tL of
0.05 M dithiothreitol and 0, 0.5, 1 or 1.5 gL of ExollI (New England BioLabs) was added
to the tubes. The DNA was incubated at 37 oC for 30 min and the reactions were then
ethanol precipitated and analyzed by 5% urea-PAGE.
Enzymatic digestion-coupled analytical-scale photo-cross-linking of 157-bp
duplex containing a 1,2-d(GpG) intrastrand adduct ofPtBP6
To 1 pmol of 157-bp duplex was added 20 ig of nuclear extract and 20 gL of
binding buffer (10 mM Tris-HCI pH 7.5, 10 mM MgCl 2, 50 mM KC1, 1 mM EDTA,
0.05% NP-40, 0.2 gg/mL BSA). The samples were UV irradiated for 2 h on ice. To the
sample was added 0.5 gL of 0.05 M dithiothreitol and 0.5 [iL of ExolII. The reactions
were incubated at 37 'C for 20 min and then analyzed by 5% SDS-PAGE.
III. RESULTS
A 157-bp duplex site-specifically platinated with a 1,2-d(GpG) adduct of PtBP6
was synthesized and used for preliminary photo-cross-linking experiments. This probe
was built from six separate DNA fragments, including a 25-base platinated DNA (Figure
B.1). The synthesis and characterization of this DNA fragment are described in Chapter
2.
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Synthesis of a 157-bp duplex containing a 1,2-d(GpG) intrastrand adduct of
PtBP6
A 157-bp duplex containing a 1,2-d(GpG) intrastrand adduct of PtBP6 was
synthesized from six DNA fragments using standard methodology. The DNA was
phosphorylated, annealed, and ligated using commercially available enzymes. The DNA
was analyzed by 6% urea-PAGE (Figure B.2). This gel indicates that a significant
amount of 157-base DNA was formed in the reaction, and this DNA was then purified by
preparative 6% urea-PAGE.
Analytical-scale photo-cross-linking of 157-bp duplex containing a 1,2-d(GpG)
intrastrand adduct of PtBP6
Standard analytical-scale photo-cross-linking experiments, described in Chapter
2, were carried out using this 157-bp duplex. The protein-platinum-DNA complexes were
not resolved and a long smear is visible on the gel (Figure B.3). Photo-cross-linking
experiments using shorter probes, described in Chapters 2-4, resolved into distinct
protein-platinum-DNA complexes. These results indicate that shorter DNA strands lead
to better resolution of the bands. In order to shorten the 157-bp probe following photo-
cross-linking but before the gel was carried out, the DNA was digested with an
exonuclease.
Exonuclease digestion of 157-bp duplex
To decrease the size of the DNA and increase the resolution of the photo-cross-
linking experiments, we digested the 157-bp duplex with exonuclease III. In initial
experiments, the DNA was digested without exposure to nuclear extracts to ensure that
this method would sufficiently degrade the DNA. Urea-PAGE analysis of the digested
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DNA shows that the protocol was effective in producing a smaller DNA strand (Figure
B.4). The band at about 80 bases in lane 4 indicates that the platination site is able to
block the nuclease from completely degrading the DNA. This property is important
because the radiolabel and the photo-cross-linker must remain tethered in order to
visualize protein-platinum-DNA adducts by PAGE.
Exonuclease digestion-coupled photo-cross-linking
The duplex was then used in photo-cross-linking experiments, followed by
incubation with exonuclease III prior to SDS-PAGE analysis. The gel revealed a number
of more clearly resolved bands (Figure B.5), although the resolution still needs to be
improved before preparative-scale experiments can be carried out.
IV. DISCUSSION
Chapters 2-4 describe the photo-cross-linking and identification of proteins with
an affinity for platinum-modified DNA using a photo-activatable cisplatin analogue,
PtBP6. In that work, 25-bp and 90-base dumbbell probes were site-specifically modified
with a platinum adduct. In the present work, a site-specifically platinated 157-bp duplex
was synthesized and used in preliminary photo-cross-linking experiments. The longer
DNA probe provides a better mimic of the environment of DNA damage inside a cell.
Further, this type of duplex could be synthesized and used to reconstitute nucleosomes,
and the proteins that bind to platinum-modified nucleosomal DNA could be identified.
Initial photo-cross-linking experiments using this 157-bp probe indicated that the
protein-platinum-DNA complexes will not separate well by SDS-PAGE (Figure B.3).
Exonuclease digestion of the DNA following UV irradiation but prior to gel analysis
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leads to better resolution of complexes (Figure B.5). The resolution of the DNA-
platinum-protein complexes needs to be improved further before photo-cross-linking
experiments on nucleosomal DNA will be possible, which may require other DNA
digestion techniques to shorten the DNA prior to analysis.
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VI. FIGURES
-= biotin P= PtBP6
25
63 69
48 49 60
63-base DNA:
5'-ATCAATATCCACCTGCAGATTCTACCAAAAGTGTATTTGGAA
ACTGCTCCATCAAAAGGCATG-3'
69-base DNA:
5'-CCTCAACATCGGAAAACTACCTCGTCAAAGGTTTATGTGAAA
ACCATCTTAGACGTCCACCTATAACTA-biotin-3'
25-base DNA:
5'-CCTCTCCTCTCAGGATCTTICTCTCC-3'
60-base DNA:
5'-TAGTTATAGGTGGACGTCTAAGATGGTTTTCACATAAACCTT
TGACGAGGTAGTTTTCCG-3'
49-base DNA:
5'-ATGTTGAGGGGAGAGAAGATCCTGAGAGGAGAGGCATGCC
TTTTGATGG-3'
48-base DNA:
5'-AGCAGTTTCCAAATACACTTTTGGTAGAATCTGCAGGTGGAT
ATTGAT-3'
Figure B.1. The 157-bp duplex is synthesized from six shorter DNA fragments.
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Figure B.2. 6% urea-PAGE analysis of 157-base DNA probe.
1) Unplatinated DNA. 2) PtBP6-modified DNA.
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1
Figure B.3. Analytical-scale
extracts.
2
photo-cross-linking of 157-bp probe with HeLa nuclear
Lane 1: Unplatinated DNA. Lane 2: PtBP6-modified DNA. The PtBP6-modified probe
photo-cross-links to several proteins, however, these protein-platinum-DNA complexes
are not resolved on the gel.
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Figure B.4. Exonuclease III digestion of 157-bp duplexes.
Lane 1: Unplatinated duplex. Lane 2: Exonuclease III digested unplatinated 157-bp
duplex. Lane 3: PtBP6-modified 157-bp duplex. Lane 4: Exonuclease III digested PtBP6-
modified 157-bp duplex. The exonuclease is stalled at the platination site, resulting in a
band at 81 bases.
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Figure B.5. Exonuclease-coupled photo-cross-linking experiment with 157-bp duplex.
Lane 1: Unplatinated DNA. Lane 2: PtBP6-modified DNA. The arrows indicate protein-
platinum-DNA complexes.
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Appendix C: Synthesis of PtBP6-modified d(GpG).
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I. INTRODUCTION
Chapters 2-4 describe the identification of nuclear proteins that bind to platinum-
modified DNA using the photoactive cisplatin analogue cis-[Pt(NH3)(N-(6-aminohexyl)-4-
benzophenonamide)C1 2] (PtBP6). The binding of this molecule to DNA should afford two
orientational isomers as demonstrated with similarly asymmetric platinum compounds. The
orientational isomers of cis-[Pt(NH 3)(C6HiINH2){d(GpG)}]l 1 were investigated using a d(GpG)
containing an 15N-labeled N7 atom on the 3'-guanine.1 The study of cis-[Pt(NH3)(4-
aminoTEMPO){d(GpG)}] +2 was aided by the presence of the paramagnetic nitroxide moiety. 2
These studies demonstrated that an asymmetric cis-[Pt(NH3)(NH2R)2+ {d(GpG)}] cross-link can
have the RNH 2 ligand oriented toward either the 5'- or 3'-end of the DNA (Figure C. 1).
The d(pGpG) dinucleotide itself can also align into different conformers. 3-8 In order to
characterize these conformers, platinum compounds containing bulky amine ligands were
synthesized that slow the dynamic motion of the dinucleotide. Using 2-2'-bipiperidine-modified 6
and N,N'-dimehtyl-2,4-diaminopentane-modified 8 platinum compounds, the structures of several
such conformers were established (Figure C.2). In the present study, cis-[Pt(NH3)(N-(6-
aminohexyl)-4-benzophenonamide) {d(GpG) } ] was prepared and preliminary NMR
spectroscopy experiments were performed to characterize the platinated DNA.
II. MATERIALS AND METHODS
Solvents and chemical reagents were purchased from commercial sources. The d(GpG)
molecule was prepared using solvents and reagents supplied by Glen Research. UV-vis spectra
were obtained on an HP 8453 UV-visible spectrometer. Analytical and preparative HPLC work
was performed either on an HP Waters or an Agilent 1200 HPLC system. LC/MS was performed
on an Agilent 1100 Series LC/MSD system. NMR spectroscopy was performed on a Bruker
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AVANCE-400 NMR spectrometer at the MIT department of chemistry instrumentation facility
(DCIF).
Synthesis of d(GpG) dinucleotide
This synthesis is outlined in Scheme C. 1. In a column containing a frit was placed 1.0 g
of d(G)-CPG high load glass bead tethered guanine oligonucleotide (Glen Research) and a small
stir bar. The column was sealed with a septum through which a tube flowing N2(g) was inserted.
On the bottom of the column, a stopcock was attached such that the column could either be
closed or open to a line of tubing passing through a septum into a curved glass connector
attached to a vacuum line and a round-bottom flask. In this manner, with the stopcock open and
the vacuum on, the solution in the column would flow into the round-bottom flask. The column
was positioned over a stir plate.
After purging the column with N2(g) for five min, 10 mL of acetonitrile was injected into
the column and the beads were stirred for five min. The acetonitrile was evacuated from the
column and 10 mL of 3% trichloroacetic acid in dichloromethane was added. The solution was
stirred for five min and the supernatant was removed by vacuum. This step was repeated three
times. A 10 mL portion of acetonitrile was added to the column and it was stirred for one min
before evacuation. This step was repeated three times.
To the column was added 4 mL of 0.45 M tetrazole in anhydrous acetonitrile and 0.25 g
of d(G) phosphoramidite. The slurry was stirred for five min before removing the solvent by
vacuum. This step was repeated three times. In total, 40 molar equivalents of tetrazole were
added together with 10 equivalents of the phosphoramidite. A 10 mL portion of 0.2 M 12 in
pyridine/THF/water was added and the suspension was stirred for one min and removed by
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vacuum. This step was repeated once. Next, 10 mL of acetonitrile was added to the column and
the solution was stirred for one min before evacuation. This step was repeated four times.
To the column was added 10 mL of 3% trichloroacetic acid in dichloromethane. The
solution was stirred for five min and the supernatant was removed by vacuum. This step was
repeated three times. Next, 10 mL of acetonitrile was added to the column and was stirred for
one min before evacuation. This step was repeated three times. To the column was then added 20
mL of 30% NH40H and the beads were stirred for one h. The round-bottom flask was then
replaced and the NH40H solution was collected. The column was washed with 5 mL of 30%
NH40H that was combined with to the previously collected aliquot. The solution was heated to
55 'C overnight. The solution was then cooled on ice and the NH40H was removed by vacuum
centrifugation. The DNA pellet was then dissolved in 25 mL of ddH20 and syringe filtered to
remove insoluble particles.
Purification of the d(GpG) dinucleotide
The solution was analyzed by LC/MS. The larger of two LC peaks corresponded to an
ESI-MS reading of 595.5 m/z in accord with the expected value for the d(GpG)- of to 595.1 m/z.
The mixture was then purified by C18 RP-HPLC, the method employed 20% - 40% B, where
solvent A was 0.1 M ammonium acetate in water and solvent B was 0.1 M ammonium acetate in
50% water and 50% acetonitrile. The peak corresponding to the product eluted at 7.0 min and
was collected and lyophilized. The lyophilized compound was then dissolved in water and
dialyzed against water with a molecular weight cutoff of 500. A total of 14.1 p.mol of DNA was
collected, a 14.1% yield from the d(G)-CPG high load glass bead starting material.
Characterization of d(GpG) dinucleotide
233
The concentration of DNA was determined by UV-vis spectroscopy. The product was
characterized by 1H NMR spectroscopy; (D20, pH 5.0): 8.01 (1H, s), 7.75 (1H, s), 6.162 (1H, t),
6.02 (IH, dd), 4.18 (2H, m), 4.11 (2H, m), 2.76 (1H, m), 2.45 (2H, m), 2.25 (1H, m). The DNA
was also characterized by ESI-MS, with a peak at 595.5 m/z and the expected value for the
d(GpG) equal to 595.1 m/z.
Synthesis of'PtBP6-modified d(GpG) dinucleotide
PtBP6 was activated as described in Chapter 2. To a solution of 14.1 pmol of d(GpG)
was added 28 pmol activated PtBP6 in 10 mM Na2HPO 4 buffer. The solution was incubated with
mixing at 370 C overnight in the dark. The reaction was then purified by RP-HPLC, 5 - 95% B
over 60 min where solvent A was 0.1% TFA in water and solvent B was 0.1% TFA in
acetonitrile.
Characterization of PtBP6-modified d(GpG) dinucleotide
The concentration of DNA was determined by UV-vis spectroscopy. The mass of the
platinated dinucleotide was determined by ESI-MS and showed peaks at 566.4 and 1131.2 m/z
with the expected platinum isotope pattern. For a d(GpG) dinucleotide in which PtBP6 was
cross-linked to both guanines, the expected mass for [M+H] 2+ is 565.7 m/z and for [M]+ is
1130.3 m/z. The compound was characterized by 1H NMR spectroscopy (D20, pH 5.0): 8.60
(1H, s, br), 8.41 (lH, s), 8.29 (1H, s), 8.08 (IH, s), 7.84-7.68 (7H, m), 7.54 (2H, td), 6.13 (2H,
m), 4.70 (1H, s, br), 4.55 (1H, s, br), 4.15 (1H, s), 4.00, (3H, m), 3.72 (1H, t), 3.45 (1H, s, br),
3.34 (2H, q), 2.78-2.45 (6H, m), 1.69 (2H, m), 1.55 (2H, m), 1.28 (4H, m). 'H NMR
spectroscopy experiments were repeated at pH values 4, 5, 7, 10 using DCl and NaOD solutions
(Cambridge Isotope Labs) to adjust the pH. The DNA was further characterized by COSY NMR
spectroscopy.
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III. RESULTS
Synthesis and characterization of d(GpG) dinucleotide
A total of 14.1 gmole of purified dinucleotide was synthesized by this method, a 14.1%
yield. ESI-MS analysis shows a mass of 595.5 m/z, with the calculated mass for [M]- being 595.1
m/z. NMR spectroscopy of the product showed the expected peaks for this compound (Figure
C.3).
Synthesis of PtBP6-modified d(GpG) dinucleotide
Platination of the dinucleotide with PtBP6 was carried out using standard methodology
for this type of reaction. The reaction was purified by RP-HPLC with two major products
corresponding to the unreacted dinucleotide and the platinated dinucleotide (Figure C.4). A 3.3
jmole portion of platinated dinucleotide was collected as determined by UV-vis spectroscopy, a
23.4% yield.
Characterization of PtBP6-modified d(GpG) dinucleotide
The product was analyzed by ESI-MS, and showed peaks at 566.4 and 1131.2 m/z with
the expected platinum isotope pattern. For a d(GpG) dinucleotide in which PtBP6 was cross-
linked to both guanines, the expected mass for [M+H] 2+ is 565.7 m/z and for [M]+ it is 1130.3
m/z. The purified compound was analyzed by 1H NMR spectroscopy (Figure C.5). All the peaks
were assigned except for the H8 atoms of the guanine bases. There were four peaks in the region
where the H8 proton peaks are expected at 8.07, 8.28, 8.42, and 8.60 ppm. It is likely that the H8
peaks are split due to multiple conformers of the compound in the solution.6 '8' 9 pH-Dependent
NMR spectroscopy was also carried out to determine whether these peaks showed similar pH-
dependent values to other platinated DNA in the literature (Figure C.6). 10 -14 No shift of the H8
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peaks occurs from pH 4 to 5 (Figure C.6A and C.6B). At pH 7 (Figure C.6C), one small broad
peak is visible at 8.29 ppm. At pH 10 (Figure C.6D), the peak at 8.29 ppm remains, and four
small peaks at 7.95, 8.58, 8.88 and 9.28 ppm, which integrate to less than one fourth of a proton
each, and a larger peak at 7.90 ppm appear. The significance of these shifts is discussed in the
next section.
COSY analysis confirms the peaks assignments from the ID NMR spectroscopy (Figure
C.7). All of the expected cross-peaks are present except a Bi - Al, Al' cross-peak. This
omission is most likely due to the separate broad signals from the two Al protons. For
comparison, the two analogous A2 proton signals create a single sharp peak at 4.0 ppm, and the
cross-peak with the B2 proton at 4.15 ppm is weak. Since the Al peaks are broad and separated,
the cross-peaks are not strong enough to show up by COSY at this concentration. Every other
through-bond interaction results in a strong cross-peak, as indicated in Figure C.7.
IV. DISCUSSION
The major DNA adduct of the anticancer drug cisplatin is a 1,2-d(GpG) intrastrand cross-
link in which the platinum binds to the N7 of adjacent guanine bases. The NMR structures of
platinum-modified short oligomers have been reported extensively in the literature.1
-3
,5,6,8-10,13,15
In the work described in Chapters 2-4, a new platinum compound, cis-[Pt(NH3)(N-(6-
aminohexyl)-4-benzophenonamide)C12] (PtBP6), containing a photoactive benzophenone moiety
tethered to a platinum amine ligand through a six-carbon linker was used to identify proteins that
bind to platinum-modified DNA. The binding of this compound to DNA should afford
orientational isomers in which the benzophenone is directed towards either the 3' or 5'-end of
the DNA (Figure C.1). This type of isomerism was demonstrated for the DNA-bound forms of
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the compounds cis-[Pt(NH3)(C6HItNH2)C12] and cis-[Pt(NH3)(4-aminoTEMPO)ClI],1,2 which
also have two different N-donor ligands. Here, NMR spectroscopic studies were carried out on
PtBP6-modified d(GpG).
Assignment ofNMR spectroscopic peaks
All expected peaks were identified in the NMR spectroscopic analysis of the unplatinated
d(GpG) (Figure C.3). Signals from protons on the 3'- or 5'-guanosine were assigned tentatively
based on literature values for small unplatinated oligomers. 9' 10,13 The dinucleoside
monophosphate was allowed to react with PtBP6 and the product was purified by RP-HPLC,
yielding one major species (Figure C.4, Peak 2). The binding of platinum to d(GpG) draws the
guanine bases closer to one another, and proton resonance are generally shifted downfield. 3' 5 One
characteristic chemical shift in platinated DNA is the H8 proton. A downfield shift in H8 is a
benchmark of platinum-DNA binding interactions.11-13 The two H8 peaks in d(GpG), which shift
downfield upon binding to PtBP6 (Figures C.3 and C.5), split into four peaks. This splitting
could be caused by the presence of two orientational isomers in solution (Figure C. 1). The two
isomers of the compound cis-[(Pt)(NH3)(NH2CH 2CH3) {r(GpG)}]+ resulted in H8 resonances of
8.10, 8.20, 8.79 and 8.82 ppm,' 6 whereas the present work reveals resonances of 8.07, 8.28, 8.42,
and 8.60 ppm. Conversely, the four H8 resonances could be due to conformers of the
dinucleoside monophosphate (Figure C.2). Platination also causes the H8 protons to exchange
more readily with deuterium from the aqueous solvent,1 7 and the four peaks integrate into less
than one-half proton each. The H8 resonance at 8.60 ppm is broader than the other three peaks.
This behavior could be due to either slow interconversion of conformers of the d(GpG) (Figure
C.2) or faster exchange with the solvent of one H8 proton from a specific orientational isomer
(Figure C. 1).
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The sample was also analyzed by COSY (Figure C.7) to ensure that the peaks were
correctly attributed. All the expected cross-peaks were seen, showing that the spectrum was
correctly assigned. No cross-peaks were found for the peaks assigned to the H8 protons,
indicating that they are assigned correctly, since no through-bond interactions are expected.
pH-Dependent NMR of PtBP6-d(GpG)
In order to further characterize the four H8 peaks for this compound, pH-dependent NMR
spectroscopy experiments were carried out. At higher pH, H8 peaks on platinated DNA will shift
upfield.10- 14 This shift is attributed to the deprotonation of the NI of guanine.' 3 For the d(GpG)-
PtBP6 complex, raising the pH from 4 to 5 does not shift the peaks (Figures C.6A and C.6B). At
pH 7 only a small broad peak at 8.29 ppm is visible (Figure C.6C). At pH 10, this peak remains
and four small peaks, at 7.95, 8.58, 8.88 and 9.28 ppm, and a larger peak at 7.90 ppm appear
(Figure C.6D). NMR studies of the orientational isomers of platinum compounds with
asymmetric ammine ligands bound to DNA have been reported in the literature. One
orientational isomer of the compound cis-[(Pt)(NH3)(C6HilNH2){d(GpG)}] showed H8
resonance of 8.3 and 8.1 ppm at pH 6, which shifted to 8.2 and 7.4 at pH 12.' The orientational
isomers of to cis-[(Pt)(NH 3)(NH 2CH 2CH 3) {r(GpG)} ] _ were also isolated and analyzed by NMR
spectroscopy.16 The H8 chemical shifts of one isomer deviate from 8.82 and 8.10 to 8.55 and
7.62 ppm from pH 5 to pH 10. The other orientational isomer has shifts of 8.79 and 8.20 that
change to 8.25 and 8.00 from pH 2 to pH 10. These shifts are depicted in Figure C.8. All of these
data exhibit an inflection point at pH 8.5, corresponding to deprotonation of N1.
The four H8 peaks for d(GpG)-PtBP6 are present at pH 5 and only one is present at pH 7.
The aromatic signal from the benzophenone moiety could potentially overlap with these peaks if
they shifted upfield, but its integration remains constant, suggesting that the H8 hydrogen atoms
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exchange with the solvent at increased pH (Figure C.6C). At pH 10 (Figure C.6D), small peaks
appear downfield of the four peaks at pH 4 and 5, and one peak is present upfield very close to
the aromatic signal. According to the literature, at pH 10 the H8 signals should have shifted
upfield, which is not the case for this molecule. The pH-dependent NMR experiments were
unable to yield any new structural information on the isomers present in solution.
V. CONCLUSIONS AND FUTURE DIRECTIONS
The compound cis-[Pt(NH3)(N-(6-aminohexyl)-4-benzophenonamide) {d(GpG)}] + was
synthesized and purified by RP-HPLC. ESI-MS indicates that the desired compound was formed.
It was analyzed by 1H NMR spectroscopy and COSY, but these methods were unable to fully
characterize the orientational isomers. Four H8 resonances were revealed, indicating the
presence of either two orientational isomers (Figure C. 1) or multiple d(GpG) conformers (Figure
C.2). pH-Dependent NMR experiments did not give any new structural information about these
isomers because the behavior of the compound at basic pH did not reflect that of similar
complexes from the literature. In the future, low temperature NMR experiments will determine
whether the one broad H8 signal at 8.60 ppm is due to slow interconversion of multiple
conformers or faster exchange with the solvent of one H8 proton of a specific orientational
isomer. If the signal splits into multiple peaks at low temperature, we will know that there are
multiple conformers present (Figure C.2). If the signal sharpens without splitting, the broadening
is due to exchange with the solvent, making it more likely that orientational isomers are present
(Figure C.1). NOESY studies will also be performed to characterize the through-space
interactions between the two bases, and possibly interactions between the benzophenone moiety
and one of the bases, depending on the orientational isomer.
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VII. SCHEMES
N 0
HO \ NH
TCAA NH
NHBz
0
DMTO ~ N NH
0 N NH
P-N(iPr)2
EtCN
EtCN
Acetonitrile
Tetrazole
NCEtO
1. NH4 0H
2. Heat
Scheme C.1. Synthesis of d(GpG).
TCAA, 3% trichloroacetic acid in dichloromethane.
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VIII. FIGURES
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Figure C.1. Orientational isomers of PtBP6 on DNA.
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Figure C.2. Conformers of d(GpG).
Adapted from Williams et al.8 The "N" ligands of the platinum are either ammine or BP6,depending on the orientation of the BP6 ligand illustrated in Figure C. 1. The orientation of theguanine represent by the arrows is shown at the top of the figure.
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Figure C.3. 'H NMR spectrum of d(GpG).
244
*L: -; ir -- u ~-:i JIr/~ / /;3 :I ;i1 J I
1.60-
1.40-
1.20-
1.00-
0.80-
0.60.
0 .40-
0.20-
0.00. I
0.00 200 400 6.00 800 1000 12.00 1400 16.00 1800 20.00
Minuten
22.00 24.00 25.00 28.00 30.00 32J
Figure C.4. RP-HPLC purification of d(GpG)-PtBP6.
Peak 1 is unreacted d(GpG) and peak 2 is the product, d(GpG)-PtBP6.
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Figure C.6. pH-dependent 'H NMR spectra of d(GpG)-PtBP6.
A) pH 4. B) pH 5. C) pH 7. D) pH 10.
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Figure C.7. 'H COSY of d(GpG)-PtBP6.
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Figure C.8. H8 proton chemical shifts at low and high pH.
The chemical shifts of the H8 protons of a dinucleotide containing an asymmetric
platinum compound have a distinct upfield shift at elevated pH, with an inflection point
at pH 8.5. This behavior was not exhibited by the H8 protons of the compound cis-
[Pt(NH3)(N-(6-aminohexyl)-4-benzophenonamide) {d(GpG) }]. These data suggest that
the isomers present are a product of dinucleotide positioning (Figure C.2) and not
orientation of the asymmetric platinum ligand (Figure C. 1).
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